

AUTHOR INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Page references to supplement 1 (August 1997) and 4 (November 1997) are preceded by S1: and S4:

- | | | |
|-----------------------------------|-------------------------------|----------------------------|
| Aboul-Magd, A., 16 | Béné, M. C., 64 | Chattopadhyay, J., 912 |
| Agodoa, L. Y. C., 193, S1:1 | Bennett, W. M., 71 | Checa, A. A., 483 |
| Agraharkar, A., 717 | Bergert, J. H., 646 | Chen, A., 693 |
| Agraharkar, M., 717 | Bergström, J., 459 | Chen, Y.-M., 840 |
| Aguado, S., 423 | Bernardo, I., 224 | Chertow, G. M., 428, S4:96 |
| Ahluwalia, N., 532 | Berns, J. S., 558 | Cheung, A. K., 571 |
| Ahn, C., 36 | Bhandari, S., 814 | Chin, H. J., 36 |
| Ahuja, T. S., 116 | Bigler, S. A., 710 | Chonko, A., 532 |
| Alamir, A., 851 | Birmingham, D. J., 243 | Chou, W.-Y., 693 |
| Alamo, C., 397 | Blaise, G., 665 | Chow, M. T., 568 |
| Alexander, S. R., 193 | Blake, P. G., 475 | Churchill, D. N., 899 |
| Alexiewicz, J. W., 98 | Bloembergen, W. E., S1:1, 733 | Clark, B. A., 82 |
| Alfred, H., 349 | Bonnardeaux, A., 237 | Clark, W. R., S4:10 |
| Al-Uzri, A., 134 | Bosc, J.-Y., 672 | Cohen, R. M., 558 |
| Alvarez, J., 423 | Bossi, M., 849 | Cole, L., S4:80, S4:109 |
| Amann, K., 382 | Bossini, N., 58 | Conlon, P. J., 521 |
| Andersen, R. C., 639 | Boucher, A., 237 | Cooker, L. A., 680 |
| Ando, A., 123 | Bourgoignie, J. J., 822 | Copleston, P., 334 |
| Andoh, T. F., 71 | Boxerman, S. B., 766 | Copley, J. B., 846 |
| Andress, D. L., 809 | Boyce, M. L., 180 | Corey, R. G., 521 |
| Andreucci, V. E., 4:i | Boyd, T. A., 253 | Correa-Rotter, R., 229 |
| Appel, G. B., 872 | Boyer-Hassen, L. V., 134 | Cosio, F. G., 243 |
| Apsner, R., 802 | Bradfield, E., 475 | Costley, K., 343 |
| Argilés, À., 672 | Brady, H. R., 428 | Coulshed, S. J., 219 |
| Aronson, A. J., 725 | Breiterman-White, R., 525 | Cruz, D. N., 772 |
| Arrigo, G., 404 | Brennan, D. C., 766 | Cueto-Manzano, A. M., 229 |
| Arruda, J. A. L., 361 | Bresin, E., 174 | Curhan, G. C., 428 |
| Ashby, V. B., S1:1 | Brezin, J. H., 760 | |
| Austin, J. S., 665 | Brezsnyak, W., 28 | Dacko, C., 356 |
| Avasthi, P. S., 180 | Bridges, R. M., 343 | Dahan, M., 780 |
| Avram, M. M., 896, 912 | Bro, S., 606 | Dahl, D. C., 639 |
| | Brown, A. J., 105 | D'Amico, G., 404 |
| Baid, S., S4:32 | Brownjohn, A., 814 | Danielsson, A., 459 |
| Bailey, T. C., 766 | Buades, J., S4:57 | Davenport, A., S4:20 |
| Baldwin, I. C., S4:112 | Buffington, D. A., S4:28 | Davenport, K., 134 |
| Baker, P., 851 | Buhsmer, J. D., 495 | Davila, R. M., 586 |
| Bald, M., 23 | Bunchman, T. E., S4:84 | De Heer, F., 466 |
| Baliga, R., 710 | Burke, J. F., 495 | Deiss, A., 571 |
| Balow, J. E., 879 | Bussard, R., 739 | Delfino, R., 659 |
| Bana, G., 849 | | Denda, M., 105 |
| Bankir, L., S:xx | Callard, S., S1:1 | DeOreo, P. B., 41, 204 |
| Barama, A., 271 | Camerini, C., 58 | Desmeules, M., 334 |
| Bartosch, S. M., 725 | Camussi, G., S4:57 | De Solo, B. O., 483 |
| Bass, E. B., 793 | Canaud, B., 672, S4:2 | Dickinson, D., S1:1 |
| Bastacky, S., 113 | Cancarini, G. C., 445 | Dillon, J. J., 243 |
| Bazzi, C., 404 | Cannella, G., 659 | Di Silvestro, V. A., 568 |
| Beasley, C. L., 549 | Cardinal, J., 237 | Distant, D. A., 253 |
| Beaver, S., 165 | Cartwright, K., 253 | Dooley, M. A., 872 |
| Becker, B. N., 525 | Cendoroglo, M., 680 | Douglas, J. F., 219 |
| Bellomo, R., S4:15, S4:80, S4:109 | Chan, T.-m., 433 | Druml, W., 802 |
| Beltrame, A., 404 | Chang, D.-M., 693 | Dunagan, W. C., 766 |

AUTHOR INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Page references to supplement 1 (August 1997) and 4 (November 1997) are preceded by S1: and S4:

- Aboul-Magd, A., 16
 Agodoa, L. Y. C., 193, S1:1
 Agraharkar, A., 717
 Agraharkar, M., 717
 Aguado, S., 423
 Ahluwalia, N., 532
 Ahn, C., 36
 Ahuja, T. S., 116
 Alami, A., 851
 Alamo, C., 397
 Alexander, S. R., 193
 Alexiewicz, J. W., 98
 Alfred, H., 349
 Al-Uzri, A., 134
 Alvarez, J., 423
 Amann, K., 382
 Andersen, R. C., 639
 Ando, A., 123
 Andoh, T. F., 71
 Andress, D. L., 809
 Andreucci, V. E., 4:i
 Appel, G. B., 872
 Apsner, R., 802
 Argilés, À., 672
 Aronson, A. J., 725
 Arrigo, G., 404
 Arruda, J. A. L., 361
 Ashby, V. B., S1:1
 Austin, J. S., 665
 Avasthi, P. S., 180
 Avram, M. M., 896, 912
 Baid, S., S4:32
 Bailey, T. C., 766
 Baldwin, I. C., S4:112
 Baker, P., 851
 Bald, M., 23
 Baliga, R., 710
 Balow, J. E., 879
 Bana, G., 849
 Bankir, L., S:xx
 Barama, A., 271
 Bartosh, S. M., 725
 Bass, E. B., 793
 Bastacky, S., 113
 Bazzi, C., 404
 Beasley, C. L., 549
 Beaver, S., 165
 Becker, B. N., 525
 Bellomo, R., S4:15, S4:80, S4:109
 Beltrame, A., 404
 Béné, M. C., 64
 Bennett, W. M., 71
 Bergert, J. H., 646
 Bergström, J., 459
 Bernardo, I., 224
 Berns, J. S., 558
 Bhandari, S., 814
 Bigler, S. A., 710
 Birmingham, D. J., 243
 Blaise, G., 665
 Blake, P. G., 475
 Bloembergen, W. E., S1:1, 733
 Bonnardeaux, A., 237
 Bosc, J.-Y., 672
 Bossi, M., 849
 Bossini, N., 58
 Boucher, A., 237
 Bourgoignie, J. J., 822
 Boxerman, S. B., 766
 Boyce, M. L., 180
 Boyd, T. A., 253
 Boyer-Hassen, L. V., 134
 Bradfield, E., 475
 Brady, H. R., 428
 Breiterman-White, R., 525
 Brennan, D. C., 766
 Bresin, E., 174
 Brezin, J. H., 760
 Brezsnayak, W., 28
 Bridges, R. M., 343
 Bro, S., 606
 Brown, A. J., 105
 Brownjohn, A., 814
 Buades, J., S4:57
 Buffington, D. A., S4:28
 Buhsmer, J. D., 495
 Bunchman, T. E., S4:84
 Burke, J. F., 495
 Bussard, R., 739
 Callard, S., S1:1
 Camerini, C., 58
 Camussi, G., S4:57
 Canaud, B., 672, S4:2
 Cancarini, G. C., 445
 Cannella, G., 659
 Cardinal, J., 237
 Cartwright, K., 253
 Cendoroglo, M., 680
 Chan, T.-m., 433
 Chang, D.-M., 693
 Chattopadhyay, J., 912
 Checa, A. A., 483
 Chen, A., 693
 Chen, Y.-M., 840
 Chertow, G. M., 428, S4:96
 Cheung, A. K., 571
 Chin, H. J., 36
 Chonko, A., 532
 Chou, W.-Y., 693
 Chow, M. T., 568
 Churchill, D. N., 899
 Clark, B. A., 82
 Clark, W. R., S4:10
 Cohen, R. M., 558
 Cole, L., S4:80, S4:109
 Conlon, P. J., 521
 Cooker, L. A., 680
 Copleston, P., 334
 Copley, J. B., 846
 Corey, R. G., 521
 Correa-Rotter, R., 229
 Cosio, F. G., 243
 Costley, K., 343
 Coulshed, S. J., 219
 Cruz, D. N., 772
 Cueto-Manzano, A. M., 229
 Curhan, G. C., 428
 Dacko, C., 356
 Dahan, M., 780
 Dahl, D. C., 639
 D'Amico, G., 404
 Danielsson, A., 459
 Davenport, A., S4:20
 Davenport, K., 134
 Davila, R. M., 586
 De Heer, F., 466
 Deiss, A., 571
 Delfino, R., 659
 Denda, M., 105
 DeOreo, P. B., 41, 204
 Desmeules, M., 334
 De Solo, B. O., 483
 Dickinson, D., S1:1
 Dillon, J. J., 243
 Di Silvestro, V. A., 568
 Distant, D. A., 253
 Dooley, M. A., 872
 Douglas, J. F., 219
 Druml, W., 802
 Dunagan, W. C., 766

- Dunea, G., 361
 Dunn, S. R., 495
 Dusso, A. S., 105

 Edelstein, C. L., S4:89
 Eiser, A. R., 291
 Eknayan, G., 4:001
 Endo, M., 123
 Endoh, M., 389
 Epstein, F. H., 82
 Erickson, R., S1:1
 Espinosa, A., 229
 Ettenger, R. B., 193

 Faict, D., 680
 Falk, R. J., 872
 Farrell, J., 690
 Faubert, P. F., 265
 Faure, G. C., 64
 Felgar, R., 301
 Fenton, S. S. A., 334
 Fernandez, A., 423
 Finch, J. L., 105
 Fine, L. G., 1:xliv
 Fink, N. E., 793
 Fitzwater, D. S., 710
 Flanigan, M. J., 165
 Fleishhacker, J. F., 253
 Fogo, A., 729
 Fontaine, A. B., 851
 Foreman, J. W., 713
 Foster, A., 180
 Fotiadis, C., 525
 Fowler, V. G., 521
 Francoeur, M., 665
 Frederick, P., 165
 Freedman, S., 120
 Freyschuss, U., 459
 Fricke, H., 366
 Friedman, E. A., 28, 253
 Funke, A. J., S4:28

 Gadallah, M. F., 343
 Gangam, N., 374
 Gardner, J. J., S4:84
 Garred, L. J., 672, S4:2
 Gaughan, W. J., 495
 Gellens, M., 690
 Gentile, D. E., 165
 Gerigk, M., 23
 Gibson, J., 786
 Goerd, P. J., 639
 Goldwasser, P., 16
 Gómez, E., 423
 Gooneratne, R., 116
 Goral, S., 301
 Gotch, F. A., 1
 Gourgon, R., 780
 Gowrishankar, M., 829

 Grabensee, B., 413
 Grantham, J. J., 703
 Greer, J. W., S1:1
 Grey, S. F., 41
 Guardia, J. A., 822
 Gupta, R., 271

 Haas, M., 621, 725
 Halperin, M. L., 829
 Han, J. S., 36
 Hartmann, J., 366
 Hassol, A., 749
 Hattori, M., 632
 Hawkins, I. F., 213
 Hays, R. D., 140
 Hebert, L. A., 243, 851
 Heim-Duthoy, K. L., 639
 Held, P. J., 50, 193, S1:1
 Helgersen, S. D., 165
 Hernández, A., 229
 Hernández, E., 397
 Hiesmayr, M., 802
 Higashihara, M., 123
 Hillis, G. S., 279
 Hirth, R. A., 50, S1:1
 Hogan, S. L., 872
 Holley, J. L., 356
 Holmes, C. J., 680
 Holzer, H., 282
 Honda, K., 123
 Horina, J. H., 282
 Horita, S., 632
 Horn, S., 282
 Hotta, N., 275
 Houde, M., 237
 Howell, D. N., 713
 Hoyt, D. B., S4:102
 Huang, C.-C., 840
 Hulbert-Shearon, T., S1:1
 Hull, A. R., 549
 Humes, H. D., S4:28

 Ideura, T., 287
 Ifudu, O., 28
 Inenaga, T., 160
 Ing, T. S., 568
 Irish, W., 739
 Ishibashi-Ueda, H., 160
 Ishimitsu, T., 160
 Ito, K., 632
 Iverius, P.-H., 571
 Iwasaki, S., 287

 Jaber, B. L., 561, 680, S4:44
 Jacobs, D. M., 639
 Jang, I.-J., 36
 Jassal, S. V., 219
 Jeffery, J. R., 334
 Jenckes, M., 793

 Jennette, J. C., 872
 Jeon, U. S., 36
 Johnson, H. J., 639
 Johnson, J. P., 113
 Johnson, M. L., 134
 Jones, C. A., 193, S1:1
 Joshua, D. E., 786

 Kanta, B., 140
 Kaplan, B. S., 760
 Karrison, T. G., 621
 Kasahara, M., 703
 Kashem, A., 389
 Kasiske, B. L., 639
 Kates, D. M., 809
 Katzarski, K. S., 459
 Kawaguchi, H., 632
 Kawahara, H., 275
 Kawano, Y., 160
 Kaye, M., 440
 Kaysen, G. A., 923
 Kelly, J. H., S4:66
 Kennel-De March, A., 64
 Kerns, S. R., 213
 Kessler, M., 64
 Ketis, M., 440
 Khan, I. H., 279
 Kim, D., 82
 Kim, S., 36
 Kim, S. B., 507
 Kim, Y. S., 36
 Kirchner, K. A., 577
 Kjellstrand, C. M., 334
 Knight, J. A., 571
 Kone, B. C., 311
 Koo, L. C., 489
 Koshikawa, S., 287
 Kovalik, E. C., 448
 Kraus, M. A., S4:10
 Krejs, G. J., 282
 Kritzing, M., 802
 Kumar, D., 98
 Kurokawa, N., 389
 Kurtzman, N. A., 576

 Lai, K. N., 260
 Lam, G., 449
 Landreneau, M., 343
 Langos, V., 374
 Larson, T. S., 646
 Lau, J., 297
 Leblanc, M., 672, S4:2
 Lee, J. S., 36
 Lee, W.-H., 693
 Leehey, D. J., 568
 Leggat, J., S1:1
 Leu, M.-L., 653
 Leunissen, M. L., 466
 Léveillé, M., 665

- Levey, A. S., 297
 Levin, N., 793
 Levin, N. W., 1
 Levine, G. N., S1:1
 Lew, S. Q., 879
 Lewy, J. E., 193
 Li, P. K. T., 260
 Liang, S.-C., 693
 Liedtke, R. R., 646
 Lin, C.-L., 840
 Lin, F.-G., 693
 Lin, J.-L., 653
 Lindsay, R. M., 475
 Ling, H., S4:89
 Liss, K. A., 495
 Lo, C.-y., 433
 Lo, W.-k., 433
 Lockett, R., 739
 Loghman-Adham, M., 571
 Loos, E., S1:1
 Lopez, E. A., 483
 Lowe, G., 440
 Luik, A. J., 466

 McCallister, C., 243
 McCauley, J., 739
 McClellan, W. M., 165
 McClendon, E., 28
 MacDonald, A. S., 271
 McDonald, J. C., 343
 Macey, L. J., 28
 McKenzie, C. R., 586
 McMillan, R., 343
 McMurray, S. D., 542
 Macias, W. L., S4:10
 MacKay, S. M., S4:28
 Madias, N. E., 561
 Madore, F., 665
 Mahan, J. D., 243
 Mahnensmith, R. L., 772
 Maiorca, R., 58, 445
 Malek, P., 475
 Mall, G., 382
 Mangold, A. M., 495
 Mansoor, G. A., 591
 Mao, Y., 334
 Marcussen, N., 449
 Mariano, F., S4:57
 Martin, B., 475
 Martin, K. J., 690
 Martin, R. K., S4:105
 Martinez, A., 423
 Maru, M., 16
 Massry, S. G., 98
 Matsuo, S., 275
 Mattana, J., 116
 Matthew, J. J., 28
 Matthias, S., 382

 Mauger, E. A., 733
 Maxvold, N. J., S4:84
 Mayers, J. D., 28
 Meehan, S. M., 621
 Meisels, I. S., 120
 Melón, S., 423
 Meyer, K. B., 140, 349, 793
 Michael, B., 495
 Michel, C., 780
 Middendorf, D. F., 851
 Mignon, F., 780
 Miller, B. W., 586
 Miller, J., 542
 Miller, S. B., 586
 Min, W. K., 507
 Minami, J., 160
 Mion, C., 672
 Mitch, W. E., 297
 Mittman, N., 912
 Moberly, J. B., 489
 Molho, L., 116
 Molinari, S., 659
 Mon, C., 397
 Montner, P., 180
 Morandi, R., 174
 Mori, Y., 275
 Morrison, H. I., 334
 Movilli, E., 58
 Mueller, B. A., S4:10
 Muhm, M., 802
 Mukherjee, A. B., 720
 Murphy, M., 749
 Mushnick, R., 912

 Nabokov, A., 87
 Nagao, S., 703
 Nahman, N. S., Jr., 851
 Nawab, Z. M., 568
 Neimeier, K. A., 382
 Nelson, C., 180
 Neves, P. L., 224
 Ney, A. L., 639
 Nihei, H., 123
 Nisell, J., 459
 Nissenson, A. R., 907
 Nitta, K., 123
 Nolin, L., 237
 Nomoto, Y., 389
 Norfolk, D., 814
 Nseka, N. M., 836
 Nyimi, L. M., 836
 Nylander, W., 525

 Odland, M. D., 639
 Ojo, A. O., S1:1
 Olgaard, K., 606
 O'Neill, W. C., 579
 Oreopoulos, D. G., 445
 O'Rourke, S. G., 514

 Orth, S. R., 382
 Ortiz-Butcher, C., 822
 Orzol, S. M., S1:1
 Ouimet, D., 237
 Ouseph, R., 501
 Owen, W. F., Jr., 349
 Ozminkowski, R. J., 749

 Paillole, C., 780
 Pakasa, N. M., 836
 Pan, M.-J., 840
 Paoletti, E., 659
 Papadimitriou, M., 760
 Park, J. S., 507
 Parkerson, G. R., Jr., 140
 Parry, W. W., 710
 Pascual, M., S4:32
 Patrick, D. L., 140
 Peloso, G., 659
 Perazella, M. A., 772
 Pereira, B. J. G., 680, S4:44
 Peterlin, B., 174
 Petrini, C., 404
 Pham, P.-T., 879
 Phelan, D. L., 766
 Pichette, V., 237
 Pignatti, P. F., 174
 Plum, J., 413
 Polder, J., 165
 Ponssen, H. H., S4:72
 Poon, A. S. Y., 260
 Poon, P., 260
 Popovtzer, M. M., 6:i
 Port, F. K., 1, 50, 193, S1:1, 733
 Portal, C., 423
 Porush, J. G., 265
 Posen, G., 475
 Powe, N. R., 793
 Prabhu, P. N., 213
 Praga, M., 397
 Pressley, T. A., 720
 Prowant, B. F., 165
 Prud'homme, L., 665
 Prud'homme, M., 665

 Quintana, M. J. L., 483

 Radndmaa, I., 459
 Raj, D. S. C., 374
 Rao, T. K. S., 28, 156
 Rao, V. K., 639
 Rascher, W., 23
 Ratschek, M., 282
 Rault, R., 356
 Rayner, D., 449
 Reaven, G. M., 928
 Rees, A. J., 279
 Reeves, J., S4:80, S4:109
 Rennke, H. G., 428

- Renoult, E., 64
 Rettig, R. A., 140
 Reydel, C., 28
 Richie, R. E., 525
 Riera, J. A. S.-I., 483
 Ritz, E., 87, 382
 Rizza, V., 404
 Robergs, R. A., 180
 Robinson, D. L., 521
 Robinson, L. A., 713
 Rocco, M. V., 165
 Rodicio, J. L., 397
 Roldan, C., 180
 Rolla, D., 659
 Ronco, C., S4:15, S4:57
 Roscoe, J., 374
 Rosenthal, T., 549
 Ross, E. A., 213, 489
 Rossetti, S., 174
 Roy-Chaudhury, P., 120
 Rubin, H. R., 793
 Rutecki, G. W., 131
- Sabatelli, F. W., 213
 Sabatini, S., 856
 Sadler, J. H., 140
 Sakai, H., 389
 Sánchez, E., 423
 Sánchez, M. L., 423
 Sankaran, R. T., 116
 Sarac, E., 113
 Savin, V., 532
 Saxena, R., 131
 Scarpero, H. M., 846
 Schaubel, D. E., 334
 Schiffers, P. M. H., 466
 Schiffl, H., 366
 Schmidt, G., 349
 Schneider, W., 440
 Schnitzler, M. A., 766
 Schoenicke, G., 413
 Schrier, R. W., S4:89
 Schulman, G., 525
 Schwab, S. J., 448
 Schwarz, U., 382
 Schwarzwald, E., 116
 Sedmak, D. D., 243
 Segieda, G., S1:1
 Sehgal, A. R., 41, 514
 Seiden, D. J., 291
 Sekkarie, M. A., 437
 Selmanovic, D., 912
 Selva, A., 849
 Sexton, D. J., 521
 Shappell, S., 301
 Sharland, A., 786
 Shaykh, M., 361
 Shen, X.-P., 243
- Sherrard, D. J., 809
 Sheu, L.-F., 693
 Shihad, F. S., 71
 Shimizu, K., 123
 Shin, S.-G., 36
 Siegal, F. P., 116
 Silva, A. P., 224
 Silverman, M., 558
 Silvester, W., S4:38, S4:80, S4:109
 Simpson, J. G., 279
 Singhal, P. C., 116
 Siohan, P., 780
 Skikne, B. S., 532
 Slatopolsky, E., 105
 Smith, B. P., 501
 Smith, M. C., 156
 Smoyer, W. E., S4:84
 Snowdon, L., 786
 Snyder, C., 514
 Solez, K., 449
 Somerville, P. J., 440
 Sorgorzewski, M., 98
 Spargo, B. H., 621
 Spek, J., 466
 Spira, A., 829
 Spitznagel, E. L., 766
 Sreedhara, R., 912
 Stackiewicz, L., 356
 Stahl, R. A. K., 3:xlx
 Stapleton, F. B., 2:xxxvii
 Stark, D., 180
 Steer, M., 120
 Steinman, T. I., 120
 Stevenson, J., 739
 Stim, J., 361
 Stout, R. W., 219
 Strada, A., 58
 Strawderman, R. L., 50, 193, S1:1
 Sudo, M., 287
 Sundaram, S., 680
 Sunder-Plassmann, G., 802
 Surgue, T., 28
 Sussman, N. L., S4:66
 Sutoh, H., 275
 Swinford, R. D., S4:32
 Szeto, C. C., 260
- Takahashi, F., 105
 Takahashi, H., 703
 Takishita, S., 160
 Tang, S., 433
 Tanner, A. M., 71
 Tarif, N., 361
 Taylor, L., 165
 Tedeschi, P. J., S1:1
 Tetta, C., S4:57
 Theodorou, A. A., 134
 Thompson, L., 739
- Tiberti, G., 849
 Tiller, D. J., 786
 Toledo, T., 397
 Tomlanovich, S. J., 760
 Törig, J., 382
 Toriyama, T., 275
 Trpkov, K., 449
 Tsai, S.-C., 693
 Tsen, Y.-T., 840
 Tumlin, J. A., 884
 Turco, A. E., 174
 Turenne, M. N., 50, 193
 Turner, J., 558
 Turney, J., 814
- Uehlinger, D. E., 1
- Van Bommel, E. F. H., S4:72
 Van Bortel, L. M. A. B., 466
 Van Buren, D., 525
 Van Hooff, J. P., 466
 Van Kuijk, W. H. M., 466
 Vaseghi, M., 912
 Vela, J. L. P., 483
 Vinay, P., 665
 Viola, B. F., 58
 Viron, B., 780
- Waldherr, R., 87
 Walshe, J., 690
 Walton, D., 571
 Wang, P. H., 297
 Wangsiripaisan, A., S4:89
 Ward, J. M., 720
 Ward, R. A., 501
 Warnock, D. G., 932
 Washington, M., 739
 Wasson, J. H., 140
 Webb, R. L., S1:1
 White, A. J., 749
 White, W. B., 591
 Whitehouse, P. J., 41
 Whittier, F. C., 131
 Wigfall, D. R., 713
 Wilson, D. M., 646
 Wolfe, R. A., 1, S1:1, 733
 Woods, J. D., 50, S1:1
 Woodward, R. S., 766
 Work, J., 343
 Wratten, M. L., S4:57
 Wu, A. W., 793
 Wu, C.-H., 840
 Wu, M.-S., 840
- Yamaguchi, T., 703
 Yamaguchi, Y., 632
 Yamauchi, F., 389
 Yang, C.-W., 840

Yang, S.-S., 653
 Yang, W. S., 507
 Yang, Y.-J., 653
 Yano, N., 389
 Yeun, J. Y., 923

Yorgin, P. D., 134
 Yoshimura, A., 287
 Yoshioka, T., 632
 Young, E. W., 50, S1:1
 Yu, A. W. Y., 260

Yung, C. Y., 568
 Zhang, Z., 720
 Zibari, G. B., 343
 Zulkharnain, 760

SUBJECT INDEX

Articles under the rubric *Of Nephrology and Nephrologists* are referred to by journal number, a colon, and page numbers.

Page references to supplements 1 (August 1997), 2 (September 1997), 3 (October 1997), and 4 (November 1997) are preceded, respectively, by S1:, S2:, S3:, and S4:

AAU (ammonium acid citrate) urolithiasis, 237-242
 Ab(s), *see* Antineutrophil cytoplasmic antibodies
 Abbreviations in NKF-DOQI guidelines, S2:16, S2:68, S3:151, S3:193
 Abdominal wall infection, as contraindication to PD, S2:102
 ABPM, *see* Ambulatory blood pressure monitoring
 Abstraction forms in NKF-DOQI guidelines, S2:8-10, S3:144-146
 Acceptance into ESRD therapy, USRDS 1997 ADR on, S1:202-204
 Access
 to bloodstream with catheters, S3:167-169
 to dialysis facility, means of transportation used, S1:84
 to renal transplantation, *see* Access to renal transplantation, USRDS 1997 ADR on; Race and ethnicity of ESRD patients, access to renal transplantation and vascular, *see* Vascular access
 Access to renal transplantation, USRDS 1997 ADR on, S1:16, S1:123-126
 pediatric, S1:136-138
 Access routes for gene transfer to kidney, 1:xlvi
 Accreditation for renal ultrasonography, 582
 ACE, *see* Angiotensin-converting enzyme inhibitor(s)
 ACHP (activated charcoal hemoperfusion) for sepsis, S4:45-47
 Acidosis
 dilutional, as complication of right ventricular myocardial infarction, 561-567
 see also Metabolic acidosis
 Acknowledgment for use of USRDS data, S1:36
 Acquired immunodeficiency syndrome (AIDS)
 advanced ARF in membranous nephropathy associated with, prednisone therapy of, 116-119
 indinavir therapy of, oliguric ARF caused by crystalluria and nephrolithiasis due to, 558-560
 severity of, and response of HD ESRD patients with, to rHuEPO, 28-35
 see also HIV infection; HIVAN

Acronyms
 in NKF-DOQI guidelines, S2:16, S2:68, S3:151, S3:193
 in USRDS 1997 ADR, S1:8-9
 Actin, α -smooth muscle, in primary FSGS, 634-635
 Activated charcoal hemoperfusion (ACHP) for sepsis, S4:45-47
 Acute effects of PTH excess on nonclassical target organs, 608
 Acute graft rejection, renal graft with lymphocytic infiltrate as PTLD or, 449-454
 Acute hemodialysis (HD), noncuffed catheters for, S3:158-159
 Acute liver failure (ALF), ELAD for, S4:66-71
 Acute methanol intoxication, ethanol-enriched HCO₃-based dialysate HD for, 568-570
 Acute myocardial infarction (AMI) in renal transplantation recipients, systemic thrombolysis for, 849-850
 Acute-phase proteins, peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients, 923-927
 Acute renal failure (ARF)
 advanced, in AIDS-associated membranous nephropathy, prednisone therapy of, 116-119
 due to leptospirosis, 840-845
 emerging therapies for, S4:89-95
 see also Acute renal failure, CRRT of
 granulomatous IN and, 586-588
 HD for, Tesio twin catheter in, 213-218
 with HUS, 760-765
 as indication for large-bore central venous catheter, 803
 oliguric, due to crystalluria and nephrolithiasis associated with indinavir therapy of AIDS, 558-560
 postischemic, NO role in, 324-325
 radiocontrast exposure-associated, 82-86
 renal vasculitis with HIV infection and, 428-432
 temporal changes and reversibility of carbamylated Hb in, 36-40
 Acute renal failure (ARF), CRRT of

- analysis of multicenter trials of, S4:96-101
 in Australia, S4:80-83
 bioartificial RAD to enhance, S4:28-31
 dialysis membrane adsorption during, S4:32-37
 extracorporeal circuit effects on coagulation system in, S4:20-27
 IHD compared with, *see* Intermittent hemodialysis for ARF, CRRT compared with
 role of CRRT quantification in, S4:10-14
 UKM for, S4:2-9
see also Intensive care unit, management of CRRT of ARF in; Prescription of CRRT for ARF
- Acute tubular necrosis, *see* Acute renal failure
- Address of USRDS World Web Site, S1:25
- Adenosine monophosphate, *see* cAMP
- Adenosine triphosphatase (ATPase), Na/K-, serine-threonine phosphatase regulating activity of, in nephron, 888-889
- Adequacy of HD
 carbamylated Hb and URR as indices of, compared, 361-365; *see also* Urea reduction ratio
 patient assessment of protein nutrition and, 514-520
see also Adequacy of HD and/or PD; Kt/V
- Adequacy of HD and/or PD
 of CAPD ESRD Core Indicators Study report on, 165-173
 of HD in ESRD Core Indicators Study, 349-355
see also Clinical practice guidelines, NKF-DOQI, on HD and PD adequacy; Kt/V, HD, PD, and/or CAPD for ESRD and
- ADH, *see* Antidiuretic hormone
- Adhesion molecules, intercellular, in ARF, S4:92
- Adjustment
 PD prescription, S2:90
 of rates in USRDS 1997 ADR, S1:204-206
 standard population for, in USRDS 1997 ADR, S1:11-12, S1:196
- Admissions, USRDS 1997 ADR on
 total, crude rates of hospitalization for ESRD based on, S1:147-151
see also Hospitalization for ESRD, USRDS 1997 ADR on
- ADPKD, *see* Autosomal dominant polycystic kidney disease
- ADR (Annual Data Report) of USRDS, *see* United States Renal Data System, 1996 ADR of; United States Renal Data System, 1997 ADR of
- Adrenal cortex, excess PTH effects on, 609-610
- Adsorption
 dialysis membrane, during CRRT for ARF, S4:32-37
 and extracorporeal adsorbent-based strategies in sepsis, S4:44-56
- Adults
 with autosomal recessive inheritance of HUS, renal transplantation in, 760-765
 with CRF on HD and/or PD, plasma NPY in, 23-27
see also specific conditions
- Advance directives, factors influencing completion of, by chronic PD and HD patients, 356-360
- Advanced acute renal failure (ARF) in AIDS-associated membranous nephropathy, prednisone therapy of, 116-119
- Advanced glycosylated end products (AGEs), hyperglycemia-induced, vasculopathic complications of DM and, 253-259
- Advantages
 of living kidney donation, 551
 of renal ultrasound, 580
- Adverse effects
 of rHuEPO therapy, S3:222-223, S3:226
see also Complications, vascular access; Side effects *specific therapeutic modalities and conditions*
- Advisory Council, NKF-DOQI, S2:2, S2:10-11, S3:138, S3:146-147
- African Americans, *see* Race and ethnicity
- AG, *see* Anion gap
- AGE(s) (advanced glycosylated end products), hyperglycemia-induced, vasculopathic complications of DM and, 253-259
- Age
 of ARF patients, 37, S4:73, S4:85
 of chronic renal insufficiency patients, 19, 21, 655
 of CRF and/or ESRD patients, *see* Age of ESRD patients and etiology of NS, 625
 of IgA nephropathy patients, and enalapril effects on von Willebrand factor levels, 399
 and Ki-67 cell proliferation in renal disease, 88
 of multiple myeloma-induced renal failure patients, 787
 of NIDDM patients, elevated cytosolic Ca and B lymphocyte proliferation and, 99
 of primary FSGS patients, 634
 of radiocontrast-exposed patients, 83
 of renal transplant recipients, 640, 763
 of trauma patients with MOF, 485
- Age of ESRD patients
 in ESRD Core Indicators Study, 351
 serum PTH and serum phosphate association and, 810
see also Age of ESRD patients, USRDS 1997 ADR on; Age of ESRD patients on HD, PD, and/or CAPD
- Age of ESRD patients, incidence and prevalence of treated ESRD by, USRDS 1997 ADR on
 of adult patients, S1:41-45, S1:51
 of pediatric patients, S1:128-130, S1:132-134
- Age of ESRD patients, USRDS 1997 ADR on
 DMMS data by, S1:72
 and graft loss, S1:123-124, S1:126
 and hospitalization, S1:147, S1:149
 incidence of treated ESRD by, *see* Age of ESRD patients, incidence and prevalence of treated ESRD by, USRDS 1997 ADR on
 Medicare expenditures by, S1:170-172
 mortality and, *see* Age of ESRD patients, USRDS 1997 ADR on mortality and
 remaining years of life and, S1:99
- Age of ESRD patients, USRDS 1997 ADR on mortality and on causes of mortality, S1:109-110
 on national rates, S1:101, S1:105
 on trends, S1:89-91
- Age of ESRD patients on HD, PD, and/or CAPD, 167-169
 carbamylated Hb and, 37, 362, 364
 completion of advance directives and, 357
 functional health status self-assessment and, 206, 207
 and HD adequacy and protein nutrition self-assessment, 516
 hypoalbuminemia and, 509, 924, 925
 IE and, 522
 internal jugular vein catheter placement and, 691

- intradialytic hypotension and, 773
- LVH and, 661, 782
- of mentally impaired patients, 43, 45, 46
- mortality and, 336-338
- and NO effects on BP in, 667
- and patients' view of quality of care, 796
- of pediatric patients, 195
- peritoneal transport kinetics and, 233
- PET, urea kinetics and, 375, 376
- rHuEPO therapy and, 30, 497
- and RRF preservation, 368
- vascular access and, 52, 53, 216, 526
- Agreement for release of USRDS data, S1:38-39
- AIDS, *see* Acquired immunodeficiency syndrome
- Al, *see* Aluminum
- Albumin
- in dilutional acidosis with right ventricular myocardial infarction, 562, 566
 - in IgAN, *see* Albumin in IgAN
 - serum, in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
 - urinary excretion of, in IgAN, IL-1 receptor antagonist effects on, 696; *see also* Urinary excretion, protein
 - see also* Albumin in ESRD patients on HD, PD, and/or CAPD; Hypoalbuminemia in ESRD patients; Serum albumin
- Albumin in ESRD patients on HD, PD, and/or CAPD
- carbamylation of Hb and, 364
 - effects of hypoalbuminemia on serum Lp(a) in, 507-513
 - effects of low-dose rHuEPO alone or combined with androgens on, 497
 - in elderly CHD patients, LVH and, 225, 226
 - and intradialytic hypotension, 773
 - mentally impaired patients, 47
 - and patient self-assessment of protein nutrition, 516
 - in PD patients, S2:98-99
 - survival and, 207, 208
- Albumin in IgAN
- characterization of proteinuria in IgAN with urinary polymers of, 404-412
 - IL-1 receptor antagonist effects on urinary excretion of, 696
- ALF (acute liver failure), ELAD for, S4:66-71
- Alkalosis, metabolic, hypocalcemic tetany and, in CRF patient on HD, 440-444
- Allergic conditions, *see* Hypersensitivity
- Alpha (α)-interferon (interferon- α) for CML, thrombotic microangiopathy associated with, 123-130
- Alpha (α)-smooth muscle actin (ASMA) in primary FSGS, 634-635
- Alport's syndrome (AS)
- prenatal DNA-based diagnosis of, by genetic linkage in families with AS, 174-179
 - as primary disease in ESRD, IV Fe therapy effects and, 815
- Alternate-day steroid therapy for transplanted ESRD children, 193-204
- Alternative end-stage renal disease (ESRD) care, Medicare expenditures for, USRDS 1997 ADR on, S1:169-172
- Aluminum (Al)
- contribution of kitchen utensils made of, to Al accumulation in renal disease, 653-658
 - intoxication with, and inadequate response to rHuEPO, S3:219
 - plasma, effects of low-dose rHuEPO alone or combined with androgens on, 497
- Ambulatory blood pressure monitoring (ABPM), 591-605
- in CRF, *see* Chronic renal failure, ABPM and hypertension
 - in
 - data analysis and reporting with, 593-594
 - devices used in, and practical issues in, 592-593
 - in diabetes mellitus, 596-597
 - of HD and/or CAPD patients, 598-600
 - of LVH patients, lisinopril therapy and, 662
 - in PKD, 597
 - in renal transplantation, 601-602
 - for vascular disease, office blood pressure compared with, 594-596
 - and white-coat hypertension, 596
- Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis for ESRD; Peritonitis with CAPD
- AMI (acute myocardial infarction) in renal transplantation recipients, systemic thrombolysis for, 849-850
- Amino acids in PD solutions, 415
- Aminoguanidine (Pimagedine), effects of, on survival, in azotemic STZ-DM, 253-259
- Ammonium acid citrate (AAU) urolithiasis, 237-242
- AMP (adenosine monophosphate), *see* cAMP
- Amputations of PD patients, BSA estimation and, S2:81, S2:124-125
- Amyloid A, serum, peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients, 923-927
- Amyloid nephropathy, NS and, 621-631
- Analysis files, USRDS
- for research, S1:27-29
 - see also* Standard Analysis Files, USRDS
- Analytical methods used in USRDS 1997 ADR, S1:195-213
- for annual mortality, hospitalization, and transplantation, S1:206-209
 - changes in, S1:195-196
 - database and, *see* Database, USRDS
 - Death Notification Form and, S1:202
 - in determination of mortality causes, S1:107-112
 - for expected remaining lifetime, S1:211
 - geography and, S1:202
 - for graft survival, S1:211
 - for incidence, prevalence, and acceptance measurement, S1:202-204
 - lost to follow-up methodology and, S1:196, S1:201-202
 - for patient survival, S1:209-211
 - reasons for changes in numbers and, S1:198-201
 - for RRT modalities, S1:211
 - summary of, S1:19
- ANCAs, *see* Antineutrophil cytoplasmic antibodies
- Androgens, rHuEPO and
- low-dose rHuEPO alone or in combination with, 495-500
 - in rHuEPO resistance, S3:220
- Anemia of CRF, *see* Clinical practice guidelines, NKF-DOQI, on treatment of CRF anemia and entries beginning with terms: Recombinant human erythropoietin
- Anemia Work Group, NKF-DOQI
- leadership and structure of, S3:143
 - membership of, S3:148, S3:238-240

- Aneurysm due to AV access, treatment of, S3:178
- Angiotensin-converting enzyme (ACE) inhibitor(s)
and inadequate response to rHuEPO, S3:219
see also Enalapril; Lisinopril
- Animal studies of space flight effects on bone metabolism, 6:i-ii
- Anion exchange sorbent resin, modified, selective hemadsorption for sepsis with, S4:52
- Anion gap (AG)
and dilutional acidosis with right ventricular myocardial infarction, 562, 566
in DM-related polyuria, 830
and HD with ethanol-enriched HCO₃-based dialysate for acute methanol intoxication, 569
normal anion gap metabolic acidosis, enterovesical fistula presenting as, 131-133
- Annual Data Report of USRDS, *see* United States Renal Data System, 1996 ADR of; United States Renal Data System, 1997 ADR of
- Annual facility survey, USRDS, *see* Facilities for ESRD care, USRDS 1997 ADR on
- Annual mortality, ESRD, USRDS 1997 ADR on, S1:206-209
- ANPs, *see* Atrial natriuretic peptides
- Antibiotics, *see* Prophylaxis, vascular access antibiotic and specific antibiotics
- Antibodies, *see* Antibody-coated aminated microspheres; Antineutrophil cytoplasmic antibodies
- Antibody-coated aminated microspheres, specific hemadsorption for sepsis, S4:54
- Anticoagulants, extracorporeal circuit and, S4:20-21, S4:26
- Anticoagulation pathways in ARF patients, extracorporeal circuit and, S4:22-23
- Antidiuretic hormone (ADH)
syndrome of inappropriate secretion of, hyponatremia following hysteroscopic endometrial ablation, 717-719
vasopressin and water conservation, 5:i-iii
- Anti-glomerular basement membrane (GBM) disease (Goodpasture's syndrome) in infant, 710-712
- Antimyeloperoxidase (anti-MPO) antineutrophil cytoplasmic antibodies (ANCAs), positive, in scleroderma, D-penicillamine effects on progressive renal failure associated with, 279-281
- Antineutrophil cytoplasmic antibodies (ANCAs)
and Ki-67 cell proliferation in renal disease, 88, 92
positive anti-myeloperoxidase, in scleroderma, D-penicillamine effects on progressive renal failure associated with, 279-281
- Antioxidant mechanisms in HD and PD patients, 489-494
- Anti-thymocyte globulin (ATG), CsA induction therapy and sequential therapy with, in renal transplantation, compared, 639-645
- APACHE II scoring system, S4:75-77
- APD (automated peritoneal dialysis), USRDS 1997 ADR on, S1:73, S1:75, S1:83
- Apolipoprotein (a) phenotype, and hypoalbuminemia effects in ESRD patients on CAPD, 507-513
- Apolipoprotein B, hypoalbuminemia effects on, in ESRD patients on CAPD, 507-513
- ARF, *see* Acute renal failure
- L-Arginine, and NO effects on BP in ESRD patients on HD, 665-671
- Arrhythmias on HD, autonomic neuropathy and predisposition to, 219-223
- Arterial compliance, and BP changes on HD, as effect of hypervolemia, 466-474
- Arterial pressure, *see* Blood pressure
- Arteriopathy in chronic CsA nephropathy, 74
- Arteriovenous fistula (AVF) and graft in HD
and BUN sampling, S2:38
IE in ESRD patients with dual-lumen catheters, PTFE grafts and, compared, 521-524
survival of, 50-57
see also Arteriovenous fistula and graft in HD, NKF-DOQI guidelines on
- Arteriovenous fistula (AVF) and graft in HD, NKF-DOQI guidelines on, S3:156-161
basis for intervention in, S3:170-172
on failure rate of, S3:181, S3:182
on maturation of, S3:160-161
on maximization of, S3:179-180
monitoring, for stenosis, S3:162-164
on patency rate of, S3:182, S3:183
preservation of veins for, S3:159-160
selection and order of preference of placement of, S3:156-157
timing of, S3:160
type and location of placement of, S3:157
- Arteriovenous hemofiltration, continuous, dose delivery with, S4:15-16
- AS (Alport's syndrome), prenatal DNA-based diagnosis of, by genetic linkage in families with, 174-179
- ASMA (α -smooth muscle actin) in primary FSGS, 634-635
- Aspartate aminotransferase (SGOT), effects of low-dose rHuEPO alone or combined with androgens on, 497
- Assessment
anemia, in CRF patients, S3:196-198, S3:224
dry weight, in normotensive CRF patients on HD, with ultrasound measurement of IVC, 459-465
Fe status, in CRF patients, S3:202-206
muscle mass, of PD patient, S2:128
nutritional status, of PD patients, S2:83-85, S2:125-127
patient, prior to access placement, S3:154-161
see also Diagnosis; Health and quality of life outcomes of dialyzed ESRD patients, assessment of; Self-assessment specific conditions and interventions
- Association for the Advancement of Medical Instrumentation (AAMI) Standards and Recommended Practices for dialyzer reprocessing, S2:43-45
- ATG (anti-thymocyte globulin), CsA induction therapy and sequential therapy with, in renal transplantation, compared, 639-645
- ATN (acute tubular necrosis), *see* Acute renal failure
- ATPase (adenosine triphosphatase), Na/K-, serine-threonine phosphatase regulating activity of, in nephron, 888-889
- Atrial natriuretic peptides (ANPs)
in ARF, S4:92-93
level of ET and, following radiocontrast exposure, 82-86
- Australia, CRRT of ARF in, S4:80-83
- Automated peritoneal dialysis (APD), USRDS 1997 ADR on, S1:73, S1:75, S1:83
- Autonomic dysfunction, and intradialytic hypotension in ESRD, 772-779

- Autonomic neuropathy, and predisposition to arrhythmias on HD, 219-223
- Autosomal dominant polycystic kidney disease (ADPKD), 691
in children, 2:xxxvii-xxxix
- Autosomal recessive inheritance of HUS, renal transplantation for, in adults, 760-765
- Average charges for inpatient and outpatient vascular access surgery, 528
- AVF, *see* Arteriovenous fistula and graft in HD
- Azotemic streptozotocin-induced diabetes mellitus (STZ-DM), aminoguanidine effects on, 253-259
- B cells
elevated $[Ca^{2+}]_i$ and proliferation of, in NIDDM, 98-104
excess PTH effects on, 612-613
- Bacterial (infective) endocarditis in HD patients, 521-524
- Bedside teaching of CRRT in ICU, S4:113
- Berger's disease, *see* IgA nephropathy
- Beta (β) cells, excess PTH effects on, 610
- Beta-interferon (interferon- β), response to high-dose, in HCV infection-associated MPGN, 113-115
- Beta₂-microglobulin, *see* β_2 -Microglobulin
- BF (blood flow), HD vascular access, measured by differential conductivity technique, 475-482
- BGG (bovine gamma-globulin), experimental GN induced by, 243-252
- Bicarbonate, *see* HCO_3
- Bilirubin, effects of low-dose rHuEPO alone or combined with androgens on, 497
- Bioartificial renal tubule assist device (RAD) to enhance CRRT in ARF, S4:28-31
- Biochemical Scientific Advisory Committee (B-SAC), USRDS, S1:6
- Biochemistry of NO, 312-313
- Biocompatibility
of PMX-B polystyrene-derivative fibers, S4:49
see also Biocompatibility of PD solutions and fluids; Biocompatible membranes on HD
- Biocompatibility of PD solutions and fluids
cytotoxicity of buffers and osmotic agents in, and monocyte cytokine release with, 413-422
effects of two-chambered HCO_3 lactate-buffered PD fluids on, 680-689
- Biocompatible membranes on HD
for ARF, S4:32-33, S4:91-92
- Biocompatible membranes on HD, S2:20
preservation of RRF with, 366-373
rHuEPO resistance and, S3:220
- Biographical sketches
of Anemia Work Group members, S3:238-240
of HD Work Group members, S2:64-66
of PD Work Group members, S2:134-136
of Vascular Access Work Group members, S3:190-191
- Biological targets of NO, 314
- Biopsy
skin, in patient with thrombotic microangiopathy associated with IFN- α therapy of CML, 124
see also Renal biopsy; Renal histology
- Blood compartment volume in peracetic acid-reprocessed dialyzers, effects of maintenance on, on urea clearance and β_2 -microglobulin removal, 501-506
- Blood flow (BF), HD vascular access, measured by differential conductivity technique, 475-482
- Blood glucose
fasting, elevated cytosolic Ca and B lymphocyte proliferation in NIDDM and, 99
and RRF preservation on HD, 369
- Blood lines, extracorporeal, S4:24
- Blood loss, chronic, rHuEPO and, S3:218
- Blood pressure (BP)
chronic CsA nephropathy effects on, 74
of hypoalbuminemic HIVAN patients with proteinuria, 823, 824
of IC-GN, 247, 250
in moderate renal failure, 384
in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
of renal transplant recipients, CsA induction and ATG sequential therapy and, 643
see also Ambulatory blood pressure monitoring; Blood pressure in ESRD patients on HD and/or CAPD; Hypertension
- Blood pressure (BP) in ESRD patients on HD and/or CAPD
ABPM, 598-600
of elderly CHD patients, LVH and, 225
ESRD Core Indicators Study report on, 165-173
hypervolemia effects on interdialytic control of, 466-474
in mentally impaired patients, 47
NO effects on, 665-671
and relationship between LVH, myocardial contractility, and volume overload, 782
and RRF preservation, 368, 369
see also Hypotension in ESRD patients on HD
- Blood pumps, extracorporeal, S4:24-25
- Blood urea nitrogen, *see* BUN
- Blood volume (BV)
during dialysate Na variation with similar intradialytic Na balances in chronic HD for ESRD, 58-63
in normotensive and hypertensive CRF patients on HD, measurement of, 459-465
- Bloodstream accessing with catheters, S3:167-169
- BMI, *see* Body mass and body mass index
- Body mass and body mass index (BMI)
of elderly CHD patients, LVH and, 225
fat-free edema-free, in nutritional status assessment of PD patients, S2:84
lean, PCR and, 672-679
of NIDDM patients, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Body size, and contraindication to PD, S2:102
- Body surface area (BSA)
of CAPD patients, PET and urea kinetics and, 375-377
in PD dose measurement, S2:80-81, S2:122-125
- Body weight (BW)
of chronic renal insufficiency patients, race and Cr excretion and, 19
of CRF patients and/or ESRD patients, *see* Body weight of ESRD patients
of IC-GN patients, 247
of IgA nephropathy patients, and enalapril effects on von Willebrand factor levels, 401
of moderate renal failure subjects, 384
of NIDDM patients, elevated cytosolic Ca and B lymphocyte proliferation and, 99

- of renal transplant recipients, CsA induction therapy and ATG sequential therapy and, 640, 643
- Body weight (BW) of ESRD patients
 - and effects of 19-NOR-1,25-(OH)₂D₃ on serum PTH, 107
 - of ARF patients, S4:85
 - predialysis, 181, 187
 - see also Body weight of ESRD patients on HD, PD, and/or CAPD
- Body weight (BW) of ESRD patients on HD, PD, and/or CAPD
 - carbamylation Hb and, 362, 364
 - dry, see Dry weight of ESRD patients on HD
 - in hypocalcemic tetany with metabolic alkalosis patients, 442
 - NO effects on BP and, 667
 - in nutritional status assessment of PD patient, S2:127-128
 - of pediatric patients, 195, 200
 - PET and urea kinetics and, 375, 376
 - see also Intradialytic weight gain on HD
- Bone loss in space flight due to immobilization, 6:i
- Bone metabolism, gravitational forces and, 6:i-iii
- Borah equation, modified, assessment of pediatric PD patient nutritional status with, S2:84-85
- Bovine gamma (γ)-globulin (BGG), experimental GN induced by, 243-252
- Bowel disease, ischemic or inflammatory, as contraindication to PD, S2:102
- BP, see Blood pressure
- BSA, see Body surface area
- B-SAC (Biochemical Scientific Advisory Committee), USRDS, S1:6
- Bubble trap in CRRT circuit, S4:25-26
- Buffers
 - nonbicarbonate, and ECF volume expansion, dilutional acidosis and, 561-567
 - osmotic agents and, in biocompatible PD solutions, monocyte cytokine release with, 413-422
- BUN (blood urea nitrogen)
 - in ARF, reversibility of carbamylated Hb and, 37
 - in dilutional acidosis with right ventricular myocardial infarction, 562, 566
 - in DM-related polyuria, 830
 - in hypoalbuminemic HIVAN patients with proteinuria, 823, 824
 - in hyponatremia following hysteroscopic endometrial ablation, 718
 - predialysis, see Predialysis BUN
 - in STZ-DM, aminoguanidine effects on, 256
 - see also BUN in ESRD patients on HD, PD, and/or CAPD
- BUN (blood urea nitrogen) in ESRD patients on HD, PD, and/or CAPD
 - in CAPD patients, hypoalbuminemia effects on serum Lp(a) and, 510
 - in elderly CHD patients, LVH and, 225, 226
 - in ESRD Core Indicators Study, 351-353
 - and 19-NOR-1,25-(OH)₂D₃ effects on serum PTH, 107
 - reversibility of carbamylated Hb and, 37
 - RRF preservation and, 369
 - sampling of, NKF-DOQI guidelines, S2:38-42, S2:61-62
- Burn patients on HD and treated with SSD cream, silver elimination in, 287-290
- BV, see Blood volume
- BW, see Body weight
- Ca (calcium)
 - calcineurin as Ca-dependent, calmodulin-stimulated serine-threonine phosphatase, 886
 - in ARF management, S4:89-90
 - in dilutional acidosis with right ventricular myocardial infarction, 562
 - serum, see Serum Ca
 - see also Ca channel blockers
 - see also Ca in HD patients; Ca²⁺; [Ca²⁺]_i; Hypercalcemia; Hypocalcemic tetany
- Ca (calcium) in HD patients
 - carbamylation Hb and, 362, 364
 - in elderly CHD patients, LVH and, 225, 226
 - ionized, with hypocalcemic tetany with metabolic alkalosis, 440-444
- Ca (calcium) channel blockers in ARF management, S4:89
- Ca²⁺ (calcium) in biocompatible PD solutions, 415
- [Ca²⁺]_i (cytosolic calcium)
 - B cell proliferation and elevated, in NIDDM, 98-104
 - excess PTH effects on, 607-608
- Cadaveric renal transplantation, USRDS 1997 ADR on graft loss with, S1:121-126
 - graft survival with, S1:121
 - patient survival with, S1:119
- Calcineurin, expression and function of, in nephron, 884-895
 - cyclosporine and FK-506 effects on, 884-886
 - expression of subunit isoform of, 886-887
 - serine-threonine phosphatase and, 886-890
 - steroid hormone receptors and transcription-independent activation of calcineurin, 890-893
- Calcineurin phosphatase, cyclosporine and FK-506 effects on, 885-886
- Calcitriol [1,25-(OH)₂D₃; 1,25-dihydroxycholecalciferol D₃]
 - in CRF, 811, 812
 - 19-NOR-1,25-(OH)₂D₃ as analog of, suppresses serum PTH and parathyroid gland growth in uremia without intestinal vitamin D receptor elevation, 105-112
- Calcium, see Ca
- Calculi, see Nephrolithiasis; Urolithiasis
- Calmodulin-stimulated serine-threonine phosphatase, calcineurin as Ca-dependent, 886
- Caloric intake by CAPD patients, 231
- Calpain in ARF management, S4:90
- cAMP (cyclic adenosine monophosphate)
 - in HD patients, RRF preservation and, 369
 - renal, accumulation and urinary excretion of, in slowly progressive PKD, 703-709
- CAPD, see Continuous ambulatory peritoneal dialysis for ESRD
- CAPD and Peritonitis Rates Study, USRDS, S1:32-33
- Capillary deficit in heart but not in skeletal muscle in moderate renal failure, 382-388
- Capillary electrophoresis, nonradiolabeled iothalamate using, to determine GFR, 646-652
- Capitation, impact of, on cost of HD for ESRD, 542-548
- Carbamylated Hb (CarbHb) in ESRD, 361-365
 - and in ARF, temporal changes and reversibility of, 36-40
- Carbohydrate intake by CRF patients, exercise training and, 187, 189
- Carbon dioxide, see CO₂
- Carcinoma, see Malignancy

- Cardiac causes of mortality among ESRD patients, USRDS 1997 ADR on, S1:109
- Cardiac output, effects of hypervolemia on, in HD, 466-474
- Cardiorespiratory endurance, effects of exercise training in PDCRF on hypertension, renal function and, 180-192
- Cardiovascular system
 excess PTH effects on, 610-611
 see also Infective endocarditis *entries beginning with elements*: Card-, Myocard-, Vascu-
- Carnitine for rHuEPO-resistant patients, S3:220
- Case Mix Adequacy Study (CMAS), USRDS, S1:33-35
 on CD, S1:35
- Case Mix Severity Study, USRDS, S1:32
- Catheters
 PD, in DMMS, USRDS 1997 ADR on, S1:78
 see also Catheters, HD
- Catheters, HD
 and BUN sampling, NKF-DOQI guidelines on, S2:38-39
 internal jugular vein, complications associated with, 690-692
 Tesiio twin, long-term performance of, 213-218
 see also Catheters, HD, NKF-DOQI guidelines on; Central venous catheters, HD; Vascular access, HD
- Catheters, HD, NKF-DOQI guidelines on
 noncuffed, for acute HD, S3:158-159
 on quality of care standards, S3:180
 tunnelled cuffed, *see* Tunnelled cuffed catheters, HD, NKF-DOQI guidelines on
- Cationically modified cellulose microspheres, selective hemadsorption for sepsis with, S4:52-53
- CAVH (continuous arteriovenous hemofiltration), dose delivery with, S4:15-16
- CC (Coordinating Center) of The University of Michigan, S1:5-6
- CCPD, *see* Continuous cycling peritoneal dialysis for ESRD
- CD(s) (compact discs), USRDS data on, S1:27, S1:29, S1:33-35
- CD₄ count in AIDs patients with ESRD, response to rHuEPO therapy and, 28-35
- CD-ROMs, SAFs on, S1:29-30
 drive needed for SAF use, S1:35
- Cell proliferation, Ki-67, in MCD and IgAN, clinical findings correlated with renal biopsy findings in, 87-97
- Cell volume, rHuEPO effects on, in Fe-deficient patients, 535, 537
- Cellular actions of excess PTH, 607-608
- Cellulose membranes
 on dialyzers reprocessed with peracetic acid, 501-506
 RRF preservation with, in ESRD patients on HD, 366-373
- Cellulose microspheres, cationally modified, selective hemadsorption for sepsis with, S4:52-53
- Cellulosic beads, polyethylenimine-coated and PMX-B-immobilized macroporous, selective hemadsorption for sepsis with, S4:52
- Census
 of ESRD networks, S1:198
 as population base for ESRD incidence and prevalence measurement in USRDS 1997 ADR, S1:203-204
- Central vein stenosis with AV graft and fistula, treatment of, S3:174
- Central venous catheters, HD
 large-bore, supraclavicular approach to subclavian/innominate vein for placement of, 802-808
 see also Dual-lumen catheters; Tunnelled cuffed catheters, HD, NKF-DOQI guidelines on
- CG (Cockcroft-Gault) formula, Cr clearance values in chronic renal insufficiency based on, 16-22
- cGMP (cyclic guanosine monophosphate), cyclic, in HD patients, RRF preservation and, 369
- CGN (chronic glomerulonephritis), 655, 691
- Charcoal hemoperfusion, activated, for sepsis, S4:45-47
- CHD, *see* Chronic hemodialysis for ESRD
- Chest x-ray following placement of internal jugular vein catheter for HD, 690-692
- Children, 710-716
 having, as factor in completion of advance directives by HD and chronic PD patients, 357
 IC-GN following onset of IDDM in, 713-716
 infant with anti-glomerular basement membrane disease, 710-712
 see entries beginning with term: Pediatric
- Chloride, *see* Cl
- CHOICE, health and quality of life outcomes of dialyzed ESRD patients assessed with, 151
- Cholesterol
 intake of, by CRF patients, exercise training and, 187, 189
 see also High-density lipoprotein cholesterol; Low-density lipoprotein cholesterol; Serum cholesterol; Total cholesterol
- Chronic blood loss, and inadequate response to rHuEPO, S3:218
- Chronic cyclosporine (CsA) nephropathy, Na depletion enhancing renal fibrosis and expression of TGF- β 1 and ECM proteins in, 71-81
- Chronic effects of PTH excess on nonclassical target organs, 608
- Chronic glomerulonephritis (CGN), 655, 691
- Chronic hemodialysis (CHD) for ESRD
 BV during dialysate Na variation with similar intradialytic Na balances in, 58-63
 risk factors for LVH in elderly patients on, 224-228
- Chronic myelocytic leukemia (CML), thrombotic microangiopathy associated with IFN- α therapy for, 123-130
- Chronic peritoneal dialysis (PD) for ESRD
 completion of advance directives by patients on, factors influencing, 356-360
 see also Continuous ambulatory peritoneal dialysis for ESRD
- Chronic pyelonephritis (CPN), and chronic renal insufficiency, 655
- Chronic renal failure (CRF)
 ABPM in, *see* Chronic renal failure, ABPM and hypertension in
 anemia of, *see* Clinical practice guidelines, NKF-DOQI, on treatment of CRF anemia and *entries beginning with terms*: Recombinant human erythropoietin
 CAPD for, *see* Continuous ambulatory peritoneal dialysis for ESRD
 carbamyated Hb in, *see* Carbamyated Hb in ESRD
 diuretics in, 4:i-iii
 HD for, *see* Hemodialysis for ESRD
 with HUS, 760-765
 as indication for large-bore central venous catheter, 803
 influence of race and sex on therapeutic options for, 856-858; *see also* Race and ethnicity of ESRD patients, sex and

- 19-NOR-1,25-(OH)₂D₃ suppresses serum PTH and parathyroid gland growth in, without intestinal vitamin D receptor elevation, 105-112
- PD for, *see* Peritoneal dialysis for ESRD
- predialysis, effects of exercise training on cardiorespiratory endurance, hypertension, and renal function in, 180-192
- serum phosphate association with serum PTH in, 809-813
- torsades de pointes in patients with, treated with cisapride and clarithromycin, 437-439
- see also* End-stage renal disease; Progression of (and to) CRF
- Chronic renal failure (CRF), ABPM and hypertension in, 597-601
- relationship between ABPM and hypertensive complications in, 600-601
- rHuEPO and, 600
- Chronic renal insufficiency
- Al kitchen utensils effects on iron levels in, 653-658
- race and Cr excretion in, 16-22
- CIS, *see* End-stage renal disease Core Indicators Study
- Cisapride with clarithromycin therapy, torsades de pointes in CRF patients on, 437-439
- Cl (chloride)
- in biocompatible PD solutions, 415
- in dilutional acidosis with right ventricular myocardial infarction, 562, 566
- in DM-related polyuria, 830, 833
- and HD with ethanol-enriched HCO₃-based dialysate for acute methanol intoxication, 569
- in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 442
- in hyponatremia following hysteroscopic endometrial ablation, 718
- in metabolic acidosis, 132
- NO role in NaCl-sensitive hypertension, 322-323
- Claims records, *see* Paid Medicare claims
- Clarithromycin and cisapride therapy, torsades de pointes in CRF patients on, 437-439
- Clinical features and presentation
- of anti-glomerular basement membrane disease in infant, 710-711
- enterovesical fistula presenting as normal anion gap metabolic acidosis, 131-133
- see also* Symptoms and specific conditions
- Clinical Practice Guideline on Adequacy of Hemodialysis (Renal Physicians Association), S2:17-21, S2:23-29, S2:32-34, S2:36, S2:58
- Clinical Practice Guideline on Adequacy of Peritoneal Dialysis (Renal Physicians Association), S2:26
- Clinical practice guidelines, NKF-DOQI, on HD and PD adequacy
- acronyms and abbreviations used in, S2:16
- guidelines defined, S2:6
- introductions to, S2:17-21, S2:69
- see also* Developmental methodology of NKF-DOQI guidelines; Hemodialysis for ESRD, NKF-DOQI guidelines on; Peritoneal dialysis for ESRD, NKF-DOQI guidelines on
- Clinical practice guidelines, NKF-DOQI, on treatment of CRF anemia
- acronyms and abbreviations used in, S3:193
- on anemia assessment, S3:196-198, S3:224
- introduction to, S3:194
- with red blood cell transfusions, S3:221
- see also* Developmental methodology of NKF-DOQI guidelines; Fe deficiency in ESRD patients on HD, NKF-DOQI guidelines on intervention in; Recombinant human erythropoietin for ESRD patients on HD and/or CAPD, NKF-DOQI guidelines on
- Clinical practice guidelines, NKF-DOQI, on vascular access
- acronyms and abbreviations used in, S3:151
- on complications, *see* Complications, vascular access, NKF-DOQI guidelines on
- introduction to, S3:152-153
- on maintenance and monitoring, S3:162-166
- on patient evaluation prior to access placement, S3:154-161
- on quality of care standards, S3:179-183
- see also* Developmental methodology of NKF-DOQI guidelines
- Clonal cell lines in ELAD for ALF, S4:68
- Clotting, HD vascular access, blood flow predictive of, 475-482
- CMAS, *see* Case Mix Adequacy Study, USRDS
- CML (chronic myelocytic leukemia), thrombotic microangiopathy associated with IFN- α therapy for, 123-130
- CMV, *see* Cytomegalovirus infection
- CO₂ (carbon dioxide)
- and ethanol-enriched HCO₃-based dialysate HD for acute methanol intoxication, 569
- PaCO₂ in dilutional acidosis with right ventricular myocardial infarction, 566
- total, in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 442
- see also* PCO₂
- Coagulation pathways, extracorporeal circuit and, S4:20, S4:26
- Coagulation system in ARF patients, effects of extracorporeal circuit on, S4:20-27
- Cockcroft-Gault (CG) formula, Cr clearance values in chronic renal insufficiency based on, 16-22
- Collaborative care pathway for outpatient surgery of HD vascular access, 525-531
- Collaborative Model of CRRT management of ARF in ICU, S4:106-108
- Collagen, type III, in primary FSGS, 634-635
- Collapsing focal segmental glomerulosclerosis (FSGS), secondary, associated with *Loa loa* filariasis, 836-839
- Combined gastric and ileocecal toxicity due to oral Kayexalate in sorbitol therapy, 120-122
- Comfort, HD patient, NKF-DOQI guidelines on maximization of, S2:20, S2:49-50
- Committee(s)
- NKF-DOQI Steering, S2:3, S3:139
- USRDS, S1:6-7, S1:21-22
- Communication, medical/nursing, in ICU, S4:115
- Comorbidity
- with ESRD, 742
- see also* Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on and specific conditions
- Compact discs, *see* CD(s); CD-ROMs, SAFs on
- Complement
- activation of, with reused dialyzers, 864
- see also* Complement in CRRT

- Complement in CRRT
dialysis membrane adsorption and activation of, S4:33
removal of, S4:41-42
- Complement factor D, dialysis membranes and, S4:34-35
- Completion of advance directives by HD and chronic PD patients, factors influencing, 356-360
- Compliance with dialysis for ESRD
with PD, *see* Prescription of PD for ESRD, NKF-DOQI guidelines on
in USRDS DMMS, S1:78-83
see also Compliance with HD for ESRD
- Compliance with HD for ESRD
NKF-DOQI guidelines, S2:20, S2:49-50
self-assessment of functional health status on SF-36 by ESRD patients as predictor of, 204-212
see also entries beginning with term: Prescription
- Complications, *see* Adverse effects; Complications, vascular access *specific conditions and therapeutic modalities*
- Complications, vascular access
with large-bore central venous catheters, 804
see also Complications, vascular access, NKF-DOQI guidelines on
- Complications, vascular access, NKF-DOQI guidelines on, S3:167-178
management of, S3:170-178
prevention of, S3:167-169
- Computed tomography (CT), renal, renal ultrasound results compared with results of, 582
- Computer(s) needed for SAF use, S1:35
- Computer modeling approach to estimation of adequate delivered PD dose, S2:88-92
- Conductivity technique, differential, HD vascular access BF measured by, 475-482
- Consumer Price Index (CPI), changes in, and changes in Medicare payments for ESRD care (1992-1995), S1:168
- Contacts, USRDS, S1:23
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
ABPM of patients on, 598-600
in children, growth rates of, compared with patients on CCPD, HD, renal transplantation and, 193-204
in ESRD Core Indicators Study, 165-173
hypoalbuminemia effects on serum Lp(a) in, 507-513
impact of capitation on cost of, 542-548
kinetics on, *see* Kinetics on CAPD
mortality with HD and, compared, 334-342, 445-447
see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1997 ADR on; Peritoneal dialysis for ESRD; Peritonitis with CAPD and entries beginning with terms: Recombinant human erythropoietin
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD, USRDS 1997 ADR on
in DMMS, S1:74, S1:75
international, S1:188-190
on Medicare expenditures for, S1: 18-19, S1:160-163, S1:169-172
on mortality and hospitalization, S1:208-209
as option, S1:55-56
on patient survival with, S1:210
for pediatric ESRD, *see* Continuous ambulatory peritoneal dialysis for pediatric ESRD, USRDS 1997 ADR on
on prescription of, S1:62-63
trends in use of, S1:56-58
see also Peritonitis with CAPD, USRDS 1997 ADR on
- Continuous ambulatory peritoneal dialysis (CAPD) for pediatric ESRD, USRDS 1997 ADR on, S1:135
on mortality, S1:139-141
- Continuous arteriovenous hemofiltration (CAVH), dose delivery with, S4:15-16
- Continuous cycling peritoneal dialysis (CCPD) for ESRD
delivered weekly dose of, S2:87
mortality with HD and, compared, 334-342, 445-447
for pediatric ESRD, effects of CAPD, HD, renal transplantation and, on growth rates, compared, 193-204
see also Continuous cycling peritoneal dialysis for ESRD, USRDS 1997 ADR on
- Continuous cycling peritoneal dialysis (CCPD) for ESRD, USRDS 1997 ADR on
for adult ESRD, S1:55-58
international, S1:188-190
on Medicare expenditures for, S1:160-163, S1:169-172
on mortality and hospitalization, S1:208-209
on patient survival with, S1:210
for pediatric ESRD, S1:135, S1:139-141
- Continuous high flux dialysis for ARF, dose delivery with, S4:16-17
- Continuous quality improvement, ESRD Core Indicators Study and, 349-355
- Continuous renal replacement therapy (CRRT)
applications of, to extracorporeal liver support, S4:66-71
cost containment of, S4:102-105
introduction to, S4:1
see also Acute renal failure, CRRT of; Intensive care unit, CRRT in; Sepsis, CRRT for
- Continuous venovenous hemodiafiltration (CVVHDF) for ARF, dose delivery with, S4:16
- Continuous venovenous hemofiltration (CVVH)
for ARF, dose delivery with, S4:16
in trauma with MOF patients, cytokine clearance with, 483-488
- Contraceptives, oral, role of, in autosomal recessive inheritance of HUS, 760-765
- Contraindications to PD, S2:101-104
- Coordinating Center (CC) of The University of Michigan, S1:5-6
- Coping with living kidney donation, addressing needs of donors, recipients, and their families in, 555-556
- Core Indicators Study, *see* End-stage renal disease Core Indicators Study
- Cortex, adrenal, excess PTH effects on, 609-610
- Corticosteroids, *see* Steroid(s)
- Cortinarius orellanus*, ESRD due to poisoning with, 282-286
- Cost
CRRT, containment of, S4:102-105
of USRDS data, S1:36
see also Cost of ESRD care
- Cost of ESRD care
and impact of capitation on dialysis facilities, 542-548
and of surgery for HD vascular access, collaborative care pathway reducing, 525-531
see also Cost of ESRD care, USRDS 1997 ADR on; Medicare expenditures for ESRD
- Cost of ESRD care, USRDS 1997 ADR on
intent-to-treat model of, S1:212-213

- see also* Medicare expenditures for ESRD, USRDS 1997 ADR on
- Course
of thrombotic microangiopathy after prednisolone treatment, 124-125
see also Progression and specific conditions
- Coverage, medical, *see* Medical coverage for ESRD, USRDS 1997 ADR on
- CPI (Consumer Price Index), changes in, and changes in Medicare payments for ESRD care (1992-1995), S1:168
- CPN (chronic pyelonephritis), and chronic renal insufficiency, 655
- Cr, *see* Creatinine and creatinine clearance
- C-reactive protein (CRP), peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients on PD, 923-927
- Creatinine (Cr) and creatinine clearance
in ARF, reversibility of carbamylated Hb and, 37
in chronic CsA nephropathy, 74
in chronic renal insufficiency, effects of Al kitchen utensils on, 655
in dilutional acidosis with right ventricular myocardial infarction, 562, 566
in Goodpasture's syndrome, 711
in hypoalbuminemic HIVAN patients with proteinuria, 823, 824
in multiple myeloma-induced renal failure, 787
serum, *see* Serum creatinine
in STZ-DM, aminoguanidine effects on, 256
see also Creatinine and creatinine clearance in ESRD patients on HD, PD, and/or CAPD
- Creatinine (Cr) and creatinine clearance in ESRD patients on HD, PD, and/or CAPD
carbamylated Hb and, 37, 362, 364
and effects of 19-NOR-1,25-(OH)₂D₃ on serum PTH, 107
in elderly patients on CHD, LVH and, 225, 226
with ethanol-enriched HCO₃-based dialysate HD for acute methanol intoxication, 569
failure to achieve target, as indication for switching from PD to HD, S2:103
hypoalbuminemia effects on serum Lp(a) in CAPD patients, 510
in hypocalcemic tetany with metabolic alkalosis patient, 442
PCR and, 672-679
serum PTH and serum phosphate association and, 810
total, in PD dose measurement, S2:75-77
weekly, ethnic variability in, 374-380
- Credentialing for CRRT in ICU, S4:115-116
- CRF, *see* Chronic renal failure
- Critical Care Model of CRRT management of ARF in ICU, S4:106
- Critically ill patients with ARF, *see* Acute renal failure, CRRT of; Intensive care unit, CRRT in
- CRP (C-reactive protein), peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients on PD, 923-927
- CRRT, *see* Continuous renal replacement therapy
- Crude rates of hospitalization for ESRD based on total admissions, USRDS 1997 ADR on, S1:147-151
- Cryoglobulinemia secondary to HCV infection, 113-115
- Crystalluria, oliguric ARF caused by nephrolithiasis and, due to indinavir therapy of AIDS, 558-560
- CsA, *see* Cyclosporine
- CT (computed tomography), renal, renal ultrasound results compared with results of, 582
- CVVH, *see* Continuous venovenous hemofiltration
- CVVHDF (continuous venovenous hemodiafiltration) for ARF, dose delivery with, S4:16
- Cyclic adenosine monophosphate, *see* cAMP
- Cycling peritoneal dialysis, *see* Continuous cycling peritoneal dialysis for ESRD
- Cyclophosphamide therapy of severe lupus nephritis, 872-878
- Cyclosporine (CsA)
chronic nephropathy induced by, Na depletion enhancing renal fibrosis and expression of TGF- β 1 and ECM proteins in, 71-81
effects of, on calcineurin expression and function, 884-886
induction therapy with, and sequential therapy with ATG, in renal transplantation, compared, 639-645
- Cyst fluid in slowly progressive PKD, lipids in, 703-709
- Cysteine (CYS), HD effects on, 489-494
- Cystic kidneys
pediatric, 2:xxxvii-xxxix
see also Polycystic kidney disease
- Cytokines
clearance of, during CVVH in trauma with MOF patients, 483-488
dialyzer reuse and formation of, 864
monocyte, biocompatible PD solutions and release of, 413-422
see also Inflammatory mediators, removal of, during CRRT and specific cytokines
- Cytomegalovirus (CMV) infection
impact of interactions between HLA-A, HLA-B, and HLA-DR loci and, on renal graft survival, 766-771
renal vasculitis with HIV infection, as manifestation of, 428-432
- Cytoplasmic antibodies, *see* Antineutrophil cytoplasmic antibodies
- Cytosolic Ca, *see* [Ca²⁺]_i
- Cytotoxicity of PD solutions, 413-422
- Dartmouth COOP Functional Health Assessment Charts, health and quality of life outcomes of dialyzed ESRD patients assessed with, 144-146, 151
- Data, ABPM, analysis and reporting for, 593-594
- Data, USRDS
acknowledgment for use of, S1:36
on CDs, S1: 27, S1: 29, S1:33-35
changes in, between 1996 ADR and 1997 ADR, S1:11
cost of, S1:36
and data collection for DMMS, S1:68
documentation on, S1:24, S1:36, S1:208
new, in 1997 ADR, S1:195-196, S1:199-201
release of, *see* Release of USRDS data
requests for, S1:27
sources of, for database, S1:196-201, S1:212; *see also* specific data sources
UNOS, S1:195, S1:197-198
see also specific data of USRDS 1997 ADR
- Data Request Review Committee (DRRC), USRDS, S1:7, S1:23

- Database, USRDS, S1:23-24
sources of data for, S1:196-201, S1:212; *see also* Data, USRDS
- DBP (diastolic blood pressure), *see* Blood pressure
- Death Notification Form, S1:107, S1:108, S1:114, S1:196, S1:202
- Degeneration of AV graft, intervention in, S3:170-171
- Delays in eligibility to Medicare ESRD program, S1:199
- Delivered continuous renal replacement therapy (CRRT) dose for ARF, S4:15-19
- Delivered hemodialysis (HD) dose, NKF-DOQI guidelines on, S2:22-34
measurement of, S2:22-31, S2:36-37
minimum, S2:32-34
optimal, S2:33-34
- Delivered peritoneal dialysis (PD) dose in DMMS, S1:73-75
see also Delivered peritoneal dialysis dose, NKF-DOQI guidelines on
- Delivered peritoneal dialysis (PD) dose, NKF-DOQI guidelines on, S2:86-92
empirical and computer modeling approaches to measurement of, S2:88-92
strategies to achieve prescribed dose, S2:93-94
in subpopulations, S2:87-88
weekly, *see* Weekly delivered peritoneal dialysis dose
- Delivery of dialysis
with reused dialyzers, 861-862
see also Delivered peritoneal dialysis dose; Delivered peritoneal dialysis dose, NKF-DOQI guidelines on
- Deoxyribonucleic acid, *see* DNA
- Department of Veterans Affairs (DVA) facilities for ESRD care, USRDS 1997 ADR on, S1:182
- Depression, self-assessment of, by ESRD patients on HD and, 208
- Development, *see* Growth and development
- Developmental methodology of NKF-DOQI guidelines, S2:6-11
evidentiary basis for, S2:6-7, S2:21, S3:142-143
and guidelines defined, S2:6, S3:142
guiding principles of, S2:6-7, S3:142
planning implementation of, S2:11, S3:147
process, S2:7-11, S3:143-147
Work Groups and, *see* Anemia Work Group, NKF-DOQI; Hemodialysis Adequacy Work Group, NKF-DOQI; Peritoneal Dialysis Adequacy Work Group, NKF-DOQI; Vascular Access Work Group, NKF-DOQI
- Diabetes mellitus (DM)
ABPM in, 596-597
and correlation of peritoneal transport kinetics with serum albumin in CAPD patients, 229-236
Cr excretion in, race and, 16-11
factors contributing to polyuria in poorly controlled, 829-835
hyperglycemia-induced AGEs and vasculopathic complications of, 253-259
non-insulin-dependent, B cell proliferation and elevated $[Ca^{2+}]_i$ in, 98-104
see also entries beginning with term: Diabetic
- Diabetic end-stage renal disease (ESRD), USRDS 1997 ADR on
on Medicare expenditures for, S1:170, S1:172
on mortality with, S1:109-111
- Diabetic end-stage renal disease (ESRD) patients on HD and/or CAPD, 741
carbamylated Hb and, 362, 364
in ESRD Core Indicators Study, 167, 168, 351
hypoalbuminemia effects in, 509
IE and, 522
internal jugular vein catheter placement in, 691
intradialytic hypotension and, 773
IV Fe therapy effects in, 815
and low-dose rHuEPO alone or in combination with androgens, 497
mental impairment and, 43, 45
minimum delivered HD dose, S2:34
mortality with, on HD and CAPD, compared, 336, 338
PET and urea kinetics in, 375, 376
and relationship between LVH, myocardial contractility, and volume overload, 782
self-assessment of HD adequacy and protein nutrition in, 516
vascular access and, 52, 526
- Diabetic nephropathy
in chronic renal insufficiency, 655
Ki-67 cell proliferation in, demonstrated by renal biopsy of, clinical findings correlated with, 87-97
see also entries beginning with terms: Diabetic end-stage renal disease
- Diagnosis
AS, prenatal DNA-based, by genetic linkage in families with Alport's syndrome, 174-179
of HSV encephalitis in renal transplant recipient with polymerase chain reaction, 423-428
primary, *see* Primary disease
see also Assessment and specific conditions and specific diagnostic techniques
- Dialysate
collections of, in PD dose measurement, S2:82, S2:121-122
see also Dialysate, HD
- Dialysate, HD
error in flow rate of, S2:61
ethanol-enriched HCO_3^- -based, for acute methanol intoxication, 568-570
modifying, to minimize hypotensive symptoms, S2:50-51
Na, BV during variation in, with similar intradialytic Na balances in chronic HD, 58-63
- Dialysis
malnutrition and initiation of, 899-906
see also Compliance with dialysis for ESRD; Dialysis dose; Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on; Dialysis-specific living will; Dialysis-unrelated deaths; Hemodialysis; Peritoneal dialysis; Withdrawal of dialysis and entries beginning with term: Interdialytic, Intradialytic
- Dialysis dose
for ARF, S4:72-79
see also Dose, PD, NKF-DOQI guidelines on; Hemodialysis dose for ESRD; Kt/V
- Dialysis membranes
adsorption by, during CRRT for ARF, S4:32-37
see also Biocompatible membranes on HD; Cellulose membranes; Dialyzers; Polysulfone membranes

- Dialysis Morbidity and Mortality Study (DMMS), USRDS
 1997 ADR on, S1:11, 14-15, S1:67-85
 by age, S1:72
 on CD, S1:35
 data collection for, S1:68
 described, S1:34
 on employment status and transportation to ESRD facilities, S1:84
 medication use data in, S1:83
 patient compliance data in, S1:78-83
 patient selection for, S1:67-68
 pre-ESRD medical care and, S1:69
 quality of life data in, S1:83-84
 RRT modality and, *see* Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on, RRT modality and
 Dialysis Morbidity and Mortality Study (DMMS), USRDS
 1997 ADR on, RRT modality and, S1:69-75
 on HD, S1: 71-73, S1:83, S1:84
 on peritoneal dialysis, S1:71-75, S1:78, S1:83, S1:84
 Dialysis prescription, *see* entries beginning with term: Prescription
 Dialysis-specific living will, factors influencing completion of, 356-360
 Dialysis-unrelated (DU) deaths in ESRD, national, USRDS
 1997 ADR on, S1:103-104
 Dialyzers, S1:63
 CRRT hemodialyzers, S4:25
see also Reused dialyzers
 Diastolic blood pressure, *see* Blood pressure
 Dietary fat intake by CRF patients, exercise training and, 187, 189
 Dietary Na (sodium) intake by CRF patients, exercise training and, 187, 189
 Dietary protein intake
 restriction of, progressive renal insufficiency and, 297-300
 vasopressin, progression of CRF and, 5:i-ii
see also Dietary protein intake of ESRD patients on HD and/or CAPD
 Dietary protein intake of ESRD patients on HD and/or CAPD, 231
 exercise training and, 187, 189
 of mentally impaired patients, 41-49
 patient assessment of, 514-520
 PCR and, 672-679
 Differential conductivity technique, HD vascular access BF measured by, 475-482
 1,25-Dihydroxycholecalciferol D₃, *see* Calcitriol
 Dilutional acidosis, as complication of right ventricular myocardial infarction, 561-567
 3-[4,5-Dimethylthiazol-2-yl]-diphenyltetra solium bromide (MTT) test of PD solutions, 417-418
 Diphosphate, guanosine, in PD fluids, 685-686
 Direct end-stage renal disease (ESRD) care, Medicare expenditures for (1991-1995), USRDS 1997 ADR on, S1:166-168
 Discontinuation of dialysis, *see* Withdrawal of dialysis
 Disk storage capacity needed for SAF use, S1:35-36
 Diuresis
 osmotic, in poorly controlled DM, factors contributing to, 829-835
see also Urinary excretion
 Diuretics in CRF, 4:i-iii
 Diverticulitis, as contraindication for PD, S2:103
 DM, *see* Diabetes mellitus
 DMMS, *see* Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on
 DNA (deoxyribonucleic acid)
 HSV, polymerase chain reaction detection of, in renal transplant recipient with HSV encephalitis, 423-428
 prenatal DNA-based AS diagnosis by genetic linkage in families with Alport's syndrome, 174-179
 Documentation on USRDS data, S1:24, S1:36, S1:208
 DOQI (Dialysis Outcomes Quality Initiative), *see* National Kidney Foundation-Dialysis Outcomes Quality Initiative
 Dose
 CsA induction therapy, 642
 dialysis, *see* Dialysis dose
 response to high IFN- β , in HCV-associated MPGN, 113-115
see also Dose, CRRT, for ARF; Dose, IV Fe; Dose, PD, NKF-DOQI guidelines on; Dose, rHuEPO, for ESRD patients; Hemodialysis dose for ESRD; Kt/V
 Dose, CRRT, for ARF
 delivered, S4:15-19
 initial prescribed, S4:7-8
 Dose, IV, Fe
 in pediatric patients, S3:208
 test dose, S3:211-212
 Dose, PD, NKF-DOQI guidelines on
 measurement of, S2:74-82, S2:122-125
see also Delivered peritoneal dialysis dose, NKF-DOQI guidelines on
 Dose, rHuEPO, for ESRD patients, S3:214, S3:216-217
 for AIDS patients, 30, 33
 effects of IV Fe supplementation on, 814-821, 907-911
 low-dose rHuEPO alone or in combination with androgens, 495-500
 Double-pool Kt/V, single-pool versus, HD dose and, S2:28-31
 Drive, CD-ROM, needed for SAF use, S1:35
 DRRC (Data Request Review Committee), USRDS, S1:7, S1:23
 Drug therapy
 ACE inhibitor, *see* Enalapril; Lisinopril
 antibiotic, *see* Prophylaxis, vascular access antibiotic and specific antibiotics
 cisapride with clarithromycin, torsades de pointes and, 437-439
 diuretic, in CRF, 4:i-iii
 with gentamicin, and polyuria in poorly controlled DM, 829-835
 hypersensitivity to, granulomatous IN and, 586-588
 IFN, *see* Interferon- α ; Interferon- β
 immunosuppressive, *see* specific immunosuppressants
 indinavir, for AIDS, oliguric ARF caused by crystalluria and nephrolithiasis due to, 558-560
 ketotifen, of eosinophilic peritonitis with CAPD, 433-436
 midodril, for intradialytic hypotension, 772-779
 of multiple myeloma, 788
 oral Kayexalate in sorbitol, combined gastric and ileocecal toxicity due to, 120-122
 D-penicillamine, for progressive renal failure associated with positive anti-myeloperoxidase ANCA in scleroderma, 279-281

- steroid, *see* Steroid(s)
see also Medications *entries beginning with terms: Recombinant human erythropoietin and specific drugs*
- Dry weight of ESRD patients on HD
 of normotensive and hypertensive patients, ultrasound measurement of IVCD to assess, 459-465
 and RRF preservation, 368, 369
- DU (dialysis-unrelated) deaths of ESRD patients, national, S1:103-104
- Dual-lumen catheters, IE in ESRD patients on HD with AVF, PTFE grafts and, compared, 521-524
- DUKE Health Profile, health and quality of life outcomes of dialyzed ESRD patients assessed with, 145-148, 151
- DUSOI, health and quality of life outcomes of dialyzed ESRD patients assessed with, 151
- DVA (Department of Veterans Affairs) facilities for ESRD care, S1:182
- EBV (Epstein-Barr virus) infection, PTLD and, 301-307, 449-454
- EC (Executive Committee), USRDS, S1:6, S1:22
- ECF, *see* Extracellular fluid
- Echocardiography of relationship between LVH, myocardial contractility, and, volume overload on HD, 780-785
- Echography, *see* Ultrasound
- ECM (extracellular matrix) proteins, Na depletion enhancing renal fibrosis, expression of TGF- β 1 and, in chronic CsA nephropathy, 71-81
- Economic Scientific Advisory Committee (E-SAC), USRDS, S1:6-7
- Economics
 of renal ultrasound, 582-583
see also Cost
- EDB (Enrollment Database) of Medicare ESRD program in USRDS 1997 ADR, S1:197
- Edema
 in CRF, diuretics for, 4:i-ii
 oncotic pressure and formation of, in hypoalbuminemic HIVAN patients with proteinuria, 822-828
- Education, *see* Training and education
- Educational materials on living kidney donation, 553
- Educational status
 and ESRD patient's view of quality of care, 796
 of mentally impaired ESRD patients on HD, 43, 45, 46
 and self-assessment of HD adequacy and protein nutrition, 516
- Effective treatment time, S2:61
- eKu/Vd, effects of variance in eKu/Vd(m) on relationship between mortality risk and, 6-8
- ELAD (extracorporeal liver-assist device) for ALF, S4:66-71
- Elderly, the, on CHD, risk factors for LVH in, 224-228
- Electron microscopy of thrombotic microangiopathy associated with IFN- α therapy of CML, 124
- Electrophoresis
 capillary, nonradiolabeled iothalamate using, to determine GFR, 646-652
 proteinuric patterns of SDS-polyacrylamide gel, in GN, 404-412
- Eligibility to Medicare ESRD program, delays in, S1:199
- ELISPOT assay of peripheral IgA-secreting cells in nontransplanted IgAN patients, 64-70
- Empirical approach
 to estimation of adequate delivered PD dose, S2:88-90
 to PD initiation, S2:88
- Employment status of ESRD patients
 DMMS data on, S1:84
 on HD or chronic PD, as factor in completing advance directives, 357
 and views on quality of care, 796
- "En bloc" renal transplantation, FSGS in pediatric, 271-274
- Enalapril
 effects of, on elevated von Willebrand factor in IgA nephropathy, 397-403
 effects of, on glomerular accumulation of ICs and mesangial matrix in IC-GN, 243-252
- Encephalitis, HSV, in renal transplant recipient, 423-428
- Endocarditis, infective, in HD patients with AVF, PTFE grafts, and dual-lumen catheters, compared, 521-524
- Endocrine glands, excess PTH effects on, 609-610
- Endometrial ablation, hysteroscopic, hyponatremia following, 717-719
- Endothelial cells, PAF in, S4:58-60
 role of PAF in adhesion to endothelial cells, S4:59-60
 synthesis of, S4:58-59
- Endothelin (ET), level of ANPs and, following radiocontrast exposure, 82-86
- Endothelium
 dysfunctional, von Willebrand factor as marker of, 397-403
 extracorporeal circuit and, S4:22
see also Endothelial cells, PAF in; Endothelin
- Endotoxin, PBMCs exposed to PD fluids stimulated by, TNF- α production by, 683-684
- End-stage renal disease (ESRD)
 and mushroom poisoning with *Cortinarius orellanus*, 282-286
 ultrasound screening for carcinoma of kidneys in, 580
see also Chronic renal failure; Continuous ambulatory peritoneal dialysis for ESRD; End-stage renal disease Core Indicators Study; Hemodialysis for ESRD; Peritoneal dialysis for ESRD; Renal transplantation; United States Renal Data System, 1997 ADR of and *entries beginning with terms: Pediatric end-stage renal disease*
- End-stage renal disease (ESRD) Core Indicators Study (CIS)
 limitations of, 349-355
 on PD, 165-173
- Enrollment Database (EDB) of Medicare ESRD program in USRDS 1997 ADR, S1:197
- Enterovesical fistula presenting as normal anion gap metabolic acidosis, 131-133
- Enzymology of NOS, 313-315
- Eosinophilic peritonitis with CAPD, ketotifen therapy of, 433-436
- Epithelial cells, proliferation of, in slowly progressive PKD, 703-709
- EPO, *see* Erythropoietin
- Epstein-Barr virus (EBV) infection, PTLD and, 301-307, 449-454
- Equipment needed to use SAFs, S1:35-36
- Erythrocytes, *see entries beginning with terms: Red blood cell*
- Erythropoietin (EPO)
 deficiency of, and anemia in CRF, S3:198

- see also Clinical practice guidelines, NKF-DOQI, on treatment of CRF anemia and entries beginning with terms: Recombinant human erythropoietin
- E-SAC (Economic Scientific Advisory Committee), USRDS, S1:6-7
- ESRD, *see* End-stage renal disease
- Estimated Medicare expenditures for ESRD, *see* Medicare expenditures for ESRD, USRDS 1997 ADR on
- ET (endothelin), level of ANPs and, following radio contrast exposure, 82-86
- Ethanol-enriched HCO₃ (bicarbonate)-based dialysate hemodialysis (HD) for acute methanol intoxication, 568-570
- Ethical issues surrounding living kidney donation, need to respond to, 555
- Ethnicity, *see* Race and ethnicity
- Etiology
of nephrotic syndrome, 621-631
see also specific conditions
- Evaluation, *see* Assessment
- Evidence-based guidelines, NKF-DOQI, S2:6-7, S2:21, S3:153
- Executive Committee (EC), USRDS, S1:6, S1:22
- Executive summary of USRDS 1997 ADR, S1:10-20
- Exercise training in PDCRF, effects of, on cardiorespiratory endurance, hypertension, and renal function, 180-192
- Expected remaining years of life of ESRD patients, USRDS 1997 ADR on, S1:86, S1:97-100, S1:211
- Expenditures, *see* Cost
- Experience needed for CD-ROM operation, S1:36
- Expertise, nursing, and CRRT in ICU, S4:106, S4:113-115
- Extracellular fluid (ECF)
role of overload of, in HD-related hypertension, 459-465
volume of, and dilutional acidosis, 561-567
- Extracellular matrix (ECM) proteins, Na depletion enhancing renal fibrosis, expression of TGF- β 1 and, in chronic CsA nephropathy, 71-81
- Extracorporeal adsorbent-based strategies in sepsis, S4:44-56
- Extracorporeal blood lines, S4:24
- Extracorporeal blood pumps, S4:24-25
- Extracorporeal circuit in CRRT, effects of, on coagulation system in ARF patients, S4:20-27
- Extracorporeal liver-assist device (ELAD) for ALF, S4:66-71
- Facilities for ESRD care
capitation impact on, 542-548
see also Facilities for ESRD care, USRDS 1997 ADR on
- Facilities for ESRD care, USRDS 1997 ADR on, S1:178-186
in database, S1:198
on dialyzer reuse in, S1:182-185
DMMS data on transportation used to travel to, S1:84
on DVA facilities, S1:182
on number and location of, S1:178, S1:179
on number of patients and types of, S1:178-181
on number of treatments administered, S1:181
SHRs by, S1:26-27, S1:154-157
SMRs by, S1:26-27, S1:100-103, S1:156-157
summary of, S1:19
- Failure rate of AVF, S3:181, S3:182
- Familial Alport's syndrome (AS), prenatal AS dialysis by genetic linkage in, 174-179
- Familial focal segmental glomerulosclerosis (FSGS), 265-270
- Fasting blood glucose in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Fat-free, edema-free body mass, determining, in PD patient nutritional status assessment, S2:84
- FcaR mRNA (messenger ribonucleic acid), expression of glomerular, and disease activity in IgA nephropathy, 389-396
- Fe (iron)
in chronic renal insufficiency, Al kitchen utensils effects on levels of, 653-658
see also Fe deficiency in ESRD patients on HD, NKF-DOQI guidelines on intervention in; Recombinant human erythropoietin for ESRD patients on HD and/or CAPD, Fe deficiency and
- Fe (iron) deficiency in ESRD patients on HD, NKF-DOQI guidelines on intervention in, S3:202-212
Fe needs of patients and, S3:204
on Fe status assessment, S3:202-206
on Fe supplementation, *see* Supplementation, Fe, in ESRD patients on HD
on target Fe level, S3:202-203
- Federal regulation of reused dialyzers, 866-867
- Ferritin
plasma, in PD patients, hypoalbuminemia and, 924, 925
see also Ferritin, rHuEPO effects on; Serum ferritin
- Ferritin, rHuEPO effects on, 916, 918, 920
evaluation of RBC ferritin and reticulocyte measurements in monitoring response to IV Fe therapy and its effects on rHuEPO requirements, 814-821
of low-dose rHuEPO alone or combined with androgens, 497, 499
on serum ferritin in Fe-deficient patients, 534, 535, 537
- FHF (fulminant hepatic failure), ELAD for, S4:66-71
- Fibrillary glomerulonephritis (GN), NS and, 624
- Fibrinolysis, extracorporeal circuit and, S4:21-22
- Fibrosis, renal, Na depletion enhancing expression of TGF- β 1 and ECM proteins and, in chronic CsA nephropathy, 71-81
- Filariasis, *Loa loa*, secondary collapsing FSGS associated with, 836-839
- Final NKF-DOQI guidelines, issuing, S2:11, S3:147
- First service date (FSD) of ESRD care, S1:198, S1:199
- First-transplantation rate, S1:196, S1:209
- Fistula
AV, *see* Arteriovenous fistula and graft in HD
enterovesical, presenting as normal anion gap metabolic acidosis, 131-133
- FK-506, effects of, on calcineurin expression and function, 884-886
- Flow rate of HD dialysate, error in, S2:61
- Fluid
interdialytic load of, effects of, on BP, 466-474
see also Extracellular fluid; Fluid therapy
- Fluid therapy of dilutional acidosis in right ventricular myocardial infarction, 565-566
- Focal segmental glomerulosclerosis (FSGS), 265-274, 621-638
and "en bloc" pediatric renal transplantation for ESRD, 271-274
familial, 265-270

- NS and, 621-631
 primary, mesangial phenotypic changes associated with mesangial cell lesions in, 632-638
 secondary collapsing, associated with *Loa loa* filariasis, 836-839
 urinary PAs in characterization of proteinuria in, 404-412
 Folate, effects of low-dose rHuEPO alone or combined with androgens on, 497
 Folic acid deficiency, and inadequate response to rHuEPO, S3:219
 Follow-up
 on delivered PD dose, S2:90
 lost to follow-up methodology, S1:196, S1:201-202
 Foreign bodies, intra-abdominal, as contraindications to PD, S2:102
 Form 2728 (Medical Evidence Form), S1:195, S1:197
 Formal policies on living kidney donation, 553
 Formats, SAF, S1:35
 Formulation of NKF-DOQI guidelines, S2:10, S3:146
 Frequency of delivered HD dose measurement, S2:36-37
 FSD (first service date) of ESRD care, S1:198, S1:199
 FSGS, *see* Focal segmental glomerulosclerosis
 Fulminant hepatic failure (FHF), ELAD for, S4:66-71
 Function/structure correlation, NOS, 317-318
 Functional Fe (iron) deficiency, reticulocyte Hb content predicting, 912-922
 Functional health status, self-assessment of, on SF-36 by ESRD patients on HD, as predictor of survival, hospitalization, HD compliance, 204-212
 Gamma (γ)-globulin, bovine, experimental GN induced by, 243-252
 Gastric toxicity, combined ileocecal and, due to oral Kayexalate in sorbitol therapy, 120-122
 GCKD (glomerular cystic kidney disease) in children, 2:xxxviii-xxxix
 GDP (guanosine diphosphate) in PD fluids, 685-686
 Gender, *see* Sex
 Gene
 knockout, *see* Knockout gene subjects
 polymorphism of TCR C- α chain, IgAN associated with, 260-264
see also DNA; mRNA and entries beginning with terms: Autosomal, Gene, Genetic, Heritable
 Gene switching, 1:xlvi
 Gene therapy of renal disease, 1:xliv-xlviii
 cautionary words on, 1:xlvi-xlviii
 gene switching and, 1:xlvi
 gene transfer to kidney and, 1:xliv-xlv
 genetic manipulation and, 1:xliv-xlv
 targets of, 1:xlvi-xlvii
 Gene transfer to kidney, 1:xliv-xlv
 General factors affecting care delivery in ICU, S4:105
 Genetic diseases, renal, as targets of gene therapy, 1:xlvi-xlvii
 Genetic linkage in families with Alport's syndrome, prenatal DNA-based diagnosis of AS by, 174-179
 Genetic manipulation, 1:xliv-xlv
 Gentamicin, and polyuria in poorly controlled DM, 829-835
 Geography
 geographic patterns in incidence and prevalence of treated ESRD, USRDS 1997 ADR on, S1:53
 SHRs for ESRD by region, S1:153-154
see also Location
 Germicides, toxicity to dialyzers of prolonged exposure to, 865-866
 GF(s), *see* Growth factor(s)
 GFR, *see* Glomerular filtration rate
 Globulin
 anti-thymocyte, CsA induction therapy and sequential therapy with, in renal transplantation, compared, 639-645
 bovine gamma-, experimental GN induced by, 243-252
 role of, in oncotic pressure and edema formation in hypoalbuminemic HIVAN patients, 822-828
see also β_2 -Microglobulin
 Glomerular cystic kidney disease (GCKD) in children, 2:xxxviii-xxxix
 Glomerular Fc α R mRNA (messenger ribonucleic acid), expression of, and disease activity in IgA nephropathy, 389-396
 Glomerular filtration rate (GFR)
 and initiation of dialysis, 902
 nonradiolabeled iohalamate using capillary electrophoresis to determine, 646-652
 in poorly controlled DM, 831
 Glomerular inflammation
 genetic manipulation of, 1:xliv-xlvii
 as target of gene therapy, 1:xlvi
 Glomerular macrophages, infiltration of, in primary FSGS, 634-635
 Glomerular morphometry in IC-GN, 247-250
 Glomerulonephritis (GN)
 progressive postinfectious, with multiple tubuloreticular inclusions in HIV-negative patient, 725-728
 proteinuria in, urinary PAs in characterization of, 404-412
see also Glomerulonephritis, as primary disease in ESRD and specific types of glomerulonephritis
 Glomerulonephritis (GN), as primary disease in ESRD
 chronic, 691
 in ESRD Core Indicators Study, 167-169, 351
 hypoalbuminemia effects and, 509
 IV Fe therapy effects and, 815
 and low-dose rHuEPO alone or in combination with androgens, 497
 in mentally impaired patients, 43, 45
 mortality on HD and CAPD and, 336, 338
 and relationship between LVH, myocardial contractility, and volume overload, 782
 and self-assessment of HD adequacy and protein nutrition, 516
 vascular access care pathway and, 526
see also Primary disease in ESRD, USRDS 1997 ADR on
 Glomerulopathy
 immunotactoid, renal biopsy of, and prednisolone for, 160-163
 NO role in, 323-324
 UG role in, knockout gene subjects as model of, 720-724
see also specific glomerular conditions
 Glomerulosclerosis (GS)
 focal segmental, *see* Focal segmental glomerulosclerosis
 genetic manipulation of, 1:xliv-xlv
 Glucose
 dialysate, in PD measurement, S2:120
 in DM, *see* Glucose in DM
 heat sterilization of, and effects of two-chambered HCO₃

- lactate-buffered PD fluids on PBMCs and PMNLs, 680-689
- in IgA nephropathy, enalapril effects on, 401
- in PD solutions, 415
- in PDCRF patients, exercise training effects on, 186
- vasculopathic complications of DM and hyperglycemia-induced AGEs, 253-259
- Glucose in DM
- fasting blood glucose in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- plasma glucose in poorly controlled DM, polyuria and, 830
- Glutathione (GSH), levels of whole blood and RBC, in HD and PD patients, 489-494
- Glycemic control of DM, poor, factors contributing to polyuria with, 829-835
- Glycosylated end products, hyperglycemia-induced advanced, vasculopathic complications of DM and, 253-259
- GMP (guanosine monophosphate), cyclic, in HD patients, RRF preservation and, 369
- GN, *see* Glomerulonephritis
- Goodpasture's syndrome (anti-glomerular basement membrane disease) in infant, 710-712
- Graft(s), *see* Arteriovenous fistula and graft in HD and entries beginning with term: Graft
- Graft function, delayed, with CsA induction and ATG sequential therapy, compared, 642
- Graft loss, cadaveric, USRDS 1997 ADR on, S1:121-126
- Graft rejection, acute, renal graft with lymphocytic infiltrate as PTLD or, 449-454
- Graft survival
- AV, in HD, 50-57
- impact of interactions between CMV, HLA-A, HLA-B, and HLA-DR loci on, 766-771
- see also* Graft survival, USRDS 1997 ADR on
- Graft survival, USRDS 1997 ADR on
- in adults, S1:119-121
- analytical methods to determine, S1:211
- pediatric, S1:141
- Granulomatous interstitial nephritis (IN), drug hypersensitivity, infections, sarcoidosis and, 586-588
- Gravitational forces, bone metabolism and, 6:i-iii
- Growth and development
- of ESRD children, *see* Growth and development of ESRD children
- parathyroid gland, 19-NOR-1,25-(OH)₂D₃ suppresses serum PTH and, in uremia, without intestinal vitamin D receptor elevation, 105-112
- renal, genetic manipulation of, 1:xlvi
- Growth and development of ESRD children
- on CAPD, CCPD, HD, or with renal transplantation, compared, 193-204
- on PD, S2:97-98
- USRDS Pediatric Growth and Development Study, S1:33
- Growth factor(s), (GF)
- in ARF, S4:93
- Na depletion enhancing renal fibrosis, expression of ECM proteins and TGF-β1 in chronic CsA nephropathy, 71-81
- nonselective, S4:45-47
- selective, S4:47-52
- specific, S4:53
- GS, *see* Glomerulosclerosis
- GSH (glutathione), levels of whole blood and RBC, in HD and PD patients, 489-494
- Guiding principles, NKF-DOQI, S2:6, S3:142
- Guanosine diphosphate (GDP) in PD fluids, 685-686
- Guanosine monophosphate (GMP), cyclic, in HD patients, RRF preservation and, 369
- Hb (hemoglobin)
- in IgA nephropathy, enalapril effects on, 401
- normal values of, S3:196
- and relationship between LVH, myocardial contractility, and volume overload on HD, 782
- in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
- see also* Hb in ESRD
- Hb (hemoglobin) in ESRD
- in CAPD patients, nutritional status and, 231
- carbamyated, *see* Carbamyated Hb in ESRD
- in HD patients with LVH, effects of lisinopril therapy and, 661
- predialysis, exercise training effects on, 186
- see also* Hb in ESRD, rHuEPO therapy, Fe deficiency and
- Hb (hemoglobin) in ESRD, rHuEPO therapy, Fe deficiency and, 534, 535, 537
- IV Fe therapy effects on requirements for rHuEPO and, 818
- NKF-DOQI guidelines on, S3:199-200, S3:215-216, S3:224-225
- reticulocyte Hb predicting functional Fe deficiency, 912-922
- HbA_{1c} (hemoglobin A_{1c}) in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- HCFA, *see* Health Care Financing Administration
- HCO₃ (bicarbonate)
- concentration of, in dilutional acidosis, 561-567
- in metabolic acidosis, 132
- in PD solutions, 415
- plasma, in DM-related polyuria, 830
- see also* HCO₃ in HD; HCO₃ lactate-buffered peritoneal dialysis fluids
- HCO₃ (bicarbonate) in HD
- carbamyated Hb and, 362, 364
- HCO₃-based ethanol-enriched dialysate HD for acute methanol intoxication, 568-570
- in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 440-444
- HCO₃ (bicarbonate) lactate-buffered peritoneal dialysis (PD) fluids, effects of two-chambered, on PBMCs and PMNLs, 680-689
- Hct, *see* Hematocrit
- HCV (hepatitis C virus) infection, response of MPGN associated with, to high-dose IFN-α, 113-115
- HD, *see* Hemodialysis
- HDL (high-density lipoproteins) in PDCRF patients, exercise training effects on, 186
- HDL-C, *see* High-density lipoprotein cholesterol
- Health Care Financing Administration (HCFA), S1:5
- see also* specific aspects of USRDS 1997 ADR
- Health and quality of life (QOL) outcomes of dialyzed ESRD patients, assessment of, 140-159
- with CHOICE and DUSOI, 151

- with Dartmouth COOP Functional Health Assessment Charts, 144-146, 151
- with DUKE Health Profile, 145-148, 151
- with HEMO study, 150-151
- instruments evaluated, 143-144
- with KDQOL Instrument, 145-146, 149-152
- with Kidney Disease Questionnaire, 150
- with MOS SF-36 Health Survey, 145-146, 148-149, 151
- with special USRDS study, 150
- Health status, self-assessment of functional, on SF-36 by ESRD patients on HD, as predictor of survival, hospitalization, and HD compliance, 204-212
- Heat sterilization of glucose, and effects of two-chambered HCO₃ lactate-buffered PD fluids on PBMCs and PMNLs, 680-689
- Height
 - of NIDDM patients, elevated cytosolic Ca and B lymphocyte proliferation and, 99
 - see also* Height of ESRD patients
- Height of ESRD patients
 - carbamyated Hb and, 362
 - of ESRD children, 195, 199-200
 - on HD, RRF preservation and, 368
 - predialysis, 181
- Hemadsorption for sepsis, S4:45-53
 - nonselective, S4:45-47
 - selective, S4:47-52
 - specific, S4:53
- Hematocrit (Hct)
 - in dilutional acidosis with right ventricular myocardial infarction, 562, 566
- normal values of, S3:196
 - reversibility of carbamyated Hb in ARF and, 37
 - see also* Hematocrit in ESRD, rHuEPO therapy and; Hematocrit in ESRD on HD, PD, or CAPD
- Hematocrit (Hct) in ESRD, rHuEPO therapy and, 916, 918, 920
 - in AIDS patients, 28-35
 - NKF-DOQI guidelines on, S3:200-201, S3:215-216, S3:224-225
- Hematocrit (Hct) in ESRD on HD, PD, or CAPD
 - in elderly CHD patients, LVH and, 225, 226
 - in ESRD Indicators Study report on, 165-173
 - and hypoalbuminemia effects, 510
 - and intradialytic hypotension, 773
 - in mentally impaired patients, 47
 - in PD patients, S2:99
 - predialysis, exercise training effects on, 186
 - reversibility of carbamyated Hb in, 37
 - rHuEPO therapy and, *see* Hematocrit in ESRD, rHuEPO therapy and
 - RRF preservation and, 371
- Hematology consultation for rHuEPO-resistant patients, S3:220
- Hematopoietic system, excess PTH effects on, 613
- Hematuria
 - in IgAN, *see* Hematuria in IgAN
 - and Ki-67 cell proliferation in renal disease, 88, 92
- Hematuria in IgAN
 - glomerular FcαR expression and disease activity and, 389-396
 - IL-1 receptor antagonist effects on, 696
- HEMO study of dialyzed ESRD patients
 - of HD dose and outcome of ESRD, 13-14
 - health and quality of life outcomes assessed with, 150-151
- Hemodialysis (HD)
 - ethanol-enriched HCO₃-based dialysate, for acute methanol intoxication, 568-570
 - intermittent, *see* Intermittent hemodialysis for ARF, CRRT
 - compared with
 - for multiple myeloma-induced renal failure, 786-792
 - see also* Hemodialysis for ESRD; Vascular access, HD
- Hemodialysis Adequacy Work Group, NKF-DOQI
 - leadership and organizational structure of, S2:7
 - members of, S2:7, S2:12-13, S2:64-66
- Hemodialysis (HD) dose for ESRD
 - in ESRD Core Indicators Study, 351
 - patient assessment of protein nutrition and adequacy of, 514-520; *see also* Kt/V, HD, PD, and/or CAPD for ESRD and
 - USRDS 1997 ADR on, S1:61-62
 - see also* Hemodialysis dose for ESRD, mortality and; Hemodialysis dose for ESRD, NKF-DOQI guidelines on
- Hemodialysis (HD) dose for ESRD, mortality and, 1-15
 - definitions of Kt/V and, 3-4
 - HEMO study on, 13-14
 - infective endocarditis and, 521-524
 - mortality/dose data analyzed, 8-13
 - mortality risk and, *see* Risk of mortality in ESRD patients on HD
- Hemodialysis (HD) dose for ESRD, NKF-DOQI guidelines
 - on
 - on adequacy of, S2:19
 - on nutrition and, S2:21
 - prescribed, S2:34-35
 - troubleshooting, S2:46-48, S2:59-62
 - see also* Delivered hemodialysis dose, NKF-DOQI guidelines on
- Hemodialysis (HD) for ESRD
 - autonomic neuropathy and predisposition to arrhythmias on, 219-223
 - biocompatible membranes and preservation of RRF with, 366-373
 - BP on, *see* Blood pressure in ESRD patients on HD and/or CAPD
 - of burn patients treated with SSD cream, elimination of silver in, 287-290
 - carbamyated Hb with, 361-365
 - chronic, *see* Chronic hemodialysis for ESRD
 - completion of advance directives by patients on, factors influencing, 356-360
 - effects of prolonged therapy with lisinopril on LVH in patients on, 659-664
 - health and quality of life outcomes with, *see* Health and quality of life outcomes of dialyzed ESRD patients, assessment of
 - hypertension and, *see* Hypertension in ESRD patients on HD and/or CAPD
 - hypocalcemic tetany and metabolic alkalosis in, 440-444
 - hypotension on, *see* Hypotension in ESRD patients on HD
 - impact of capitation on cost of, 542-548
 - IVCD on, *see* Inferior vena cava diameter in ESRD patients on HD
 - LBM and PCR and, 672-679

- LVH and, *see* Left ventricular hypertrophy in HD patients mortality with, *see* Mortality, ESRD, on HD patient survival with, *see* Patient survival with ESRD on HD and/or PD patient's view of quality of, 793-801 plasma NPY in, 23-27 prevalence, recognition, and implications of mental impairment in patients on, 41-49 vascular access for, *see* Vascular access, HD whole blood and RBC GSH levels on, 489-494 *see also* Hemodialysis dose for ESRD; Hemodialysis for ESRD, NKF-DOQI guidelines on; Hemodialysis for ESRD, USRDS 1997 ADR on; Pediatric end-stage renal disease, HD for and *entries beginning with terms*: Recombinant human erythropoietin
- Hemodialysis (HD) for ESRD, NKF-DOQI guidelines on indications for switching from PD to, S2:103-104 on initiation of, S2:20-21 *see also* Clinical practice guidelines, NKF-DOQI, on HD and PD adequacy; Hemodialysis dose for ESRD, NKF-DOQI guidelines on
- Hemodialysis (HD) for ESRD, USRDS 1997 ADR on in DMMS, S1:71-73, S1:83, S1:84 on dose of, S1:61-62 by facilities, S1:182 on hospitalization, S1:208-209 international, S1:188-190 on Medicare expenditures for, S1:160-163 on membranes used in, S1:63 on mortality with, S1:110, S1:112-114, S1:208-209 as option, S1:55 on patient survival with, S1:210 *see also* Vascular access, HD, USRDS 1997 ADR on
- Hemodynamics, *see* Blood flow; Blood pressure; Renal hemodynamics
- Hemofilter/hemodialyzer, CRRT, S4:25
- Hemofiltration (HF) plasma exchange compared with, in silver accumulation in burn MD patients treated with SSD cream, 287-290 *see also* Continuous renal replacement therapy
- Hemoglobin, *see entries beginning with acronym*: Hb
- Hemoglobinopathies, and inadequate response to rHuEPO, S3:219
- Hemolysis, and inadequate response to rHuEPO, S3:219
- Hemolytic uremic syndrome (HUS), adults with autosomal recessive inheritance of, renal transplantation in, 760-765
- Hemoperfusion (HP) for sepsis, S4:45-52 activated charcoal, S4:45-47 PMX-B-immobilized polystyrene-derivative fiber, S4:47-52
- Heparin, and adverse effects of rHuEPO therapy, S3:223
- Hepatitis C virus (HCV) infection, response of MPGN associated with, to high-dose IFN- α , 113-115
- Hepatocytes, primary, needed for ELAD in ALF, S4:67-68
- Heritable malformation syndromes associated with GCKD, 2:xxxviii, 2:xxxix
- Herpes simplex virus (HSV) encephalitis in renal transplant recipient, 423-428
- Heterogeneity, NOS structural, 315-317
- HF, *see* Hemofiltration
- High-density lipoprotein(s) (HDL) in PDCRF patients, exercise training effects on, 186
- High-density lipoprotein cholesterol (HDL-C) hypoalbuminemia effects on, in ESRD patients on CAPD, 509, 510 in IgA nephropathy, enalapril effects on, 401 in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99 in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
- High-dose interferon- β (IFN- β), response to, in HCV infection-associated MPGN, 113-115
- High flux dialysis for ARF, continuous dose delivery with, S4:16-17
- High volume hemofiltration (HF) for ARF, dose delivery with, S4:17-18
- Histology, *see* Renal biopsy; Renal histology
- HIV (human immunodeficiency virus) infection progressive postinfectious GN with multiple tubuloreticular inclusions in patient negative for, 725-728 renal vasculitis with, as manifestation of CMV infection, 428-432 *see also* Acquired immunodeficiency syndrome; HIVAN
- HIVAN (human immunodeficiency virus-associated nephropathy), 741, 773 with hypoalbuminemia and proteinuria, oncotic pressure and edema formation in, 822-828 renal function and proteinuria in, prednisone effects on, 156-159
- HLA-A locus, impact of interactions between CMV infection, HLA-B, and HLA-DR and, on renal graft survival, 766-771
- HLA-B locus, impact of interactions between CMV infection, HLA-A, and HLA-DR and, on renal graft survival, 766-771
- HLA-DR locus, impact of interactions between CMV infection, HLA-A, and HLA-B and, on renal graft survival, 766-771
- Hospitalization for ESRD as factor in completion of advance directives, 357 impact of capitation on cost of, 542-548 of PD patients, S2:96-98 self-assessment of functional health status on SF-36 by ESRD patients on HD as predictor of, 204-212 for surgery of HD vascular access, collaborative care pathway and, 525-531 *see also* Hospitalization for ESRD, USRDS 1997 ADR on
- Hospitalization for ESRD, USRDS 1997 ADR on, S1:34, S1:145-159 analytical methods to determine, S1:206-209 on crude rates of hospitalization based on total admissions, S1:147-151 SHR and, *see* Standard hospitalization ratio summary of, S1:17-18 trends in, S1:146-147
- HP, *see* Hemoperfusion for sepsis
- HSV (herpes simplex virus) encephalitis in renal transplant recipient, 423-428
- HTN, *see* Hypertension
- Human erythropoietin, *see* Erythropoietin
- Human immunodeficiency virus, *see* HIV infection
- Human studies of space flight effects on bone metabolism, 6:ii-iii
- HUS (hemolytic uremic syndrome), adults with autosomal

- recessive inheritance of, renal transplantation in, 760-765
- Hydraulic compression test during HD, S2:62-63
- Hypercalcemia
 - granulomatous IN and, 586-588
 - membrane types and episodes of, RRF preservation and, 370
- Hyperchloremic acidosis, enterovesical fistula presenting as, 131-133
- Hyperglycemia, AGEs induced by, vasculopathic complications of DM and, 253-259
- Hyperkalemia
 - cyclosporine and FK-506-induced, 884-885
 - and rHuEPO therapy, S3:223
- Hyperparathyroidism, severe secondary, parathyroidectomy for, in CRF patients on HD, hypocalcemic tetany and metabolic alkalosis and, 440-444
- Hypersensitivity
 - to allergens, and eosinophilic peritonitis with CAPD, 433-436
 - drug, granulomatous IE and, 586-588
- Hypertension (HTN)
 - in chronic renal insufficiency, 655
 - excess PTH effects on, 611-612
 - exercise training effects on cardiorespiratory endurance, renal function and, in PDCRF, 180-192
 - and Ki-67 cell proliferation in renal disease, 88
 - salt-sensitive, role of NO in, 322-323
 - white-coat, ABPM, 596
 - see also Hypertension in ESRD
- Hypertension (HTN) in ESRD
 - indications for diuretics to treat, 4:i-iii
 - see also Chronic renal failure, ABPM and hypertension in; Hypertension in ESRD patients on HD and/or CAPD
- Hypertension (HTN) in ESRD patients on HD and/or CAPD, 577-578, 741
 - carbamylated Hb and, 361
 - in ESRD Core Indicators Study, 167-169, 351
 - and hypoalbuminemia effects on CAPD patients, 509
 - internal jugular vein catheter placement and, 691
 - and low-dose rHuEPO alone or in combination with androgens, 497
 - in mentally impaired patients, 43, 45
 - rHuEPO therapy and, S3:222
 - and self-assessment of HD adequacy and protein nutrition, 516
 - and ultrasound measurement of IVCD to assess dry weight, 459-465
 - vascular access care pathway and, 526
 - see also Primary disease in ESRD, USRDS 1997 ADR on
- Hypertriglyceridemia, severe, as indication for switching from PD to HD, S2:104
- Hypertrophy, left ventricular, see Left ventricular hypertrophy in HD patients
- Hypervolemia, effects of, on interdialytic hemodynamics and BP in HD patients, 466-474
- Hypoalbuminemia in ESRD patients
 - on CAPD, effects of, on serum Lp(a), 507-513
 - HIVAN patients with proteinuria and, oncotic pressure and edema formation in, 822-828
 - on PD, acute-phase proteins and dialysate albumin loss and, 923-927
- Hypocalcemic tetany, metabolic alkalosis and, in CRF patient on HD, 440-444
- Hyponatremia following hysteroscopy, 717-719
- Hypophosphatemia, spurious, in multiple myeloma patient, 571-575
- Hypotension in ESRD patients on HD
 - midodrine for, 772-779
 - symptoms of, strategies to minimize, S2:50-51
- Hysteroscopy, hyponatremia following, 717-719
- ICAMs (intercellular adhesion molecules) in ARF, S4:92
- IC-GN, see Immune complex-glomerulonephritis
- ICU, see Intensive care unit, CRRT in
- IDDM, see Insulin-dependent diabetes mellitus
- IHD, see Intermittent hemodialysis for ARF, CRRT compared with
- Idiopathic focal segmental glomerulosclerosis (FSGS), 265-270
- IE (infective endocarditis) on HD with AVF, PTFE grafts, and dual-lumen catheters, compared, 521-524
- IFN, see Interferon- α ; Interferon- β
- IgA (immunoglobulin A) nephropathy (IgAN; Berger's disease), 389-412
 - albumin in, see Albumin in IgAN
 - association of, with TCR C- α chain gene polymorphism, 260-264
 - enalapril effects on elevated von Willebrand factor in, 397-403
 - glomerular Fc α R mRNA expression and disease activity in, 389-396
 - IL-1 receptor antagonist modulating progression of, 693-702
 - Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
 - NS and, 621-631
 - peripheral IgA-secreting cells in nontransplanted patients with, 64-70
- IgG (immunoglobulin G), interference of abnormal, and spurious hypophosphatemia in multiple myeloma patient, 571-575
- IL, see entries beginning with term: Interleukin
- Ileocecal toxicity, combined gastric, due to oral Kayexalate in sorbitol therapy, 120-122
- Immobilization, bone loss due to, in space flights, 6:i
- Immune complex-glomerulonephritis (IC-GN)
 - enalapril effects on glomerular accumulation of mesangial matrix and ICs in, 243-252
 - following onset of IDDM in child, 713-716
- Immune system, excess PTH effects on, 612-613
- Immunofluorescence of thrombotic microangiopathy associated with IFN- α therapy of CML, 124
- Immunoglobulin, see entries beginning with acronym: Ig
- Immunohistochemistry
 - of chronic CsA nephropathy, 76-77
 - IgA nephropathy, glomerular Fc α R expression and, 393-394
- Immunotactoid (IT) glomerulopathy, renal biopsy of, and prednisolone for, 160-163
- Implementation
 - of NKF-DOQI guidelines, planning, S2:11, S3:147
 - of quality survey, experience of ESRD networks in, 123-130
- IN, see Interstitial nephritis

- Incidence
 of urinary PAs in GN, 406-407
see also Incidence of ESRD, USRDS 1997 ADR on
- Incidence of ESRD, USRDS 1997 ADR on
 increase in, compared with previous reports, S1:11
see also Incidence and prevalence of treated ESRD, USRDS 1997 ADR on; Incidence of treated ESRD, USRDS 1997 ADR on
- Incidence and prevalence of treated ESRD, USRDS 1997 ADR on, S1:40-53
 international, S1:187-188
 interpreting, S1:43-47
 measuring, S1:41-43, S1:202-204
 and medical coverage for ESRD, S1:40-41
 overall, S1:47-49
 by patient characteristics, S1:41-45, S1:49-53
 of pediatric ESRD, S1:128-130, S1:132-134
- Incidence of treated ESRD, USRDS 1997 ADR on, S1:12, S1:14
 by primary disease, S1:41, S1:51-52
see also Incidence and prevalence of treated ESRD, USRDS 1997 ADR on
- Income, self-assessment of HD adequacy and protein nutrition and, 516
- Indications
 for diuretics to treat hypertension of CRF, 4:i
 for large-bore central venous catheters, 803
 for PD, S2:101-104
see also specific conditions
- Indinavir for AIDS, oliguric ARF caused by crystalluria and nephrolithiasis due to, 558-560
- Induction therapy with CsA in renal transplantation, sequential therapy with ATG compared with, 639-645
- Infant with anti-glomerular basement membrane disease, 710-712
- Infarction, *see* Myocardial infarction; Renal infarction
- Infections
 granulomatous IN and, 586-588
 leptospirosis, ARF associated with, 840-845
Loa loa filariasis, secondary collapsing FSGS associated with, 836-839
 mortality due to, among ESRD patients, USRDS 1997 ADR on, S1:110
 with reused dialyzers, 863-864
see also Infections, vascular access; Sepsis and specific infections; for example: Hepatitis C virus infection, HIV infection
- Infections, vascular access
 postoperative, preoperative vancomycin prophylaxis of, 343-348
see also Infections, vascular access, NKF-DOQI guidelines on
- Infections, vascular access, NKF-DOQI guidelines on
 management of, S3:170-171, S3:176
 prevention of, S3:167-169
 quality of care standards and, S3:181
- Infective endocarditis (IE) on HD with AVF, PTFE grafts, and dual-lumen catheters, compared, 521-524
- Inferior vena cava diameter (IVCD) in ESRD patients on HD RRF preservation and, 369
 ultrasound measurement of, to determine dry weight in normotensive and hypertensive patients, 459-465
- Infiltrating leukocyte activation, bioincompatible membranes in ARF and, S4:91-92
- Inflammatory bowel disease, as contraindication for PD, S2:102
- Inflammatory mediators, removal of, during CRRT, S4:34-35
 in sepsis, S4:38-43
- Initial recombinant human erythropoietin (rHuEPO) administration in ESRD patients, S3:213-214
- Initiation
 of anemia work-up in CRF, S3:196-198
see also Initiation of dialysis
- Initiation of dialysis
 of HD, timing of, S2:20-21
 nutritional status and earlier, 899-906
see also Initiation of PD, NKF-DOQI guidelines on
- Initiation of PD, NKF-DOQI guidelines on, S2:70-73, S2:109-118
 empirical approach to, S2:88, S2:89
- Injury, *see* Trauma and injury
- Inpatient vascular access surgery, average charges for, 528
- Inservice training programs on CRRT in ICU, S4:112-113
- Institution-specific factors affecting care delivery in ICU, S4:105-106
- Insulin-dependent diabetes mellitus (IDDM; type I diabetes mellitus)
 in child, IC-GN following onset of, 713-716
see also Diabetes mellitus
- Intensive care unit (ICU), CRRT in
 credentialing for, S4:115-116
 CRRT management, S4:113-115; *see also* Intensive care unit, management of CRRT of ARF in
 training and education for, S4:112-113
- Intensive care unit (ICU), management of CRRT of ARF in viewpoints on, S4:105-111
see also Acute renal failure, CRRT of
- Intensivist's viewpoint on CRRT management of ARF in ICU, S4:109-111
- Intent-to-treat model of ESRD care cost, USRDS 1997 ADR on, S1:212-213
- Intercellular adhesion molecules (ICAMs) in ARF, S4:92
- Intercurrent illness, rHuEPO therapy with, dosage of, S3:217
- Interdialytic hemodynamics in HD patients, effects of hypervolemia on, 466-474
- Interferon- α (IFN- α) for CML, thrombotic microangiopathy associated with, 123-130
- Interleukin-1 β (IL-1 β)
 CRRT and removal of, in sepsis, S4:40-41
 response to high-dose, in HCV infection-associated MPGN, 113-115
- Interleukin-1 (IL-1) receptor antagonist, progression of IgAN modulated by, 693-702
- Interleukin-6 (IL-6)
 clearance of, during CVVH in trauma with MOF patients, 483-488
 CRRT and removal of, in sepsis, S4:41
 PD solution effects on release of, 415, 417
- Interleukin-8 (IL-8), CRRT and removal of, in sepsis, S4:41
- Intermittent hemodialysis (IHD) for ARF, CRRT compared with, S4:11-13
 cost of IHD and CRRT compared, S4:103-104
 in Netherlands, S4:72-79

- in pediatric patients, S4:84-88
- Intermittent peritoneal dialysis (PD), nightly, delivered weekly dose of, S2:87
- Internal jugular vein catheter for HD, complications associated with placement of, 690-692
- International renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1997 ADR on, S1:187-194
 - on HD, CAPD, and CCPD, S1:188-190
 - on incidence and prevalence of treated ESRD, S1:187-188
 - on patient survival, S1:191-193
 - on renal transplantation, S1:190-191
 - summary of, S1:19
- Internet World Wide Web, USRDS on, S1:25, S1:26
- Interstitial nephritis (IN), 741, 782
 - granulomatous, drug hypersensitivity, infections, sarcoidosis and, 586-588
 - and leptospirosis-associated ARF, 840-845
 - see also Tubulointerstitial nephritis
- Intervention, see Therapy and management
- Intestinal vitamin D receptor, 19-NOR-1,25-(OH)₂D₃ suppresses serum PTH and parathyroid gland growth in uremia without elevation of, 105-112
- Intolerance
 - to PD volumes, as contraindication to PD, S2:102
 - to SC rHuEPO, S3:216-217
- Intoxication
 - Al, and inadequate response to rHuEPO, S3:219
 - ethanol-enriched HCO₃-based dialysate HD for acute, 568-570
- Intra-abdominal foreign bodies, as contraindications for PD, S2:102
- Intracellular Ca, see [Ca²⁺]_i
- Intradialytic hypotension, midodrine for, in ESRD patients, 772-779
- Intradialytic Na (sodium) balance in chronic HD for ESRD, BV during variation in dialysate Na with similar, 58-63
- Intradialytic symptoms with reused dialyzers, 862-863
- Intradialytic weight gain (IWG) on HD
 - by elderly CHD patients, LVH and, 225, 226
 - RRF preservation and, 369
- Intraperitoneal (IP) recombinant human erythropoietin (rHuEPO) for ESRD patients, S3:217
- Intrarenal distribution of NOS isoforms, 318-320
- Intravenous (IV) Fe (iron) in ESRD patients on HD, S3:206-212
 - effects of, S3:207
 - effects of, on rHuEPO requirements for, 814-821
 - Fe overload and, S3:209-210
 - preparations for, S3:208-209
 - protocol for, S3:207-208
 - test dose of, S3:211-212
- Intravenous (IV) recombinant human erythropoietin (rHuEPO) for ESRD patients, S3:212-217
- Investigator-initiated research, policy on USRDS data release for, S1:36-37
- IP (intraperitoneal) recombinant human erythropoietin (rHuEPO) for ESRD patients, S3:217
- Ionized Ca (calcium), and hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 440-444
- Iothalamate, nonradiolabeled, using capillary electrophoresis to determine GFR, 646-652
- Iron, see Fe
- Iron dextran and iron gluconate, see Supplementation, Fe, in ESRD patients on HD
- Ischemia in limb bearing AV access, intervention in, S3:170
- Ischemic bowel disease, as contraindication to PD, S2:102
- Isozymes, NOS, 315
- IT (immunotactoid glomerulopathy), renal biopsy of, and prednisolone for, 160-163
- IV, see entries beginning with term: Intravenous
- IVCD, see Inferior vena cava diameter in ESRD patients on HD
- IWG, see Intradialytic weight gain on HD
- Jugular vein catheter for HD, internal, complications associated with placement of, 690-692
- K (potassium)
 - in dilutional acidosis with right ventricular myocardial infarction, 562, 566
 - in hyponatremia following hysteroscopic endometrial ablation, 718
 - in metabolic acidosis, 132
 - plasma, in DM-related polyuria, 830
 - urinary excretion of, see Urinary excretion, K
 - see also Hyperkalemia; K on HD; Na/K-ATPase
- K (potassium) on HD
 - with ethanol-enriched HCO₃-based dialysate for acute methanol intoxication, 569
 - and hyperkalemia with rHuEPO therapy, S3:223
 - in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 442
- Kayexalate in sorbitol therapy, oral, combined gastric and ileocecal toxicity due to, 120-122
- KDQOL (Kidney Disease Quality of Life) Instrument, health and quality of life outcomes of dialyzed ESRD patients assessed with, 145-146, 149-152
- Ketotifen therapy of eosinophilic peritonitis with CAPD, 433-436
- Kidney Disease Quality of Life (KDQOL) Instrument, health and quality of life outcomes of dialyzed ESRD patients assessed with, 145-146, 149-152
- Kidney Disease Questionnaire, health and quality of life outcomes of dialyzed ESRD patients assessed with, 150
- Kidney donation, living, professional attitudes and practices regarding, 549-557
- Kidney supply, USRDS 1997 ADR on, S1:122-123
- Kinetics
 - kinetic determination of urea distribution volume, S2:59
 - of PAF removal in sepsis with CRRT, S4:57-65
 - see also Kinetics on CAPD; Urea kinetic modeling
- Kinetics on CAPD
 - peritoneal transport, correlated with serum albumin but not with overall nutritional status on, 229-236
 - urea, ethnic variability in PET and, 374-381
- Ki-67 cell proliferation in MCD and IgAN demonstrated by renal biopsy of, clinical findings correlated with, 87-97
- Kitchen utensils, Al-made, Al accumulation in renal disease and, 653-658
- Knockout gene subjects
 - as model for UG role in glomerulopathy, 720-724
 - renal NO in, lessons learned from, 325-326
- Kt/V

- defined, 3-4
see also Kt/V, HD, PD and/or CAPD for ESRD and; Urea clearance
- Kt/V, HD, PD, and/or CAPD for ESRD and ethnic variability in, 374-381
 hypoalbuminemia and, 924, 925
 and outcome of mentally impaired patients, 47
 in patients with LVH, effects of lisinopril therapy and, 661
 peritoneal transport kinetics and, 231
 and post-dialysis BUN sampling on HD, NKF-DOQI guidelines on, S2:40; *see also* Kt/V_{urea}, NKF-DOQI guidelines on
 RRF preservation and, 371
 survival and, 207, 208
- Kt/V_{urea}, NKF-DOQI guidelines on
 as criterion for PD initiation, S2:70-72, S2:109-115
 failure to achieve target, as indication for switching from PD to HD, S2:103
 measurement of, S2:75-77
- Lactate
 in DM-related polyuria, 830
 effects of two-chambered HCO₃ lactate-buffered PD fluids on PBMCs and PMNLs, 680-689
 in PD solutions, 415
- Lactate dehydrogenase (LDH), biocompatible PD solutions and release of, 418
- Large-bore central venous catheters, HD, supraclavicular approach to subclavian/innominate vein for placement of, 802-808
- Large molecular weight solutes, flux of, S2:20
- LBM (lean body mass), PCR and, in ESRD patients on HD, 672-679
- LDH (lactate dehydrogenase), biocompatible PD solutions and release of, 418
- LDL (low-density lipoproteins) in PDCRF patients, exercise training effects on, 186
- LDL-C, *see* Low-density lipoprotein cholesterol
- Leadership, NKF-DOQI Work Group, S2:7, S3:143
- Lean body mass (LBM), PCR and, in ESRD patients on HD, 672-679
- Left ventricular function in PDCRF, exercise training effects on, 186, 190
- Left ventricular hypertrophy (LVH) in HD patients
 in elderly patients on CHD, risk factors for, 224-228
 prolonged lisinopril therapy effects on, 659-664
 relationship between myocardial contractility, volume overload and, echocardiography of, 780-785
- Leptospirosis, ARF due to, 840-845
- Leukemia, chronic myelocytic, thrombotic microangiopathy associated with IFN- α therapy of, 123-130
- Leukocytes
 activation of infiltrating, by bioincompatible membranes in ARF, S4:91-92
see also specific types of leukocytes
- Light microscopy of thrombotic microangiopathy associated with IFN- α therapy of CML, 124
- Limb bearing AV access, management of ischemia in, S3:170
- Lipids
 cyst fluid, in slowly progressive PKD, 703-709
 metabolism of, excess PTH effects on, 613-614
see also specific lipids
- Lipopolysaccharide (LPS) in sepsis, S4:47-48
- Lipoprotein (Lp)
 serum, and hypoalbuminemia effects in ESRD patients on CAPD, 508-510
see also High-density lipoprotein(s); Lipoprotein(a); Low-density lipoprotein(s)
- Lipoprotein(a) [Lp(a)], serum, effects of increasing serum albumin on, in ESRD patients on CAPD, 507-513
- Lisinopril, effects of prolonged therapy with, on LVH in ESRD patients on HD, 659-664
- Literature searches and reviews in preparation of NKF-DOQI guidelines, S2:8-10, S3:144-147
- Lithiasis, *see* Nephrolithiasis; Urolithiasis
- Liver failure, acute, ELAD for, S4:66-71
- Living kidney donation, professional attitudes and practices regarding, 549-557
- Living-related donor (LRD) renal transplantation, USRDS 1997 ADR on, S1:119-121
 graft survival with, S1:120-121
 patient survival with, S1:119
- Living situation, as factor influencing completion of advance directives, 357
- Living will, dialysis-specific, factors influencing completion of, 356-360
- Loa loa filariasis, secondary collapsing FSGS associated with, 836-839
- Location
 of AVF placement, S3:157
 of ESRD care facilities, S1:178
 of ESRD patients' residence, S1:202
 of tunneled cuffed catheter placement, S3:157-158
- Long-term lisinopril therapy, effects of, on LVH in ESRD patients on HD, 659-664
- Long-term patient survival, ESRD, USRDS 1997 ADR on, S1:86, S1:93-94
- Long-term vascular access for HD with Tesio twin catheter system, 213-218
- Lost to follow-up methodology, S1:196, S1:201-202
- Low-density lipoprotein(s) (LDL) in PDCRF patients, exercise training effects on, 186
- Low-density lipoprotein cholesterol (LDL-C)
 hypoalbuminemia effects on, in ESRD patients on CAPD, 507-513
 in IgA nephropathy, enalapril effects on, 401
 in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
 in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
- Low-dose recombinant human erythropoietin (rHuEPO) alone or in combination with androgens for ESRD patients on HD and/or CAPD, 495-500
- Lower urinary tract stones containing AAU crystals, 239, 240
- Lp, *see* Lipoprotein
- Lp(a) [lipoprotein(a)], serum, effects of increasing serum albumin in ESRD patients on CAPD, 507-513
- LPS (lipopolysaccharide) in sepsis, S4:47-48
- LRD, *see* Living-related donor renal transplantation, USRDS 1997 ADR on
- Lungs, excess PTH effects on, 613
- Lupus nephritis, 872-883
 severe, cyclophosphamide therapy of, 872-878
 sickle cell nephropathy during postpartum period in SLE patient, 879-883

- LVF (left ventricular function) in PDCRF, exercise training effects on, 186, 190
- LVH, *see* Left ventricular hypertrophy in HD patients
- Lymphocyte count in CAPD patients, nutritional status and, 231
- Lymphocytic infiltrate, renal graft with, PTLT, acute graft rejection and, 449-454
- Lymphoproliferative disorder, *see* Posttransplantation lymphoproliferative disorder
- Macrophages
glomerular, infiltration of, in primary FSGS, 634-635
see also Monocytes/macrophages
- Macroporous cellulosic beads, polyethylenimine-coated and PMX-B-immobilized, selective hemadsorption for sepsis with, S4:52
- Magnesium (Mg) in PD solutions, 415
- Maintenance, vascular access, S3:162-169
- Maintenance Fe (iron) therapy, 909
- Malformation syndromes, heritable, associated with GCKD, 2:xxxviii, 2:xxxix
- Malignancy
and inadequate response to rHuEPO, S3:219-220
ultrasound in screening kidneys for, in ESRD patients, 580
see also Leukemia; Multiple myeloma; Posttransplantation lymphoproliferative disorder
- Malnutrition
and earlier initiation of dialysis, 899-906
and inadequate response to rHuEPO, S3:219
see also Nutritional status of ESRD patients; Severe malnutrition
- Managed end-stage renal disease (ESRD) care, Medicare expenditures for, USRDS 1997 ADR on, S1:169-172
- MAP (mean arterial pressure), *see* Blood pressure
- Maturation of AVF, S3:160-161
- MCD, *see* Minimal-change disease
- Mean arterial pressure, *see* Blood pressure
- Mechanical (technical) problems on PD, as indication for switching from PD to HD, S2:104
- Medical care, pre-ESRD, in DMMS, S1:69
- Medical coverage for ESRD, USRDS 1997 ADR on, S1:40-41
see also entries beginning with term: Medicare
- Medical Evidence Form (Form 2728), S1:195, S1:197
- Medical/nursing communication in ICU, S4:115
- Medical outcomes Study 36-item Short Form (MOS SF-36)
Health Survey, health and quality of life outcomes of dialyzed ESRD patients assessed with, 145-146, 148-149, 151
- Medicare claims, *see* Paid Medicare claims
- Medicare end-stage renal disease (ESRD) program
delays in eligibility to, S1:199
Enrollment Database of, S1:197
see also Medicare expenditures for ESRD
- Medicare expenditures for ESRD
for HD vascular access surgery, 525, 526, 529
impact of capitation on, 542-548
see also Medicare expenditures for ESRD, USRDS 1997 ADR on
- Medicare expenditures for ESRD, USRDS 1997 ADR on, S1:165-172
data on, on CDs, S1:34-35
for direct care (1991-1995), S1:166-168
for managed care alternatives, S1:169-172
by modality, *see* Medicare expenditures for ESRD by modality, USRDS 1997 ADR on
summary of, S1:18-19
total (1991-1995), S1:165
see also Medicare reimbursements for vascular access in ESRD, USRDS 1997 ADR on; Paid Medicare claims
- Medicare expenditures for ESRD by modality, USRDS 1997 ADR on
for CAPD, S1: 18-19, S1:160-163, S1:169-172
for CCPD, S1:160-163, S1:169-172
changes in CPI and changes in, S1:168
for HD, S1:160-163
for renal transplantation, S1:18-19, S1:160-163, S1:169-172
see also Paid Medicare claims
- Medicare reimbursements for vascular access in ESRD, USRDS 1997 ADR on
amount of, S1:163-165, S1:172-177
summary of, S1:18-19
- Medications
containing significant amounts of propylene glycol, 135
used by ESRD patients, DMMS data on, S1:83
see also Drug therapy
- Membrane receptor signal transduction, serine-threonine phosphatase and, 889-890
- Membranoproliferative glomerulonephritis (MPGN)
associated with HCV infection, response of, to high-dose IFN- α , 113-115
glomerular Fc α R expression and disease activity in, 389-396
NS and, 624
proteinuria characterization in, with urinary PAs, 404-412
- Membranous nephropathy
advanced ARF with AIDS-associated prednisone therapy of, 116-119
NS and, 621-631
- Menorrhagia, hyponatremia following hysteroscopic endometrial ablation for, 717-719
- Mental impairment in ESRD patients on HD, prevalence, recognition, and implications of, 41-49
- Mesangial cells
phenotypic changes associated with lesions in, in primary FSGS, 632-638
proliferation of, in IgAN, IL-1 receptor antagonist effects on, 693-699
- Mesangial matrix, enalapril effects on glomerular accumulation of ICs and, in IC-GN, 243-252
- Messenger ribonucleic acid, *see* mRNA
- Metabolic acidosis
dilutional acidosis as cause of, 561-567
normal anion gap, enterovesical fistula presenting as, 131-133
- Metabolic alkalosis, hypocalcemic tetany and, in CRF patient on HD, 440-444
- Metabolism
bone, gravitational forces and, 6:i-iii
Fe, 908
lipid, excess PTH effects on, 613-614
muscle, and Cr excretion in chronic renal insufficiency, race and, 16-22
PAF, S4:58

- uric acid, syndrome X and, 928-929
- Methanol intoxication, acute, ethanol-enriched HCO_3^- -based dialysate HD for, 568-570
- Methodology, USRDS 1997 ADR, S1:25-26
 - lost to follow-up, S1:196, S1:201-202
 - see also Analytical methods used in USRDS 1997 ADR
- Mg (magnesium) in PD solutions, 415
- β_2 -MG, see β_2 -Microglobulin
- MI, see Myocardial infarction
- Microangiopathy, see Thrombotic microangiopathy
- β_2 (beta₂)-Microglobulin (β_2 -MG)
 - clearance of, with reused dialyzers, 501-506, 865
 - in multiple myeloma-induced renal failure, 787
- Microscopy, see Electron microscopy
- Microspheres in specific hemadsorption for sepsis, S4:52-54
 - antibody-coated aminated, S4:54
 - cationically modified cellulose, S4:52-53
- Midodrine for intradialytic hypotension in ESRD patients, 772-779
- Mini Mental Status Exam (MMSE) of ESRD patients on HD, 41-49
- Minimal-change disease (MCD)
 - Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
 - proteinuria in, characterized with urinary PAs, 404-412
- Minimal change nephropathy, NS and, 621-631
- Minimum aggregation size in USRDS 1997 ADR, S1:196
- Minimum delivered hemodialysis (HD) dose, S2:32-34
- MMSE (Mini Mental Status Exam) of ESRD patients on HD, 41-49
- Mock setup, CRRT training in ICU with, S4:113
- Modality Sequence (Treatment History) Standard Analysis File (SAF), S1:30
- Moderate renal failure, capillary deficit in heart but not in skeletal muscle in, 382-388
- Modern intensive care, nature of, S4:109-110
- Modified anion exchange sorbent resin, selective hemadsorption for sepsis with, S4:52
- Modified Borah equation, assessment of pediatric PD patient nutritional status with, S2:84-85
- Modified cellulose microspheres, cationically, selective hemadsorption for sepsis with, S4:52-53
- MOF (multiple organ failure), cytokine clearance during CVVH of trauma patients with, 483-488
- Molecular diagnosis, prenatal, of AS, by genetic linkage in families with AS, 174-179
- Monitoring
 - Fe status, in CRF patients, S3:202-203
 - Hct and Hb, during rHuEPO therapy, S3:215-216
 - of CRRT in ICU, S4:4:115
 - of response to IV Fe therapy with RBC ferritin evaluation and reticulocyte measurements, 814-821
 - vascular access, S3:162-166
- Monocytes/macrophages
 - biocompatible PD solutions and release of monocyte cytokines, 413-422
 - glomerular Fc α R expression in, in IgA nephropathy, 392-393
- Mononuclear cells
 - peripheral blood, effects of two-chambered HCO_3^- lactate-buffered PD fluids on, 680-689
 - see also Monocytes/macrophages
- Monophosphate, see cAMP; cGMP
- Monounsaturated fat intake by CRF patients, exercise training and, 187, 189
- Morbid obesity, as contraindication to PD, S2:103
- Morbidity, see Comorbidity
- Morphometry, glomerular, in IC-GN, 247-250
- Mortality, cause(s) of ESRD, USRDS 1997 ADR on, S1:107-117
 - analytical methods used to determine, S1:107-112
 - with diabetic ESRD, S1:109-111
 - with HD and PD, S1:110, S1:112-114, S1:208-209
 - with renal transplantation, S1:111, S1:114, S1:141-144, S1:209
 - summary of, S1:16
 - withdrawal from dialysis as, S1:114-116
- Mortality, ESRD, on HD
 - and CAPD/CCPD, compared, 334-342, 445-447
 - with reused dialyzers, 860-861
 - see also Hemodialysis dose for ESRD, mortality and; Mortality, ESRD, USRDS 1997 ADR on
- Mortality, ESRD, USRDS 1997 ADR on, S1:86-97
 - annual, S1:206-209
 - changes between previous reports and, S1:11
 - national rates, S1:16, S1:94-97, S1:103-106
 - 1984-1996, S1:86
 - pediatric, see Mortality, pediatric ESRD, USRDS 1997 ADR on
 - by primary disease, S1:91-92, S1:105-106
 - sex and, S1:101, S1:105, S1:109-110
 - SMR and, see Standard mortality ratio
 - summary of, S1:15-16
 - trends in, S1:87-93
 - see also Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on; Mortality, cause(s) of ESRD, USRDS 1997 ADR on
- Mortality, pediatric ESRD, USRDS 1997 ADR on, S1:139-144
 - on CAPD, S1:139-141
 - with renal transplantation, S1:141-144
- MOS SF-36 (Medical outcomes Study 36-item Short Form) Health Survey, health and quality of life outcomes of dialyzed ESRD patients assessed with, 145-146, 148-149, 151
- MPGN, see Membranoproliferative glomerulonephritis
- mRNA (messenger ribonucleic acid)
 - expression of glomerular Fc α R, and disease activity in IgA nephropathy, 389-396
 - PAI-1, in chronic CsA nephropathy, 71-81
- MTT (3-[4,5-dimethylthiazol-2-yl]-diphenyl tetrasolium bromide) test of PD solutions, 417-418
- Multicenter clinical trials of CRRT of ARF, S4:96-101
- Multiple myeloma
 - HD for renal failure induced by, 786-792
 - and inadequate response to rHuEPO, S3:219
 - spurious hypophosphatemia with, 571-575
- Multiple organ failure (MOF), cytokine clearance during CVVH of trauma patients with, 483-488
- Multiple tubuloreticular inclusions with progressive postinfectious GN in HIV-negative patient, 725-728
- Muscle(s)
 - muscle metabolism and Cr excretion in chronic renal insufficiency, race and, 16-22

- skeletal, *see* Skeletal muscle(s)
- Muscle mass, of PD patient, assessment of, S2:128
- Muscular strength of PDCRF patients, exercise training effects on, 186, 190
- Mushroom poisoning with *Cortinarius orellanus*, ESRD due to, 282-286
- Myelocytic leukemia, chronic, thrombotic microangiopathy associated with IFN- α therapy of, 123-130
- Myeloma, *see* Multiple myeloma
- Myocardial contractility, relationship between LVH, volume overload and, on HD, echocardiography of, 780-785
- Myocardial infarction (MI)
- acute, in renal transplantation recipients, systemic thrombolysis for, 849-850
 - right ventricular, dilutional acidosis as complication of, 561-567
- Myocardium, capillary deficit in, but not in skeletal muscle in moderate renal failure, 382-388
- Myofibroblasts, and mesangial cell phenotypic changes associated with cellular lesions in primary FSGS, 632-638
- N (nitrogen)
- aminoguanidine effects on azotemic STZ-DM, 253-259
 - see also* BUN
- Na (sodium)
- in dilutional acidosis with right ventricular myocardial infarction, 562, 566
 - intake of, by CRF patients, exercise training and, 187, 189
 - in metabolic acidosis, 132
 - plasma, *see* Plasma Na
 - renal fibrosis and expression of TGF- β 1 and ECM proteins enhanced by depletion of, in chronic CsA nephropathy, 71-81
 - urinary excretion of, *see* Urinary excretion, Na
 - see also* Atrial natriuretic peptides; Hyponatremia; Na in HD and/or PD; NaCl-sensitive hypertension; Na/K-ATPase
- Na (sodium) in HD and/or PD
- in chronic HD for ESRD, BV during variation of dialysate, with similar intradialytic Na, 58-63
 - with ethanol-enriched HCO₃-based dialysate for acute methanol intoxication, 569
 - in hypocalcemic tetany with metabolic alkalosis in CRF patient, 442
 - in PD solutions, 415
 - plasma, and RRF preservation, 369
- NaCl (salt)-sensitive hypertension (HTN), role of NO in, 322-323
- Na/K-ATPase (sodium/potassium-adenosine triphosphatase), serine-threonine phosphatase regulating activity of, in nephron, 888-889
- National death rate, ESRD, USRDS 1997 ADR on, S1:16, S1:94-97, S1:103-106
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), S1:5
- National Kidney Foundation-Dialysis Outcomes Quality Initiative (NKF-DOQI)
- Advisory Council of, S2:2, S2:10-11, S3:138, S3:146-147
 - clinical practice guidelines of, *see entries beginning with terms*: Clinical practice guidelines
 - co-chairs of, S2:12, S3:148
 - foreword to, S2:4-5, S3:140-141
 - Steering Committee of, S2:3, S3:139
- Native arteriovenous fistula, *see*
- Natriuretic peptides, *see* Atrial natriuretic peptides
- Natural anticoagulants, extracorporeal circuit and, S4:20-21
- Nephritis, *see* Glomerulonephritis; Interstitial nephritis; Lupus nephritis; Pyelonephritis
- Nephrolithiasis, oliguric ARF caused by crystalluria and, due to indinavir therapy of AIDS, 558-560
- Nephrology Nursing Model of CRRT management of ARF in ICU, S4:106
- Nephron, *see* Calcineurin, expression and function of, in nephron
- Nephrotic syndrome (NS)
- etiology of, 621-631
 - and GN, urinary PAs and, 404, 406-409
 - and Ki-67 cell proliferation in renal disease, 88
 - with thrombotic microangiopathy associated with IFN- α therapy of CML, 123-130
- Nervous system, excess PTH effects on, 609
- Netherlands, CRRT versus IHD for ARF in, S4:72-79
- Networks, ESRD
- experience of, in quality survey implementation, 349-355
 - see also* Networks, ESRD, USRDS 1997 ADR on
- Networks, ESRD, USRDS 1997 ADR on, S1:7
- census of, S1:198
 - incidence and prevalence of treated ESRD by, S1:52
 - patient survival by treatment modality and (1993-1996), S1:59
- Neuropathy, autonomic, and predisposition to arrhythmias on HD, 219-223
- Neuropeptide Y (NPY), plasma, in children and adults with CRF on HD and/or PD, 23-27
- Neutrophils, *see* Polymorphonuclear leukocytes
- New United States Renal Data system (USRDS) data, S1:195-196, S1:199-201
- NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), S1:5
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nightly intermittent peritoneal dialysis (NIPD), delivered weekly dose of, S2:87
- Nitric oxide (NO)
- in ARF management, S4:90-91
 - effects of, on BP on, in ESRD patients on HD, 665-671
 - see also* Nitric oxide, renal
- Nitric oxide (NO), renal, 311-333
- actions of, 312
 - biochemistry of, 312-313
 - lessons learned about, from knockout gene subjects, 325-326
 - NOS and, *see* Nitric oxide synthase
 - pathophysiologic roles of, 322-325
 - physiologic roles of, 320-322
- Nitric oxide synthase (NOS)
- enzymology of, 313-315
 - isoforms of, intrarenal distribution of, 318-320
 - see also* Structure, NOS
- Nitrogen, *see* N; PNA in PD
- NKF, *see* National Kidney Foundation-Dialysis Outcomes Quality Initiative; Reused dialyzers, NKF report on
- NO, *see* Nitric oxide
- Nonbicarbonate buffers, and ECF volume expansion, dilutional acidosis and, 561-567
- Nonclassical target organs, *see* Parathyroid hormone, effects of excess of, on nonclassical target organs

- Noncuffed catheters for acute HD, S3:158-159
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes mellitus)
- B cell proliferation and elevated $[Ca^{2+}]_i$ in, 98-104
 - see also* Diabetes mellitus
- Nonradiolabeled iothalamate using capillary electrophoresis to determine GFR, 646-652
- Nonselective hemadsorption for sepsis, S4:45-47
- Nontransplanted IgA (immunoglobulin A) nephropathy patients, peripheral IgA-secreting cells in, 64-70
- 19-NOR-1,25-(OH) $_2$ D $_3$, serum PTH and parathyroid gland growth suppressed by, in uremia without intestinal vitamin D receptor elevation, 105-112
- Normal anion gap metabolic acidosis, enterovesical fistula presenting as, 131-133
- Normalized protein catabolic rate, *see* nPCR
- Normalized protein equivalent of nitrogen appearance, *see* nPNA in PD
- Normotension, as defined by ABPM, 594
- Normotensive chronic renal failure (CRF) patients on HD, ultrasound measurement of IVCD to assess dry weight in, 459-465
- Northern blot analysis of ECM deposition in chronic CsA nephropathy, 75-76
- NOS, *see* Nitric oxide synthase
- nPCR (normalized protein catabolic rate)
- and initiation of dialysis, 902
 - see also* nPCR in HD, PD, and/or CAPD
- nPCR (normalized protein catabolic rate) in HD, PD, and/or CAPD
- carbamylated Hb and, 362, 364
 - ethnic variability in, 374-381
 - hypoalbuminemia and, 924, 925
 - patient survival and, 207, 208
- nPNA (normalized protein equivalent of nitrogen appearance) in PD
- as criterion for PD initiation, S2:72-73, S2:115-118
 - measurement of, S2:99-100
- NPY (neuropeptide Y), plasma, in children and adults with CRF on HD and/or PD, 23-27
- NS, *see* Nephrotic syndrome
- Nursing expertise, and CRRT in ICU, S4:106, S4:113-115
- Nursing viewpoint on management of CRRT for ARF in ICU, S4:105-108
- Nutritional status of ESRD patients
- exercise training and, 187, 189
 - see also* Nutritional status of ESRD patients on HD, PD, and/or CAPD
- Nutritional status of ESRD patients on HD, PD, and/or CAPD
- correlation of peritoneal transport kinetics with serum albumin but not with, 229-236
 - HD dose and, S2:21
 - on PD, assessment of, S2:83-85, S2:125-127
 - see also* Dietary protein intake of ESRD patients on HD and/or CAPD; Malnutrition; Supplementation, Fe, in ESRD patients on HD
- Obesity, morbid, as contraindication for PD, S2:103
- Obstruction, tubular, proximal tubular cell injury and, S4:91
- Occlusion of AV graft, 50-57
- see also* Stenosis with AV graft and fistula
- Occult iron (Fe) deficiency, markers of, in ESRD patients, effectiveness of rHuEPO in, 532-541
- Office blood pressure (BP) in vascular disease, ABPM compared with, 594-596
- 1,25-(OH) $_2$ D $_3$, *see* Calcitriol
- OKT3 therapy of PTLD, 449-454
- Oliguric acute renal failure (ARF) with crystalluria and nephrolithiasis associated with indinavir therapy of AIDS, 558-560
- Oncotic pressure, edema formation and, in hypoalbuminemic HIVAN patients with proteinuria, 822-828
- Open review of NKF-DOQI guidelines, S2:11, S3:147
- Opinion-based guidelines, NKF-DOQI, S2:21, S3:153
- Optimal hemodialysis (HD) dose, NKF-DOQI guidelines on, S2:33-34
- Oral contraceptives, role of, in autosomal recessive inheritance of HUS, 760-765
- Oral Fe (iron) supplementation in ESRD patients on HD, S3:206, S3:212
- Oral Kayexalate in sorbitol therapy, combined gastric and ileocecal toxicity due to, 120-122
- Order of preference for AVF placement, access selection and, S3:156-157
- Organ failure, *see* Multiple organ failure; Renal failure
- Organizational review of NKF-DOQI guidelines, S2:11, S3:147
- Organizational structure
- of NKF-DOQI Work Groups, S2:7, S3:143
 - of USRDS, S1:21-22
- Oriental, *see* Race and ethnicity
- Osmolal gap, and HD with ethanol-enriched HCO $_3$ -based dialysate for acute methanol intoxication, 569
- Osmolality
- and HD with ethanol-enriched HCO $_3$ -based dialysate for acute methanol intoxication, 569
 - in hyponatremia following hysteroscopic endometrial ablation, 718
- Osmotic agents, buffers and, in biocompatible PD solutions, monocyte cytokine release with, 413-422
- Osmotic diuresis in poorly controlled DM, factors contributing to, 829-835
- Osteitis fibrosa, and inadequate response to rHuEPO, S3:218
- Outcome
- ARF, IHD versus CRRT and, S4:72-73, S4:75-77
 - of azotemic STZ-DM, with aminoguanidine therapy, 256
 - of outpatient surgery for vascular access, 528-529
 - of severe lupus nephritis with cyclophosphamide therapy, 872-878
 - see also* Follow-up; Graft survival; Outcome, ESRD; National Kidney Foundation-Dialysis Outcomes Quality Initiative; Patient survival and specific conditions
- Outcome, ESRD
- ESRD Core Indicators Study and, 349-355
 - on HD, mental impairment and, 43, 47; *see also* Health and quality of life outcomes of dialyzed ESRD patients, assessment of; Hemodialysis dose for ESRD, mortality and; Patient survival with ESRD on HD and/or PD outcome goals for adequate PD, S2:95-100
 - see also* Mortality, ESRD on HD; Outcome, ESRD, USRDS 1997 ADR on
- Outcome, ESRD, USRDS 1997 ADR on
- and access to renal transplantation, S1:16
 - see also* Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on; Graft loss; Graft survival, USRDS

- 1997 ADR on; Mortality, ESRD, USRDS 1997 ADR on; Patient survival with ESRD, USRDS 1997 ADR on
- Outpatient surgery for HD vascular access, cost of, 525-531
- Overall incidence and prevalence of treated ESRD, USRDS 1997 ADR on, S1:47-49
- Oxidant stress in ARF, S4:90-91
- P (phosphorus)
and effects of 19-NOR-1,25-(OH)₂D₃ on serum PTH in CRF, 107
in elderly CHD patients, LVH and, 225, 226
serum, in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- PA(s) (polymers of albumin), urinary, characterization of proteinuria in MCD, FSGS, MPGN, and IgAN with, 404-412
- PaCO₂ in dilutional acidosis with right ventricular myocardial infarction, 566
- PAF (platelet-activating factor), kinetics of removal of, in sepsis, with CRRT, S4:57-65
- PAI-1 (plasminogen activator inhibitor-1) mRNA (messenger ribonucleic acid) in chronic CsA nephropathy, 71-81
- Paid Medicare claims
as data sources, S1:197, S1:212
for vascular access, S1:165; *see also* Vascular access, HD, cost of
- PaO₂ in dilutional acidosis with right ventricular myocardial infarction, 566
- Parathyroid gland (PTG)
19-NOR-1,25-(OH)₂D₃ suppressing serum PTH and growth of, in uremia, without intestinal vitamin D receptor elevation, 105-112
parathyroidectomy for severe secondary hyperparathyroidism in CRF patients on HD, hypocalcemic tetany and metabolic alkalosis and, 440-444
- Parathyroid hormone (PTH)
role of, in increased renal accumulation and excretion of cAMP in slowly progressive PKD, 706, 707
see also Parathyroid hormone, effects of excess of, on nonclassical target organs; Parathyroid hormone in HD patients
- Parathyroid hormone (PTH), effects of excess of, on nonclassical target organs, 606-620
acute and chronic effects, 608
on cardiovascular system, 610-611
cellular actions of, 607-608
on endocrine glands, 609-610
on hematopoietic system and lungs, 613
on hypertension, 611-612
on immune system, 612-613
on lipid metabolism, 613-614
on nervous system, 609
on skeletal muscles, 612
on skin, 614
on vascular system, 611
- Parathyroid hormone (PTH), and LVH in HD patients
effects of lisinopril therapy and, 661
in elderly CHD patients, LVH and, 225, 226
- Parathyroid hormone (PTH) in HD patients
carbamylated Hb and, 362, 364
effects of low-dose rHuEPO alone or combined with androgens on, 497
see also Parathyroid hormone, and LVH in HD patients
- Parathyroid hormone 2 receptors, *see* Parathyroid hormone, effects of excess of, on nonclassical target organs
- Parathyroid hormone-related peptide, *see* Parathyroid hormone, effects of excess of, on nonclassical target organs
- Parathyroidectomy for severe secondary hyperparathyroidism in CRF patients on HD, hypocalcemic tetany and metabolic alkalosis and, 440-444
- Patency of vascular access, NKF-DOQI guidelines on, S3:182-183
- Pathogenesis and pathophysiology
of CRF progression, vasopressin role in, S:ii-iii
of dilutional acidosis in right ventricular myocardial infarction, 563-565
see also specific conditions
- Pathophysiologic roles of renal NO, 322-325
- Patient assessment, *see* Self-assessment by HD or PD patients
- Patient characteristics, *see* Age; Body mass and body mass index; Body weight; Educational status; Employment status of ESRD patients; Height; Income; Living situation; Patient characteristics, ESRD, USRDS 1997 ADR on; Race and ethnicity; Sex
- Patient characteristics, ESRD, USRDS 1997 ADR on
incidence and prevalence of treated patients by, S1:41-45, S1:49-53
RRT modality utilization by, S1:59-61
see also Age of ESRD patients, USRDS 1997 ADR on; Race and ethnicity of ESRD patients, USRDS 1997 ADR on; Sex of ESRD patients, USRDS 1997 ADR on
- Patient comfort, HD, maximizing, NKF-DOQI guidelines, S2:20, S2:49-50
- Patient compliance, *see* Compliance with dialysis for ESRD
- Patient evaluation prior to access placement, NKF-DOQI guidelines on, S3:154-161
- Patient history-taking prior to vascular access selection, S3:154
- Patient-related failure to achieve prescribed PD dose, S2:93, S2:132-133
- Patient selection for DMMS, S1:67-68
- Patient Standard Analysis File (SAF), S1:30
- Patient survival
with azotemic STZ-DM, aminoguanidine effects on, 253-259
and nutritional status at initiation of dialysis, 902
see also Patient survival with ESRD on HD and/or PD
- Patient survival with ESRD, USRDS 1997 ADR on, S1:15-16
and expected remaining years of life of ESRD patients, USRDS 1997 ADR on, S1:86, S1:97-100
international, S1:191-193
long-term, S1:86, S1:93-94
measurement of, S1:209-211
by network, S1:59
with renal transplantation, S1:119, S1:139-141, S1:210-211
by treatment modality, S1:59, S1:209-211
- Patient survival with ESRD on HD and/or PD, 207, 208
patient self-assessment of functional health status on SF-36 as predictor of hospitalization, compliance and, 204-212

- on PD, S2:95
- sex, race and, 739-748
- see also* Patient survival with ESRD, USRDS 1997 ADR on
- PAVF (primary arteriovenous fistula), *see* Arteriovenous fistula and graft in HD
- PBMCs (peripheral blood mononuclear cells), effects of two-chambered HCO₃ lactate-buffered PD fluids on, 680-689
- pCO₂
 - in CRF patient on HD with hypocalcemic tetany and metabolic alkalosis, 442
 - in DM-related polyuria, 830
 - with ethanol-enriched HCO₃-based dialysate HD for acute methanol intoxication, 569
 - in metabolic acidosis, 132
- PCR, *see* Protein catabolic rate on HD
- PD, *see* Peritoneal dialysis
- PDCRF (predialysis chronic renal failure), exercise training effects on cardiorespiratory endurance, hypertension, and renal function in, 180-192
- PE (plasma exchange), HF compared with, in elimination of silver accumulation in burn HD patients treated with SSD cream, 287-290
- Pediatric acute renal failure (ARF), CRRT versus IHD for, S4:84-88
- Pediatric cystic kidneys, 2:xxxvii-xxxix
- Pediatric end-stage renal disease (ESRD), HD
 - growth rates of patients on, compared with growth rates on CCPD, CAPD, and renal transplantation, 193-204
 - plasma NPY in, 23-27
 - see also* Pediatric end-stage renal disease, HD for, NKF-DOQI guidelines on; Pediatric end-stage renal disease, PD for, NKF-DOQI guidelines on
- Pediatric end-stage renal disease (ESRD), HD for, NKF-DOQI guidelines on
 - adequacy of, S2:18-19
 - delivered HD dose for, S2:26, S2:28-29, S2:32-34
 - intravenous Fe supplementation in, S3:208
- Pediatric end-stage renal disease (ESRD), PD for, NKF-DOQI guidelines on
 - assessment of nutritional status of, S2:83-85
 - empirical approach to initiation of, S2:89
 - intravenous Fe supplementation in, S3:208
 - outcome of, S2:97-98
- Pediatric end-stage renal disease (ESRD), USRDS 1997 ADR
 - on, S1:128-144
 - on CAPD for, *see* Continuous ambulatory peritoneal dialysis for pediatric ESRD, USRDS 1997 ADR on
 - on causes of, S1:130-134
 - on CCPD for, S1:135, S1:139-141
 - on incidence and prevalence of, S1:128-130, S1:132-134
- Pediatric Growth and Development Study, S1:134
 - on prevalence of, S1:134
 - on renal transplantation for, *see* Pediatric renal transplantation, USRDS 1997 ADR on
 - summary of, S1:17
- Pediatric Growth and Development Study, USRDS, S1:33
- Pediatric renal transplantation
 - effects of CAPD, CCPD, HD and, on growth rates, 193-204
 - "en bloc", FSGS in, 271-274
 - for Goodpasture's syndrome, 711
 - see also* Pediatric renal transplantation, USRDS 1997 ADR on
- Pediatric renal transplantation, USRDS 1997 ADR on, S1:132, S1:136-141
 - on access to, S1:136-138
 - on graft survival with, S1:141
 - on mortality with, S1:141-144
 - on number of, S1:136
 - on patient survival with, S1:139-141
- Peer review of NKF-DOQI guidelines, S2:10-11, S3:146-147
- D-Penicillamine, effects of, on progressive renal failure associated with positive anti-myeloperoxidase ANCA in scleroderma, 279-281
- Peptides
 - atrial natriuretic, *see* Atrial natriuretic peptides
 - parathyroid hormone-related, *see* Parathyroid hormone, effects of excess of, on nonclassical target organs
 - plasma neurotensin Y in children and adults with CRF on HD and/or PD, 23-27
- Peracetic acid, maintenance of blood compartment volume in dialyzers reprocessed with, effects of, on urea clearance and β_2 -microglobulin removal, 501-506
- Percent reduction of urea in ESRD patients with AIDS on HD, rHuEPO effects on Hct and, 28-35
- Perioperative recombinant human erythropoietin (rHuEPO) therapy, dosage of, S3:217
- Peripheral blood mononuclear cells (PBMCs), effects of two-chambered HCO₃ lactate-buffered PD fluids on, 680-689
- Peripheral IgA (immunoglobulin A)-secreting cells in non-transplanted IgAN patients, 64-70
- Peripheral renin, activity of, in chronic CsA nephropathy, 74
- Peritoneal dialysis (PD)
 - whole blood and RBC levels of GSH on, 489-494
 - see also* Peritoneal dialysis for ESRD
- Peritoneal Dialysis Adequacy Work Group, NKF-DOQI
 - leadership and organizational structure of, S2:7
 - members of, S2:7, S2:13-14, S2:134-136
- Peritoneal dialysis (PD) for ESRD
 - children and adults on, plasma NPY in, 23-27
 - ESRD Core Indicators Study report on, 165-173
 - patient's view of quality of, 793-801
 - see also* Chronic peritoneal dialysis for ESRD; Continuous ambulatory peritoneal dialysis for ESRD; Continuous cycling peritoneal dialysis for ESRD; Peritoneal dialysis for ESRD, NKF-DOQI guidelines on; Peritoneal dialysis for ESRD, USRDS 1997 ADR on; Peritoneal dialysis solutions and fluids
- Peritoneal dialysis (PD) for ESRD, NKF-DOQI guidelines
 - on, S2:95-104
 - on outcome goals, S2:95-100
 - patients suitable for, S2:101-104
 - technique survival measurement, S2:95-96
 - see also* Clinical practice guidelines, NKF-DOQI, on HD and PD adequacy; Dose, PD, NKF-DOQI guidelines on; Initiation of PD, NKF-DOQI guidelines on
- Peritoneal dialysis (PD) for ESRD, USRDS 1997 ADR
 - on automated, S1:73, S1:75, S1:83
 - in DMMS, S1:71-75, S1:78, S1:78, S1:83, S1:84
 - by facility, S1:182
 - on mortality, S1:110, S1:112-114, S1:208-209

- as option, S1:55
 see also Continuous ambulatory peritoneal dialysis for ESRD, USRDS 1997 ADR on; Continuous cycling peritoneal dialysis for ESRD, USRDS 1997 ADR on
- Peritoneal dialysis (PD) solutions and fluids
 acute-phase proteins and albumin loss from, as determinants of serum albumin level in ESRD, 923-927
 see also Biocompatibility of PD solutions and fluids
- Peritoneal equilibration test (PET), urea kinetics and, in CAPD patients, ethnic variability in, 374-381
- Peritoneal leaks, as contraindication to PD, S2:102
- Peritoneal transport kinetics, correlation of, with serum albumin but not with overall nutritional status of CAPD patients, 229-236
- Peritonitis with CAPD, S2:121
 eosinophilic, ketotifen therapy of, 433-436
 frequency of, as indication for switching to HD, S2:104
 sclerosing, corticosteroid therapy of, 275-278
 see also Peritonitis with CAPD, USRDS 1997 ADR on
- Peritonitis with CAPD, USRDS 1997 ADR on
 on hospitalization for, S1:150
 USRDS CAPD and Peritonitis Rates Study, S1:32-33
- Permanent vascular access, see Clinical practice guidelines, NKF-DOQI, on vascular access
- Persistent vegetative state (PVS), withdrawing dialysis from patients in, 291-296
- PET (peritoneal equilibration test), urea kinetics and, in CAPD patients, ethnic variability in, 374-381
- pH
 in CRF patient on HD with hypocalcemic tetany and metabolic alkalosis, 442
 in DM-related polyuria, 830
 with ethanol-enriched HCO_3^- -based dialysate HD for acute methanol intoxication, 569
 of PD solutions, 415
 see also Acidosis; Alkalosis
- Phenotype
 apolipoprotein(a), and hypoalbuminemia effects in ESRD patients on CAPD, 507-513
 changes in mesangial cell, associated with mesangial cell lesions in primary FSGS, 632-638
- Phorbol myristate acetate (PMA), superoxide production stimulated by, by PMNLs exposed to PD fluids, 684-685
- Phosphate
 in PD solutions, 415
 serum, see Serum phosphate
- Phosphorus, see P
- Physical examination prior to vascular access selection, S3:154
- Physiologic roles of renal NO, 320-322
- Pimagedine (aminoguanidine), effects of, on survival, in azotemic STZ-DM, 253-259
- Pituitary gland, excess PTH effects on, 609-610
- PKD, see Polycystic kidney disease
- Placement of vascular access, patient evaluation prior to, S3:154-161
- Planning implementation of NKF-DOQI guidelines, S2:11, S3:147
- Plasma aluminum (Al), effects of low-dose rHuEPO alone or combined with androgens on, 497
- Plasma cGMP (cyclic guanosine monophosphate) in HD patients, RRF preservation and, 369
- Plasma Cl (chloride) in DM-related polyuria, 830
- Plasma creatinine (Cr) in DM-related polyuria, 830
- Plasma exchange (PE), HF compared with, in silver accumulation elimination in burn HD patients treated with SSD cream, 287-290
- Plasma ferritin in PD patients, hypoalbuminemia and, 924, 925
- Plasma glucose in poorly controlled DM, polyuria and, 830
- Plasma HCO_3^- (bicarbonate) in DM-related polyuria, 830
- Plasma K (potassium) in DM-related polyuria, 830
- Plasma Na (sodium)
 in HD, RRF preservation and, 369
 retention of, and syndrome X, 929-930
- Plasma neuropeptide Y (NPY) in children and adults with CRF on HD and/or PD, 23-27
- Plasma renin in IC-GN, 250
- Plasminogen activator inhibitor-1 (PAI-1) mRNA (messenger ribonucleic acid) in chronic CsA nephropathy, 71-81
- Platelet(s), extracorporeal circuit and, S4:22, S4:23, S4:26
- Platelet-activating factor (PAF), kinetics of removal of, in sepsis, with CRRT, S4:57-65
- PMA (phorbol myristate acetate), superoxide production stimulated by, by PMNLs exposed to PD fluids, 684-685
- PMMIS (Program Management and Medical Information System), USRDS, S1:196-197
- PMNLs, see Polymorphonuclear leukocytes
- PMX-B, see entries beginning with term: Polymyxin B
- PNA (protein equivalent of nitrogen appearance) in PD
 normalized, see nPNA in PD
 in patient nutritional status assessment, S2:83, S2:126-127
 in PD dose measurement, S2:75-77
- pO_2 in CRF patient on HD with hypocalcemic tetany and metabolic alkalosis, 442
- Poisoning, mushroom, with *Cortinarius orellanus*, ESRD due to, 282-286
- Poisson regression in estimation of mortality with HD and CAPD/CCPD for ESRD, 334-342, 445
- Polarity, altered cell, proximal tubular cell injury and, S4:91
- Policies on CRRT in ICU, S4:114-115
- Policy
 formal, on living kidney donation, 553
 proposal of, for withdrawal of dialysis from patients in PVS, 291-926
 on USRDS data release for investigator-initiated research, S1:36-37
- Polycystic kidney disease (PKD)
 ABPM in, 597
 in children, 2:xxxvii-xxxix
 slowly progressive, renal cAMP accumulation and urinary excretion in, 703-709
 see also Autosomal dominant polycystic kidney disease; Polycystic kidney disease, as primary disease in ESRD
- Polycystic kidney disease (PKD), as primary disease in ESRD, 741
 low-dose rHuEPO alone or in combination with androgens and, 497
 and mortality on HD and CAPD compared, 336, 338
 and relationship between LVH, myocardial contractility, and volume overload, 782
- Polyethylenimine-coated macroporous cellulosic beads, selective hemadsorption for sepsis with, S4:52

- Polymer(s) of albumin (PAs), urinary, characterization of proteinuria in MCD, FSGS, MPGN, and IgAN with, 404-412
- Polymerase chain reaction, HSV encephalitis diagnosis with, in renal transplant recipient, 423-428
- Polymorphism, TCR C- α chain gene, IgAN associated with, 260-264
- Polymorphonuclear leukocytes (PMNLs; neutrophils)
effects of two-chambered HCO₃ lactate-buffered PD fluids on, 680-689
excess PTH effects on, 613
glomerular Fc α R expression in, in IgA nephropathy, 392-393
- Polymyxin B (PMX-B)-immobilized macroporous cellulosic beads, selective hemadsorption for sepsis with, S4:52
- Polymyxin B (PMX-B)-immobilized polystyrene-derivative fiber hemoperfusion (HP), selective hemadsorption for sepsis with, S4:47-52
- Polymyxin B (PMX-B)-immobilized sepharose-solid-phase column, selective hemadsorption for sepsis with, S4:52
- Polystyrene-derivative fiber hemoperfusion (HP), PMX-B-immobilized, selective hemadsorption for sepsis with, S4:47-52
- Polysulfone membranes
on dialyzers reprocessed with peracetic acid, 501-506
preservation of RRF in ESRD patients on HD with, 366-373
- Polytetrafluoroethylene (PTFE) grafts
IE in ESRD patients on HD with dual-lumen catheters, AVF and, compared, 521-524
vascular access surgery and, 526, 528, 529
- Polyunsaturated fat intake by CRF patients, exercise training and, 187, 189
- Polyuria in poorly controlled DM, factors contributing to, 829-835
- Population
census population base in ESRD incidence and prevalence measurement, S1:203-204
standard, for adjustment, S1:11-12, S1:96
- Post-dialysis BUN (blood urea nitrogen) sampling, S2:39-40, S2:62
- Postinfectious glomerulonephritis (GN), progressive, with multiple tubuloreticular inclusions in HIV-negative patient, 725-728
- Postischemic acute renal failure (ARF), NO role in, 324-325
- Postpartum period, sickle cell nephropathy during, in SLE patient, 879-883
- Posttransplantation lymphoproliferative disorder (PTLD)
EBV infection and, 301-307, 449-454
renal allograft with lymphocytic infiltrate and, 449-454
- Potassium, *see* K
- Predialysis BUN (blood urea nitrogen)
carbamylated Hb and levels of, 361-365
sampling of, S2:38, S2:61-62
- Predialysis chronic renal failure (PDCRF), effects of exercise training on cardiorespiratory endurance, hypertension, and renal function in, 180-192
- Predisposition
to arrhythmias on HD, autonomic neuropathy and, 219-223
see also Risk factors
- Prednisolone
for immunotactoid glomerulopathy, 160-163
for thrombotic microangiopathy associated with IFN- α for CML, 124-125
- Prednisone
for AIDS-associated membranous nephropathy with advanced renal failure, 116-119
for HIVAN, 156-159
- Pre-end-stage renal disease (ESRD) medical care data in DMMS, S1:69
- Pregnancy
and manifestations of HUS, 760-765
sickle cell nephropathy during postpartum period in SLE patient, 879-883
- Prenatal diagnosis, DNA-based AS, by genetic linkage in families with Alport's syndrome, 174-179
- Preoperative vancomycin, prophylaxis of postoperative vascular access infections with, 343-348
- Prescription of CRRT for ARF
delivered dose and, S4:15-19
factors influencing, S4:10-11
of initial CRRT dose, S4:7-8
- Prescription of HD for ESRD
delivery of, with reused dialyzers, 861-862
of HD dose, NKF-DOQI guidelines on, S2:34-35
rHuEPO resistance and, S3:220
see also Prescription of PD for ESRD, NKF-DOQI guidelines on
- Prescription of PD for ESRD, NKF-DOQI guidelines on, S2:121
achieving prescribed dose of, S2:93-94
of CAPD, USRDS 1997 ADR on, S1:62-63
empirical approach to, S2:88-90
patient-related failure to achieve, S2:93, S2:132-133
- Preservation
of RRF in ESRD patients on HD with biocompatible membranes, 366-373
of veins for AV access, S3:159-160
- Pressure
oncotic, edema formation and, in hypoalbuminemic HIVAN patients with proteinuria, 822-828
see also Blood pressure
- Prevalence
of mental impairment in ESRD patients on HD, 41-49
see also Prevalence of ESRD, USRDS 1997 ADR on *and specific conditions*
- Prevalence of ESRD, USRDS 1997 ADR on, S1:12, S1:14
pediatric, S1:134
see also Incidence and prevalence of treated ESRD, USRDS 1997 ADR on
- Prevention
of vascular access complications, S3:167-169
see also Prophylaxis, vascular access antibiotic
- Previous renal transplantation, as factor influencing completion of advance directives, 357
- Primary arteriovenous fistula, *see* Arteriovenous fistula and graft in HD
- Primary disease
in chronic renal insufficiency, effects of AI kitchen utensils on, 655
see also Primary disease in ESRD, USRDS 1997 ADR on *and specific conditions*

- Primary disease in ESRD, USRDS 1997 ADR on, S1:12
incidence of treated patients by, S1:41, S1:51-52
mortality and, S1:91-92, S1:105-106
in pediatric patients, S1:130-134
- Primary focal segmental glomerulosclerosis (FSGS), mesangial phenotypic changes associated with mesangial cell lesions in, 632-638
- Primary hepatocytes needed for ELAD in ALF, S4:67-68
- Procedural supplements to HD adequacy NKD-DOQI guidelines, S2:18
- Products, USRDS, S1:12, S1:24-36; *see also specific USRDS products*
- Professional attitudes (and practices) regarding living kidney donation, 549-557
- Profit status of dialysis facilities for ESRD, SHR by, USRDS 1997 ADR on, S1:155-157
- Prognosis of multiple myeloma-induced renal failure with HD, 786-792
- Program Management and Medical Information System (PMMIS), USRDS, S1:196-197
- Progression
of IgAN, IL-1 receptor antagonist modulating, 693-699
see also Course; Progression of (and to) CRF and entries *beginning with term*: Progressive
- Progression of (and to) CRF
by MCD, MPGN, FSGS, and IgAN, urinary PAs and, 404-412
vasopressin and, 5:i-ii
- Progressive polycystic kidney disease (PKD), slowly, accumulation and excretion of renal cAMP in, 703-709
- Progressive postinfectious glomerulonephritis (GN) with multiple tubuloreticular inclusions in HIV-negative patient, 725-728
- Progressive renal failure associated with positive anti-myeloperoxidase ANCA in scleroderma, D-penicillamine effects on, 279-281
- Progressive renal insufficiency, dietary protein restriction and, 297-300
- Projects goals of USRDS, S1:21
- 1,2 Propandiol (propylene glycol), proximal tubular cell injury due to, 134-139
- Prophylaxis, vascular access antibiotic
of postoperative vascular access infections with preoperative vancomycin, 343-348
for vascular access placement, 448
- Propylene glycol (1,2 propandiol), proximal tubular cell injury due to, 134-139
- Protein(s)
acute-phase, peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients, 923-927
dialyzer reuse and loss of, 864-865
dietary, *see* Dietary protein intake
ECM, Na depletion enhancing renal fibrosis, expression of TGF- β 1 and, in chronic CSA nephropathy, 71-81
total, in IgA nephropathy, enalapril effects on, 401
see also Protein catabolic rate on HD; Proteinuria
- Protein catabolic rate (PCR) on HD
lean body mass and, 672-679
normalized, *see* nPCR in HD, PD, and/or CAPD
and patient assessment of protein nutrition, 516, 518
- Protein equivalent of nitrogen appearance, *see* PNA in PD
- Proteinuria, 397-412
in HIVAN, *see* Proteinuria in HIVAN
in IgA nephropathy, 397-403
and Ki-67 cell proliferation in renal disease, 88
urinary PAs in characterization of, in MCD, FSGS, MPGN, and IgAN, 404-412
see also Urinary excretion, protein
- Proteinuria in HIVAN
oncotic pressure and edema formation in hypoalbuminemia in patients with, 822-828
prednisone and, 156-159
- Proteoglycans in chronic CSA nephropathy, 71-81
- Protocols on CRRT in ICU, S4:114-115
- Proximal tubular cell injury
altered polarity and tubular obstruction and, S4:91
propylene glycol-related, 134-139
- Pseudoaneurysm formation with AV access, treatment of, S3:170-171, S3:177
- PTFE grafts, *see* Polytetrafluoroethylene grafts
- PTG, *see* Parathyroid gland
- PTH, *see entries beginning with terms*: Parathyroid hormone
- PTHrP (parathyroid hormone-related peptide), *see* Parathyroid hormone, effects of excess of, on nonclassical target organs
- PTLD, *see* Posttransplantation lymphoproliferative disorder
- Pumped circulation with CRRT for ARF, S4:16
- PVS (persistent vegetative state), withdrawal of dialysis from patients in, 291-296
- Pyelonephritis
chronic, and chronic renal insufficiency, 655
xanthogranulomatous, in renal transplantation recipients, 846-848
- Quality assurance (QA) for CRRT in ICU, S4:115
- Quality of care
HD and PD patient's view of, 793-801
standards of, for vascular access, S3:179-183
- Quality improvement, continuous, ESRD Core Indicators Study and, 349-355
- Quality of life (QOL) of ESRD patients
DMMS data on, S1:83-84
on HD and/or PD, *see* Quality of life of ESRD patients on HD and/or PD
see also Health and quality of life outcomes of dialyzed ESRD patients, assessment of; Self-assessment by HD or PD patients
- Quality of life (QOL) of ESRD patients on HD and/or PD with HD, S2:21
patients' view of, 793-801
with PD, S2:97
- Quantification of CRRT in ARF, role of, S4:10-14
- Race and ethnicity
and Cr excretion in chronic renal insufficiency, 16-22
of CRF and/or ESRD patients, *see entries beginning with terms*: Race and ethnicity of ESRD patients
and etiology of NS, 624, 625
and outcome of cyclophosphamide therapy of severe lupus nephritis, 872-878
of renal transplantation recipients, *see* Race and ethnicity of renal transplantation recipients
- Race and ethnicity of ESRD patients, access to renal transplantation and, 733-759

- minimizing disparity due to, 749-759
sex and, 733-748
- Race and ethnicity of ESRD patients, incidence of treated ESRD by, USRDS 1997 ADR on
of adult patients, S1:41-45, S1:51
of pediatric patients, S1:128-130, S1:132, S1:133
- Race and ethnicity of ESRD patients, sex and
and access to renal transplantation, 733-748
and patient survival, 739-748
therapeutic options and, 856-858
see also Race and ethnicity of ESRD patients, USRDS 1997 ADR on; Race and ethnicity of ESRD patients, access to renal transplantation and; Race and ethnicity of ESRD patients on HD and/or CAPD
- Race and ethnicity of ESRD patients, USRDS 1997 ADR on, S1:11, S1:196, S1:204, S1:205
DMMS data by, S1:72
and graft loss, S1:123-124, S1:126
and hospitalization, S1:149
incidence and, *see* Race and ethnicity of ESRD patients, incidence of treated ESRD by, USRDS 1997 ADR on
Medicare expenditures by, S1:171, S1:172
mortality and, *see* Race and ethnicity of ESRD patients, USRDS 1997 ADR on mortality and
remaining years of life and, S1:99
- Race and ethnicity of ESRD patients, USRDS 1997 ADR on mortality and, S1:91, S1:101, S1:105
on causes of mortality, S1:109-110
- Race and ethnicity of ESRD patients on HD and/or CAPD, 167-169
of ESRD children, 195
in ESRD Core Indicators Study, 351
as factor in completion of advance directives, 357
hypoalbuminemia effects on serum Lp(a) and, 509
intradialytic hypotension and, 773
mentally impaired, 43, 45
patient survival and, 207, 208, 739-748
and patients' view of quality of care, 796
PET and urea kinetics and, 374-381
of predialysis patients, 181
rHuEPO therapy and, 30, 497
and self-assessment of HD adequacy and protein nutrition, 516
vascular access and, 52, 526
- Race and ethnicity of renal transplantation recipients
with CMV infection, 767
see also Race and ethnicity of ESRD patients, access to renal transplantation and
- RAD (renal tubule assist device), bioartificial, to enhance CRRT of ARF, S4:28-31
- Radiocontrast exposure, ANP and ET level following, 82-86
- Radiography of chest following placement of internal jugular vein catheter for HD, 690-692
- RBC, *see entries beginning with terms*: Red blood cell
- RCC (Renal Community Council), S1:22-23
- Recirculation, vascular access
blood flow rates and, 475-482
monitoring, S3:165-166
with Tesio twin catheters, 213-218
- Recombinant human erythropoietin (rHuEPO) for ESRD patients on HD and/or CAPD
with AIDS, infection severity and response to, 28-35
with androgens, *see* Androgens, rHuEPO and
ESRD Core Indicators Study report on, 165-173
Fe deficiency and, *see* Recombinant human erythropoietin for ESRD patients on HD and/or CAPD, Fe deficiency and
hypertension and, 600
for mentally impaired patients, 47
and NO effects on BP, 667
USRDS 1997 ADR on, S1:65
see also Recombinant human erythropoietin for ESRD patients on HD and/or CAPD, NKF-DOQI guidelines on
- Recombinant human erythropoietin (rHuEPO) for ESRD patients on HD and/or CAPD, Fe deficiency and
Fe supplementation effects on requirements for, 814-821, 907-911
rHuEPO effectiveness in, 532-541
see also Reticulocytes, and rHuEPO therapy
- Recombinant human erythropoietin (rHuEPO) for ESRD patients on HD and/or CAPD, NKF-DOQI guidelines on
on adverse effects, S3:222-223, S3:226
on Hct and Hb with, S3:199-200, S3:215-216
on inadequate response to, S3:218-220, S3:226
initial, S3:213-214
IP, S3:217
IV and SC, S3:212-217
on resistance to rHuEPO, S3:220
- Recurrent hemolytic uremic syndrome (HUS) of autosomal recessive inheritance following renal transplantation, 760-765
- Red blood cell (RBC; erythrocyte) ferritin, reticulocyte measurements and evaluation of, in monitoring response to IV Fe therapy, 814-821
- Red blood cell (RBC; erythrocyte) glutathione (GSH), levels of whole blood and, in HD and PD patients, 489-494
- Red blood cell (RBC; erythrocyte) transfusions for anemia of CRF, S3:221
- Referral for transplantation, *see* Race and ethnicity of ESRD patients, access to renal transplantation and
- Region, SHRs for ESRD by, S1:153-154
- Reimbursements, *see* Medicare expenditures for ESRD, USRDS 1997 ADR on
- Rejection, acute graft, PTLd and, renal graft with lymphocytic infiltrate and, 449-454
- Release of USRDS data, S1:36-39
agreement for, S1:38-39
for investigator-initiated research, policy on, S1:36-37
- Remaining years of life of ESRD patients, expected, USRDS 1997 ADR on, S1:86, S1:97-100, S1:211
- Renal allograft, *see* Graft loss; Graft rejection; Graft survival; Renal transplantation
- Renal artery, renal infarction due to dissection of, 851-855
- Renal biopsy
of familial FSGS, 266
of immunotactoid glomerulopathy, 160-163
of MCD and IgAN, Ki-67 cell proliferation demonstrated by, clinical findings correlated with, 87-97
of NS (1976-1979; 1995-1997), 621-631
of progressive postinfectious GN with multiple tubuloreticular inclusions in HIV-negative patient, 725-728
of PTLd, 301-307

- of renal graft with lymphocytic infiltrate, 449-454
- of sickle cell nephropathy during postpartum period in SLE patient, 879-883
- of thrombotic microangiopathy associated with IFN- α therapy of CML, 124-125
- ultrasound in, 580
- Renal cAMP (cyclic adenosine monophosphate), accumulation and urinary excretion of, in slowly progressive PKD, 703-709
- Renal clearance
 - iothalamate, 646-652
 - residual, ethnic variability in, of ESRD patients on CAPD, 376, 377, 379
- Renal Community Council (RCC), S1:22-23
- Renal development, genetic manipulation of, 1:xlvi
- Renal failure
 - acute, *see* Acute renal failure
 - chronic, *see* Chronic renal failure
 - due to IFN- α therapy of CML, 123-130
 - moderate, capillary deficit in heart but not in skeletal muscle in, 382-388
 - multiple myeloma-induced, HD for, 786-792
 - progressive, associated with positive anti-myeloperoxidase ANCAs in scleroderma, D-penicillamine effects on, 279-281
- Renal fibrosis, Na depletion enhancing expression of TGF- β 1 and ECM proteins and, in chronic CsA nephropathy, 71-81
- Renal function
 - effects of exercise training in PDCRF on cardiorespiratory endurance, hypertension and, 180-192
 - with GN, urinary PAs and, 407
 - in HIVAN, prednisone and, 156-159
 - in IgAN, IL-1 receptor antagonist effects on, 697-698
 - influence of, on peripheral IgA-secreting cells in nontransplanted IgAN patients, 67-68
 - residual, *see* Residual renal function
 - see also specific aspects of renal function and specific conditions*
- Renal hemodynamics
 - interdialytic, in HD patients, effects of hypervolemia on, 466-474
 - NO effects on, 320-321
- Renal histology
 - in chronic CsA nephropathy, 74
 - of GN, urinary PAs and, 407
 - of IgA nephropathy, glomerular Fc α R expression and, 393
 - see also* Renal biopsy
- Renal infarction, renal artery dissection and, 851-855
- Renal insufficiency
 - chronic, *see* Chronic renal insufficiency
 - progressive, dietary protein restriction and, 297-300
- Renal nitric oxide, *see* Nitric oxide, renal
- Renal replacement therapy, *see* Continuous renal replacement therapy; Renal replacement therapy for ESRD, USRDS 1997 ADR on; Renal replacement therapy modality(ies) for ESRD, USRDS 1997 ADR on and *specific renal replacement therapies*
- Renal replacement therapy (RRT) for ESRD, USRDS 1997 ADR on
 - acceptance into, S1:202-204
 - see also* Renal replacement therapy modality(ies) for ESRD, USRDS 1997 ADR on
- Renal replacement therapy (RRT) modality(ies) for ESRD, USRDS 1997 ADR on, S1:14, S1:54-66
 - in DMMS, *see* Dialysis Morbidity and Mortality Study, USRDS 1997 ADR on; RRT modality and international, *see* International renal replacement therapy modality(ies) for ESRD, USRDS 1997 ADR on
 - Modality Sequence SAF and, S1:30
 - options in, S1:54-56; *see also* Hemodialysis for ESRD, USRDS 1997 ADR on; Peritoneal dialysis for ESRD, USRDS 1997 ADR on; Renal transplantation, USRDS 1997 ADR on
 - and patient survival, S1:59, S1:209-211
 - rHuEPO and, S1:65
 - trends in, S1:56-59
 - utilization of, by patient characteristics, S1:59-61
 - see also* Incidence of treated ESRD, USRDS 1997 ADR in; Renal replacement therapy modality(ies) for pediatric ESRD, USRDS 1997 ADR on
- Renal replacement therapy (RRT) modality(ies) for pediatric ESRD, USRDS 1997 ADR on
 - on CCPD as, S1:135, S1:139-141
 - see also* Continuous ambulatory peritoneal dialysis for pediatric ESRD, USRDS 1997 ADR on; Pediatric renal transplantation, USRDS 1997 ADR on
- Renal scarring, as target of gene therapy, 1:xlvi
- Renal transplantation
 - ABPM in, 601-602
 - access to, *see* Access to renal transplantation, USRDS 1997 ADR on; Race and ethnicity of ESRD patients, access to renal transplantation and
 - for autosomal recessive inheritance of HUS, 760-765
 - CsA induction and sequential therapy with ATG in, compared, 639-645
 - HSV encephalitis in recipient of, 423-428
 - and PTLN, *see* Posttransplantation lymphoproliferative disorder
 - systemic thrombolysis for acute myocardial infarction in recipients of, 849-850
 - xanthogranulomatous pyelonephritis in recipients of, 846-848
 - see also* Graft function; Graft loss; Graft rejection; Graft survival; Renal transplantation, USRDS 1997 ADR on
- Renal transplantation, USRDS 1997 ADR on, S1:16, S1:118-127
 - on access to, *see* Access to renal transplantation, USRDS 1997 ADR on
 - analytical methods to determine, S1:206-209
 - and first transplantation rate table, S1:196
 - on graft loss, S1:121-126
 - on graft survival, *see* Graft survival, USRDS 1997 ADR on
 - on hospitalization for, S1:208-209
 - international, S1:190-191
 - on Medicare expenditures for, S1:18-19, S1:160-163, S1:169-172
 - on mortality with, S1:111, S1:114, S1:209
 - as option, S1:54-55
 - on patient survival with, S1:119, S1:139-141, S1:210-211
 - pediatric, *see* Pediatric renal transplantation, USRDS 1997 ADR on
 - STR and, S1:25-27

- Transplant SAF and Transplant Follow-up SAF, S1:30, S1:32
 UNOS database and, S1:197-198
 Renal tubule(s), *see* Renal tubule assist device *entries beginning with term*: Tubular and *element*: Tubulo-
 Renal tubule assist device (RAD), bioartificial, to enhance CRRT of ARF, S4:28-31
 Renal ultrasound procedures, 579-582
 Renal vasculature, ultrasound of, 580
 Renal vasculitis with HIV infection, as manifestation of CMV infection, 428-432
 Renin
 peripheral, activity of, in chronic CsA nephropathy, 74
 plasma, in IC-GN, 250
 Renovascular disease in ESRD, internal jugular vein catheter placement and, 691
 Reproducibility of PD dose measurement, S2:80, S2:120-122
 Requests for USRDS data, S1:27
 Research, USRDS 1997 ADR on
 independently supported, USRDS SAFs used in, S1:31
 investigator-initiated, policy on USRDS data release for, S1:36-37
 USRDS analysis files for, S1:27-29
Researcher's Guide to the USRDS Database, S1:24, S1:36, S1:208
 Residence of ESRD patients, S1:202
 Residence Standard Analysis File (SAF), S1:30
 Residual renal clearance, ethnic variability in, of ESRD patients on CAPD, 376, 377, 379
 Residual renal function (RRF)
 and initiation of dialysis, 902
 see also Residual renal function in HD or PD patients
 Residual renal function (RRF) in HD or PD patients
 contribution of, to urea clearance with thrice-weekly HD, S2:59
 PD dose and, S2:77, S2:118-119, S2:121
 preservation of, with biocompatible membranes, 366-373
 Resin, modified anion exchange sorbent, selective hemadsorption for sepsis with, S4:52
 Resistance
 to diuretics, 4:iii
 to rHuEPO, S3:220
 Reticulocytes, and rHuEPO therapy, 535, 537
 Hb content in reticulocytes predicting functional Fe deficiency, 912-922
 reticulocyte measurements monitoring response to IV Fe therapy and its effects on rHuEPO requirements, 814-821
 Reused dialyzers
 in ESRD care facilities, S1:182-185
 HD adequacy with, S2:19-20
 β_2 -MG removal with, 501-506, 865
 peracetic acid-reprocessed, effects of, on urea clearance, 501-506
 TCV of, S2:43-45
 see also Reused dialyzers, NKF report on
 Reused dialyzers, NKF report on, 859-871
 complement activation and cytokine formation with, 864
 conclusions and recommendations on, 867-869
 delivery of dialysis prescription with, 861-862
 federal regulation of, 866-867
 infections with, 863-864
 intradialytic symptoms with, 862-863
 β_2 -MG clearance with, 865
 mortality with, 860-861
 patient's understanding of, 867
 protein loss with, 864-865
 toxicity of prolonged exposure to germicides and, 865-866
 Reversibility of carbamylated Hb in ARF and CRF, 36-40
 Review of NKF-DOQI guidelines, S2:10-11, S3:146-147
 rHuEPO, *see entries beginning with terms*: Recombinant human erythropoietin
 Ribonucleic acid (RNA), *see* mRNA
 Right ventricular myocardial infarction, dilutional acidosis as complication of, 561-567
 Risk factors
 for AAU urolithiasis, 242
 see also Predisposition; Risk of mortality of ESRD patients on HD
 Risk of mortality of ESRD patients on HD, 4-8
 effects of variance in eKt/Vd(m) and eKt/Vd on relationship between, 6-8
 for LVH in elderly patients on CHD, 224-228
 relative mortality risk, dialysis dose function and, 4-6
 RNA (ribonucleic acid), *see* mRNA
 RRF, *see* Residual renal function
 RRT (renal replacement therapy), *see* Continuous renal replacement therapy; Renal replacement therapy for ESRD, USRDS 1997 ADR on; Renal replacement therapy modality(ies) for ESRD, USRDS 1997 ADR on and *specific renal replacement therapies*
S aureus, *see*: *Staphylococcus aureus*; *Staphylococcus aureus* Cowan I; *Staphylococcus aureus* endocarditis
 SAA (serum amyloid A), peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients on PD, 923-927
 SACs (Scientific Advisory Committees), USRDS, S1:22
 SAFs, *see* Standard Analysis Files, USRDS
 Salt (NaCl)-sensitive hypertension (HTN), role of NO in, 322-323
 Sarcoidosis, granulomatous IN and, 586-588
 Saturated fat intake by CRF patients, exercise training and, 187, 189
 SBP (systolic blood pressure), *see* Blood pressure
 SC, *see entries beginning with term*: Subcutaneous
 Scarring, renal, as target of gene therapy, 1:xlvi
 School attendance by pediatric PD patients, S2:97-98
 Scientific Advisory Committees (SACs), USRDS, S1:22
 Scleroderma, D-penicillamine effects on progressive renal failure associated with positive anti-myeloperoxidase ANCA in, 279-281
 Sclerosing peritonitis (SCP) with CAPD, corticosteroid therapy of, 275-278
 Sclerosis, *see* Glomerulosclerosis
 SCP (sclerosing peritonitis) with CAPD, corticosteroid therapy of, 275-278
 SDS-PAGE (sodium-dodecyl-sulphate polyacrylamide gel electrophoresis) patterns of proteinuria in GN, 404-412
 Secondary collapsing focal segmental glomerulosclerosis (FSGS) associated with *Loa loa* filariasis, 836-839
 Secondary hyperparathyroidism, severe, parathyroidectomy for, in CRF patients on HD, hypocalcemic tetany and metabolic alkalosis and, 440-444

- Seizures, and rHuEPO therapy, S3:222
- Selective hemadsorption for sepsis, S4:47-52
- Self-assessment by HD or PD patients
of functional health status on SF-36, as predictor of survival, hospitalization, and HD compliance, 204-212
of HD adequacy and protein nutrition, 514-520
of quality of life by PD patients, S2:97
- Seminars on CRRT in ICU, S4:112
- Sepharose-solid-phase column, PMX-B-immobilized, selective hemadsorption for sepsis with, S4:52
- Sepsis, CRRT for, S4:38-56
adsorbent-based strategies in, S4:44-56
kinetics of PAF removal with, S4:57-65
removal of inflammatory mediators in, during CRRT, S4:38-43
see also Infections
- Sequential therapy with ATG, CsA induction therapy and, in renal transplantation, compared, 639-645
- Serpiginous ulcers, gastric and ileocecal, due to oral Kayexalate in sorbitol therapy, 120-122
- Serine-threonine phosphatase, calcineurin function and expression and, 886-890
- Serum Al (aluminum) in chronic renal insufficiency, effects of Al kitchen utensils on, 655
- Serum albumin
acute-phase proteins and peritoneal dialysate albumin loss as determinants of, 923-927
in IgA nephropathy, enalapril effects on, 401
at initiation of dialysis, 902
in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
see also Serum albumin in ESRD patients on HD, PD, and/or CAPD
- Serum albumin in ESRD patients on HD, PD, and/or CAPD
correlation of peritoneal transport kinetics with, but not with overall nutritional status of CAPD patients, 229-236
effects of increasing, on serum Lp(a) in, 507-513
ESRD Core Indicators Study report on, 167
rHuEPO effects on Hct correlated with concentrations of, in patients with AIDS, 28-35
- Serum amyloid A (SAA), peritoneal dialysate albumin loss and, as determinants of serum albumin level in ESRD patients on PD, 923-927
- Serum calcium (Ca)
in CRF, 811, 812
in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
and preservation of RRF, membrane types and, 370
- Serum cholesterol (C)
in IgA nephropathy, enalapril effects on, 399
in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Serum creatinine (Cr)
chronic CsA nephropathy effects on, 74
in chronic renal insufficiency, 19
in ESRD patients with AIDS, 30
in IC-GN, 247, 250
in IgA nephropathy, 399, 401, 696
and Ki-67 cell proliferation in renal disease, 88, 92
in moderate renal failure, 384
in multiple myeloma-induced renal failure, 787
in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
in PDCRF patients, exercise training effects on, 186
radiocontrast exposure and, 83
in renal transplantation with CMV infection, 767
- Serum Fe (iron) in chronic renal insufficiency, effects of Al kitchen utensils on, 655
- Serum ferritin
in assessment of Fe status in ESRD patients, S3:205-206
in HD patients, RRF preservation and, 371
rHuEPO effects on, in Fe deficiency patients, 534, 535, 537
- Serum lipoprotein (Lp), and hypoalbuminemia effects on, in ESRD patients on CAPD, 508-510
- Serum lipoprotein(a) [Lp(a)], effects of increasing serum albumin on, in ESRD patients on CAPD, 507-513
- Serum P (phosphorus) in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Serum parathyroid hormone (PTH)
in CRF, serum phosphate association with, 809-813
in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
19-NOR-1,25-(OH)₂D₃ suppresses parathyroid gland growth and, in uremia, without intestinal vitamin D receptor elevation, 105-112
- Serum phosphate
associated with serum PTH in CRF, 809-813
and RRF preservation, membrane types and, 370
- Serum transferrin receptors (TfRs), rHuEPO effects on, in Fe deficiency patients, 534, 535, 537
- Serum triglycerides (TGs) in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Serum urea in moderate renal failure, 384
- Serum urea nitrogen (N) in IgAN, IL-1 receptor antagonist effects on, 696
- Severe hypertriglyceridemia, as indication for switching from PD to HD, S2:104
- Severe lupus nephritis, cyclophosphamide therapy of, 872-878
- Severe malnutrition
as contraindication for PD, S2:103
as indication for switching from PD to HD, S2:104
- Severe secondary hyperparathyroidism, parathyroidectomy for, in CRF patients on HD, hypocalcemic tetany and metabolic alkalosis and, 440-444
- Severe lupus nephritis, cyclophosphamide for, 872-878
- Severity
of AIDS in HD ESRD patients, and response of, to rHuEPO therapy, 28-35
see also entries beginning with term: Severe
- Sex
of ARF patients, 216, S4:73
of chronic renal insufficiency patients, 655
of CRF and/or ESRD patients, *see* Sex of ESRD patients and IC-GN, 247
of IgA nephropathy patients, and enalapril effects on von Willebrand factor levels, 399
and Ki-67 cell proliferation in renal disease, 88
of NIDDM patients, elevated cytosolic Ca and B lymphocyte proliferation and, 99
of multiple myeloma-induced renal failure patients, 787
of renal transplant recipients, *see* Sex of renal transplantation recipients

- Sex of ESRD patients
 serum PTH and serum phosphate association and, 810
see also Race and ethnicity of ESRD patients, sex and;
 Sex of ESRD patients, USRDS 1997 ADR on; Sex of
 ESRD patients on HD PD, and/or CAPD
- Sex of ESRD patients, incidence of treated ESRD by, USRDS
 1997 ADR on
 of adult patients, S1:41-45, S1:51
 of pediatric patients, S1:128-130, S1:132, 133
- Sex of ESRD patients, USRDS 1997 ADR on
 DMMS data by, S1:72
 incidence of treated patients by, *see* Sex of ESRD patients,
 incidence of treated ESRD by, USRDS 1997 ADR on
 Medicare expenditures and, S1:171, S1:172
 mortality and, S1:101, S1:105, S1:109-110
 remaining years of life and, S1:99
 and renal graft loss, S1:123-124, S1:126
- Sex of ESRD patients on HD, PD, and/or CAPD, 167-169
 on chronic PD, as factor in completion of advance direc-
 tives, 357
 elderly patients on CHD, LVH and, 225, 226
 in ESRD Core Indicators Study, 351
 hypoalbuminemia effects on serum Lp(a) and, 509
 IE and, 522
 internal jugular vein catheter placement and, 691
 intradialytic hypotension and, 773
 LVH and, effects of lisinopril therapy and, 661
 mentally impaired, 43, 45
 and NO effects on BP in, 667
 and patients' view of quality of care, 796
 PCR and, 676
 PET and urea kinetics and, 375, 376
 predialysis, 181
 rHuEPO therapy and, 30, 497
 and self-assessment of HD adequacy and protein nutrition,
 516, 517
 survival and, 207, 208
 vascular access and, 52, 216
- Sex of renal transplantation recipients
 with CMV infection, 767
 CsA induction therapy and ATG sequential therapy and,
 640
 with HUS, 763
see also Race and ethnicity of ESRD patients, sex and
 SF-36, self-assessment of functional health status with,
 by ESRD patients on HD, as predictor of survival,
 hospitalization, HD compliance, 204-212
- SGA (subjective global assessment) of PD patient nutritional
 status, S2:83-84, S2:127
- SGOT (aspartate aminotransferase), effects of low-dose
 rHuEPO alone or combined with androgens on, 497
- SHR, *see* Standard hospitalization ratio
- SIADH (syndrome of inappropriate secretion of antidiuretic
 hormone), hyponatremia following hysteroscopic en-
 dometrial ablation for, 717-719
- Sickle cell nephropathy during postpartum period in SLE
 patient, 879-883
- Side effects
 of loop diuretics, 4:ii-iii
see also Adverse effects
- Signal transduction, membrane receptor, serine-threonine
 phosphatase and, 889-890
- Silver, elimination of, in HD burn patients treated with SSD
 cream, 287-290
- Silver sulfadiazine (SSD) cream, burn patients on HD treated
 with, silver elimination and, 287-290
- Simulation, CRRT training in ICU with, S4:113
- Single-pool Kt/V, double-pool versus, HD dose and, S2:28-
 31
- 60-Day Rule, hospitalization and, S1:148, S1:208
- Size
 of dialysis facility for ESRD, SHR by, S1:154-155
 of USRDS SAFs, S1:35
- Skeletal muscle(s)
 capillary deficit in myocardium but not in, in moderate
 renal failure, 382-388
 excess PTH effects on, 612
- Skin
 biopsy of, in patient with thrombotic microangiopathy as-
 sociated with IFN- α therapy of CML, 124
 excess PTH effects on, 614
 preparation of, for AV access, S3:166
- Skin wall infection, as contraindication for PD, S2:102
- SLE (systemic lupus erythematosus), sickle cell nephropathy
 during postpartum period in patient with, 879-883
- Slow flow/stop pump technique for BUN sampling, S2:40-
 42
- Slowly progressive polycystic kidney disease (PKD), accu-
 mulation and excretion of renal cAMP in, 703-709
- Smoking
 by IgA nephropathy patients, and enalapril effects on von
 Willebrand factor levels, 399
 and NO effects on BP in ESRD patients on HD, 667
 α (alpha)-Smooth muscle actin (ASMA) in primary FSGS,
 634-635
- SMR, *see* Standard mortality ratio
- Sodium, *see* Na
- Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis
 (SDS-PAGE) patterns of proteinuria in GN, 404-412
- Software needed for SAF use, S1:36
- Solutes
 inadequate transport of, as indication for switching from
 PD to HD, S2:103-104
 large molecular weight, flux of, on HD, S2:20
 total clearance of, PD dose measurement and, S2:74-76
see also specific solutes
- Sonogram, *see* Ultrasound
- Sorbitol therapy, oral Kayexalate in, combined gastric and
 ileocecal toxicity due to, 120-122
- Sorbent resin, modified anion exchange, selective hemad-
 sorption for sepsis with, S4:52
- Space flights, gravity and, and effects on bone metabolism,
 6:i-iii
- Special studies, USRDS, 150, S1:32-34
see also USRDS specific studies
- Special Studies Review and Implementation Committee
 (SSRIC), USRDS, S1:7, S1:23
- Specific hemadsorption for sepsis, S4:53
- Spurious hypophosphatemia in multiple myeloma patient,
 571-575
- SSD (silver sulfadiazine) cream, burn patients on HD treated
 with, silver elimination and, 287-290
- SSRIC (Special Studies Review and Implementation Com-
 mittee), USRDS, S1:7, S1:23

- Stabilized national death rates of ESRD patients, USRDS 1997 ADR on, S1:104-105
- Staff-related failure to achieve prescribed PD dose, S2:93-94
- Standard Analysis Files (SAFs), USRDS, S1:29-33
on CD-ROMs, *see* CD-ROMs, SAFs on
cost of using, S1:36
equipment needed to use, S1:35-36
formats of, S1:35
Medicare expenditures for ESRD on, S1:160-162, S1:166, S1:167
- Standard hospitalization ratio (SHR), S1:25-27, S1:145-146
by facility, S1:26-27, S1:154-157
methods of calculating, S1:151-152
by region, S1:153-154
time trends in, S1:157-158
- Standard mortality ratio (SMR), S1:25-27
defined, S1:151
facility-specific, S1:26-27, S1:100-103
SHRs and, S1:145, S1:156-157
- Standard population for adjustment in USRDS 1997 ADR, S1:11-12, S1:196
- Standard transplantation ratio (STR), S1:25-27
- Standardization (adjustment) of rates in USRDS 1997 ADR, S1:204-206
- Staphylococcus aureus* (*S. aureus*), phagocytosis of, by PMNs exposed to PD fluids, 684
- Staphylococcus aureus* (*S. aureus*) Cowan I (SAC), B cell proliferation and elevated $[Ca^{2+}]_i$ in response to, 98-104
- Staphylococcus aureus* (*S. aureus*) endocarditis in ESRD patients on HD, 521-524
- Steering Committee, NKF-DOQI, S2:3, S3:139
- Stenosis with AV graft and fistula
intervention in, S3:170-171
monitoring for, S3:162-164
with thrombosis and without thrombosis, treatment of, S3:173-175
- Sterilization of glucose, and effects of two-chambered HCO_3^- lactate-buffered PD fluids on PBMCs and PMNLs, 680-689
- Steroid(s)
alternate-day, for transplanted ESRD children, 193-204
for MPGN, FSGS, MCD, and IgAN with NS and proteinuria, 409
for sclerosing peritonitis with CAPD, 275-278
see also Prednisolone; Prednisone
- Steroid hormone receptors, and transcription-independent activation of calcineurin, 890-893
- Stones, *see* Nephrolithiasis; Urolithiasis
- STR (standard transplantation ratio), S1:25-27
- Streptozotocin-induced diabetes mellitus (STZ-DM), azotemic, aminoguanidine effects on, 253-259
- Structure, NOS, 313-318
correlation between function and, 317-318
general, 313-315
heterogeneity of, 315-317
- STZ-DM (streptozotocin-induced diabetes mellitus), azotemic, aminoguanidine effects on, 253-259
- Subclavian/innominate vein, supraclavicular approach to, for placement of large-bore central venous catheters, 802-808
- Subcutaneous (SC) recombinant human erythropoietin (rHuEPO) for ESRD patients, S3:212-217
- Subcutaneous (SC) tissue of PD patient, assessment of, S2:128
- Subjective global assessment (SGA) of PD patient nutritional status, S2:83-84, S2:127
- Superoxide production, PMA-stimulated, by PMNs exposed to PD fluids, 684-685
- Supplementation, Fe, in ESRD patients on HD
effects of, on rHuEPO requirements, 814-821, 907-911
NKD-DOQI guidelines on, S3:203-204, S3:225-226; *see also* Intravenous Fe in ESRD patients on HD
- Supraclavicular approach to subclavian/innominate vein for placement of large-bore central venous catheters, 802-808
- Surgery, *see* Renal transplantation; Vascular access, HD
- Survival
PD technique, measurement of, S2:95-96
see also Graft survival; Patient survival
- SV (systemic vasculitis), Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
- Symptoms
of hypotension on HD, minimizing, S2:50-51
intradialytic, with reused dialyzers, 862-863
see also Clinical features and presentation
- Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), hyponatremia following hysteroscopic endometrial ablation, 717-719
- Syndrome X, 923-927
- Systemic lupus erythematosus (SLE), sickle cell nephropathy during postpartum period in patient with, 879-883
- Systemic thrombolysis for acute myocardial infarction in renal transplantation recipients, 849-850
- Systemic vascular disease, office BP and ABPM for, compared, 594-596
- Systemic vasculitis (SV), Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
- Systolic blood pressure, *see* Blood pressure
- T cell(s), excess PTH effects on, 612
- T-cell receptor constant alpha chain (TCR C- α chain) gene polymorphism, IgAN associated with, 260-264
- TCV (total cell volume) of reused dialyzers, S2:43-45
- Technical (mechanical) problems on PD, as indication for switching from PD to HD, S2:104
- Temporal changes and reversibility of carbamylated Hb in ART, 36-40
- Tesio twin catheter system in HD, long-term performance of, 213-218
- Testes, excess PTH effects on, 609-610
- Tetany, hypocalcemic, metabolic alkalosis and, in CRF patient on HD, 440-444
- Tf, *see* Transferrin
- TfRs (transferrin receptors), serum, rHuEPO effects on, in Fe deficiency patients, 534, 535, 537
- TG(s), *see* Triglycerides
- TGF- β 1 (transforming growth factor- β 1), Na depletion enhancing renal fibrosis, expression of ECM proteins and, in chronic CsA nephropathy, 71-81
- Therapy and management
of burn patients with SSD cream, 287-290
emerging, of ARF, S4:89-95; *see also* Acute renal failure, CRRT of

- of Fe deficiency, *see* Fe deficiency in ESRD patients on HD, NKF-DOQI guidelines on intervention in fluid, of dilutional acidosis in right ventricular myocardial infarction, 565-566
- of MCD, MPGN, FSGS, and IgAN with NS and proteinuria, 409
- renal replacement, *see* Continuous renal replacement therapy; Renal replacement therapy for ESRD, USRDS 1997 ADR on; Renal replacement therapy modality(ies) for ESRD, USRDS 1997 ADR on *and specific renal replacement therapies*
- urokinase, protocols for administration of, S3:159
- of vascular access complications, S3:170-178
- see also* Drug therapy; Gene therapy of renal disease; Prevention
- Threonine phosphatase, serine-, calcineurin function and expression and, 886-890
- Thrice-weekly hemodialysis (HD), RRF contribution to urea clearance with, S2:59
- Thrombolysis, systemic, for acute myocardial infarction in renal transplantation recipients, 849-850
- Thrombosis with AV graft and fistula
 - quality of care standards for, S3:180
 - rHuEPO therapy and, S3:223
 - treatment of, S3:173-175
- Thrombotic microangiopathy
 - associated with IFN- α therapy of CML, 123-130
 - autosomal recessive inheritance of HUS and, 760-765
- Time on HD and/or CAPD for ESRD
 - carbamylation Hb and, 361
 - of elderly patients on CHD, LVH and, 225
 - as factor in completing advance directives, 357
 - and hypoalbuminemia effects, 509
 - internal jugular vein catheter placement and, 691
 - and intradialytic hypotension, 773
 - low-dose rHuEPO alone or in combination with androgens and, 497
 - of mentally impaired patients, 45
 - and relationship between LVH, myocardial contractility, and volume overload, 782
 - self-assessment of HD adequacy and, 516
- Time trends in SHRs, S1:157-158
- Timing
 - of AVF placement, S3:160
 - of HD initiation, S2:20-21
 - of PD dose measurement, S2:81-82
- TIN (tubulointerstitial nephritis), Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
- Tissue damage in IgA nephropathy, glomerular Fc α R expression and disease activity and, 389-396
- TNF- α , *see* Tumor necrosis factor- α
- Topic selection for NKF-DOQI guidelines, S2:8, S3:144
- Torsades de pointes in CRF patients on cisapride and clarithromycin therapy, 437-439
- Total admissions, crude rates of hospitalization for ESRD based on, S1:147-151; *see also* Hospitalization for ESRD, USRDS 1997 ADR on
- Total body water
 - in HD dose measurement, S2:58-59
 - in PD dose measurement, S2:80-81, S2:122-125
- Total Ca (calcium) in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 442
- Total cell volume (TCV) of reused dialyzers, S2:43-45
- Total cholesterol
 - in IgA nephropathy, enalapril effects on, 401
 - in PDCRF patients, exercise training effects on, 186
 - in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
- Total CO₂ (carbon dioxide) in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 442
- Total creatinine (Cr) clearance in PD dose measurement, S2:75-77
- Total Medicare expenditures for ESRD (1991-1995), USRDS 1997 ADR on, S1:165
- Total proteins in IgA nephropathy, enalapril effects on, 401
- Total solute clearance in PD dose measurement, S2:74-76
- Toxicity
 - combined gastric and ileocecal, due to oral Kayexalate in sorbitol therapy, 120-122
 - of prolonged dialyzer exposure to germicides, 865-866
 - see also* Chronic cyclosporine nephropathy; Cytotoxicity; Intoxication; Mushroom poisoning
- Toxins, removal of, in sepsis, with ACHP, S4:45-46
- Training and education
 - for CRRT in ICU, S4:112-116
 - in renal ultrasound use, 582
- Transcription-independent activation of calcineurin, steroid hormone receptors and, 890-893
- Transferrin (Tf)
 - in CAPD patients, nutritional status and, 231
 - see also* Transferrin receptors; Transferrin saturation
- Transferrin receptors (TfRs), serum, rHuEPO effects on, in Fe deficiency patients, 534, 535, 537
- Transferrin saturation (TSAT)
 - in chronic renal insufficiency, effects of Al kitchen utensils on, 655
 - see also* Transferrin saturation in ESRD patients
- Transferrin saturation (TSAT), rHuEPO effects on, 916
- in Fe deficiency patients, 535, 537
- of low-dose rHuEPO alone or combined with androgens on, 497, 499
- see also* Transferrin saturation in ESRD patients
- Transferrin saturation (TSAT) in ESRD patients
 - with AIDS, 30, 33
 - and Fe status assessment, S3:204-206
 - see also* Transferrin saturation, rHuEPO effects on
- Transforming growth factor- β 1 (TGF- β 1), Na depletion enhancing renal fibrosis, expression of ECM proteins and, in chronic CsA nephropathy, 71-81
- Transfusions, RBC, for anemia of CRF, S3:221
- Transplant Follow-up Standard Analysis File (SAF), S1:30
- Transplant Standard Analysis File (SAF), S1:30
- Transplantation, *see* Renal transplantation
- Transportation to ESRD facilities used by patients, DMMS data on, S1:84
- Trauma and injury
 - with MOF, cytokine clearance during CVVH of patients with, 483-488
 - proximal tubular cell, *see* Proximal tubular cell injury
 - tissue damage in IgA nephropathy, glomerular Fc α R expression, disease activity and, 389-396
- Treatment History (Modality Sequence) Standard Analysis File (SAF), S1:30
- Triglycerides (TGs)

- effects of low-dose rHuEPO alone or combined with androgens on, 497
- hypoalbuminemia effects on, in ESRD patients on CAPD, 509, 510
- in IgA nephropathy, enalapril effects on, 401
- in PDCRF patients, exercise training effects on, 186
- in renal transplantation with CsA induction and ATG sequential therapy, compared, 643
- serum, in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- severe hypertriglyceridemia as indication for switching from PD to HD, S2:104
- Troubleshooting
- HD dose, S2:46-48, S2:59-62
- PD dose, S2:77-78
- TSAT, *see* Transferrin saturation
- Tubular cells, *see* Proximal tubular cell injury
- Tubular necrosis, acute, *see* Acute renal failure
- Tubular obstruction, proximal tubular cell injury and, S4:91
- Tubular effects of NO, 321-322
- Tubular function
- disorders of, as targets of gene therapy, 1:xlvi
- genetic manipulation of, 1:xlvi
- Tubular necrosis, acute, *see* Acute renal failure
- Tubular obstruction, proximal tubular cell injury and, S4:91
- Tubulointerstitial disease, NO role in, 323-324
- Tubulointerstitial fibrosis in chronic CsA nephropathy, 74
- Tubulointerstitial nephritis (TIN), Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
- Tubuloreticular inclusions (tubulovesicular bodies), multiple, with progressive postinfectious GN in HIV-negative patient, 725-728
- Tumor necrosis factor- α (TNF- α)
- clearance of, during CVVH in trauma with MOF patients, 483-488
- CRRT and removal of, in sepsis, S4:39-40
- production of, by endotoxin-stimulated PBMCs exposed to PD fluids, 683-684
- Tunnelled cuffed catheters, HD, NKF-DOQI guidelines on dysfunctional, treatment of, S3:175-176
- on failure rate of, S3:181-182
- infected, treatment of, S3:176-177
- on location of placement of, S3:157-158
- on patency rate of, S3:182
- Twin catheter system, Tesio, in HD, long-term performance of, 213-218
- Two-chambered HCO₃ (bicarbonate) lactate-buffered peritoneal dialysis (PD) fluids, effects of, on peripheral blood mononuclear cells and PMNLs, 680-689
- Type I diabetes mellitus, *see* Insulin-dependent diabetes mellitus
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Type III collagen in primary FSGS, 634-635
- UG (ureteroglobulin), role of, in glomerulopathy, knockout gene subjects as model for, 720-724
- UKM, *see* Urea kinetic modeling
- Ulcers, serpinous, gastric and ileocecal, due to oral Kayexalate in sorbitol therapy, 120-122
- Ultrafiltration, URR and, S2:33
- Ultrasound
- echocardiography of relationship between LVH, myocardial contractility, and, volume overload on HD, 780-785
- IVCD measured with, to assess dry weight in normotensive and hypertensive CRF patients on HD, 459-465
- procedures for renal, 579-587
- United Network for Organ Sharing (UNOS) data in 1997 ADR, S1:195, S1:197-198
- United States Renal Data System (USRDS)
- committees of, S1:6-7, S1:22-23
- contacts of, S1:23
- data of, *see* Data, USRDS
- database of, *see* Database, USRDS
- organizational structure of, S1:21-22
- products of, S1:12, S1:24-36; *see also specific USRDS products*
- projects goals of, S1:21
- special studies of, 150, S1:32-34
- who's who in, S1:5-7
- see also* United States Renal Data System, 1996 ADR of; United States Renal Data System, 1997 ADR of
- United States Renal Data System (USRDS), 1996 ADR of changes between USRDS 1997 ADR and, S1:10-12
- erratum in, S1:19
- United States Renal Data System (USRDS), 1997 ADR of common acronyms used in, S1:8-9
- executive summary of, S1:10-20
- introduction to, S1:1-3
- methodology of, S1:25-26; *see also* Analytical methods used in USRDS 1997 ADR
- see also* Cost of ESRD care, USRDS 1997 ADR on; Facilities for ESRD care, USRDS 1997 ADR on; Hospitalization for ESRD, USRDS 1997 ADR on; Incidence of treated ESRD, USRDS 1997 ADR on; Mortality, ESRD, USRDS 1997 ADR on; Patient survival with ESRD, USRDS 1997 ADR on; Pediatric end-stage renal disease, USRDS 1997 ADR on; Prevalence of ESRD, USRDS 1997 ADR on; Renal replacement therapy for ESRD, USRDS 1997 ADR on; United States Renal Data System; Vascular access, HD, USRDS 1997 ADR on
- UNOS (United Network for Organ Sharing) data in 1997 ADR, S1:195, S1:197-198
- Upper urinary tract stones containing AAU crystals, 239
- Urea
- ethnic variability in PET and kinetics of, in CAPD patients, 374-381
- in hypocalcemic tetany with metabolic alkalosis in CRF patient on HD, 442
- recirculation measurement based on, protocol for, S3:166
- serum, in moderate renal failure, 384
- urinary excretion of, 399, 401, 830, 833
- see also* Kt/V_{urea} and entries beginning with term: Urea
- Urea clearance
- effects of dialyzers reprocessed with peracetic acid with their blood compartment volume maintained on β_2 -microglobulin removal and, 501-506
- in CRRT of ARF, S4:3-4
- in poorly controlled DM, 830
- RRF and, with thrice-weekly HD, S2:59
- see also* Kt/V; Urea reduction ratio
- Urea distribution volume, S2:59-60

- Urea kinetic modeling (UKM)
computer-assisted, to achieve PD target dose, S2:90-92
in measurement of delivered HD dose, S2:23-26
and PCR, 672-679
for CRRT of ARF, S4:2-9
- Urea nitrogen (N)
blood, *see* BUN
in Goodpasture's syndrome, 711
serum, in IgAN, IL-1 receptor antagonist effects on, 696
- Urea reduction ratio (URR)
in ESRD Core Indicators Study, 349-355
as index of HD adequacy, carbamylated Hb compared with, 361-365
see also Urea reduction ratio, NKF-DOQI guidelines and; Urea reduction ratio, rHuEPO and
- Urea reduction ratio (URR), NKF-DOQI guidelines and
in measurement of delivered HD dose, S2:27
post-dialysis BUN sampling and, S2:40
ultrafiltration and, S2:33
- Urea reduction ratio (URR), rHuEPO and
low-dose rHuEPO alone or in combination with androgens and, 497
rHuEPO effects on Hct correlated with, in ESRD patients with AIDS on HD, 28-35
- Uremia, *see* Chronic renal failure; End-stage renal disease
- Uremic syndrome, hemolytic, autosomal recessive inheritance of, renal transplantation in adults with, 760-765
- Ureteroglobulin (UG), role of, in glomerulopathy, knockout gene subjects as model for, 720-724
- Uric acid
in IgA nephropathy, enalapril effects on, 401
syndrome X and metabolism of, 928-929
- Urinary bladder, ultrasound of, 580
- Urinary excretion
Al, in chronic renal insufficiency, 655
albumin, in IgAN, IL-1 receptor antagonist effects on, 696;
see also Urinary excretion, protein
Cr, 16-22, 247; *see also* Creatinine and creatinine clearance in IgAN, 399, 401, 696
osmotic diuresis in poorly controlled DM, 829-835
of renal cAMP in slowly progressive PKD, 703-709
urea, 399, 401, 830, 833
see also Urinary excretion, K; Urinary excretion, Na and
entries ending with suffix: -uria
- Urinary excretion, K
cyclosporine and FK-506 effects on, 885
in hyponatremia following hysteroscopic endometrial ablation, 718
in IgAN, enalapril effects on, 399, 401
in poorly controlled DM, 830
- Urinary excretion, Na
in hyponatremia following hysteroscopic endometrial ablation, 718
in IgAN, enalapril effects on, 399, 401
in poorly controlled DM, 830
- Urinary excretion, protein
in IC-GN, 247, 250
in primary FSGS, 634
in STZ-DM, aminoguanidine effects on, 256
see also Proteinuria
- Urinary polymers of albumin (PAs), characterization of proteinuria in MCD, FSGS, MPGN, and IgAN with, 404-412
- Urinary tract stones (urolithiasis), AAU, 237-242
- Urine
collections of, in PD dose measurement, S2:82, S2:121-122
volume of, in dilutional acidosis with right ventricular myocardial infarction, 562, 566
see also entries beginning with term: Urinary
- Urokinase, protocols for administration of, S3:159
- Urolithiasis (urinary tract stones), AAU, 237-242
- URR, *see* Urea reduction ratio
- USRDS, *see* United States Renal Data System
- Vancomycin, preoperative, prophylaxis of postoperative vascular access infections with, 343-348
- Vascular access
CRRT, S4:23-24
see also Catheters; Vascular access, HD
- Vascular access, HD
blood flow rates of, measured by differential conductivity technique, 475-482
infective endocarditis and types of, 521-524
survival of, 50-57
see also Catheters, HD; Clinical practice guidelines, NKF-DOQI, on vascular access; Prophylaxis, vascular access antibiotic; Vascular access, HD, cost of; Vascular access, HD, USRDS 1997 ADR on
- Vascular access, HD, cost of
capitation impact on, 542-548
care pathway outpatient surgery reducing, 525-531
in DMMS, S1:75-77
see also Vascular access, HD, cost of, USRDS 1997 ADR on
- Vascular access, HD, cost of, USRDS 1997 ADR on
paid Medicare claims, S1:163-165, S1:172-177
see also Medicare reimbursements for vascular access in ESRD, USRDS 1997 ADR on
- Vascular access, HD, USRDS 1997 ADR on
cost of, *see* Vascular access, HD, cost of, USRDS 1997 ADR on
in DMMS, S1:75-77
- Vascular Access Work Group, NKF-DOQI
leadership and structure of, S3:143
membership of, S3:149, S3:190-191
- Vascular disease
as DM complication, hyperglycemia-induced AGEs and, 253-259
renovascular, in ESRD, internal jugular vein catheter placement and, 691
systemic, office BP and ABPM in, compared, 594-596
see also Vasculitis
- Vascular system
excess PTH effects on, 611
see also entries beginning with terms: Cardiovascular, Renovascular elements: Arter-, Vascu-, Ven- specific veins and arteries
- Vasculature, renal, ultrasound of, 580
- Vasculitis
renal, with HIV infection, as manifestation of CMV infection, 428-432
systemic, Ki-67 cell proliferation demonstrated by renal biopsy of, clinical findings correlated with, 87-97
- Vasculopathy, *see* Vascular disease
- Vasopressin, *see* Antidiuretic hormone

- Vectors of gene transfer to kidney, 1:xliv-xlv
- Vegetative state, persistent, withdrawing dialysis from patients in, 291-296
- Vena cava, *see* Inferior vena cava diameter in ESRD patients on HD
- Venous compliance, and BP changes on HD, as effect of hypervolemia, 466-474
- Venovenous hemodiafiltration, continuous, for ARF, dose delivery with, S4:16
- Venovenous hemofiltration, *see* Continuous venovenous hemofiltration
- Ventricles, *see* Right ventricular myocardial infarction and entries beginning with terms: Left ventricular
- Very-low-density lipoprotein cholesterol (VLDL-C) in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Vitamin B₁₂, rHuEPO and
effects of low-dose rHuEPO alone or combined with androgens on, 497
vitamin B₁₂ deficiency and inadequate response to rHuEPO, S3:219
- Vitamin D receptor, intestinal, 19-NOR-1,25-(OH)₂D₃ suppressing serum PTH and parathyroid gland growth in uremia without elevation of, 105-112
- VLDL-C (very-low-density lipoprotein cholesterol) in NIDDM, elevated cytosolic Ca and B lymphocyte proliferation and, 99
- Volume overload, relationship between LVH, myocardial contractility and, on HD, echocardiography of, 780-785
- Von Willebrand factor (vWF), enalapril effects on, in IgAN, 397-403
- Water conservation, vasopressin and, 5:i-iii
- WBC (white blood cell count) in IE patients, 522
- Weekly creatinine (Cr) clearance, ethnic variability in, by ESRD patients on CAPD, 374-380
- Weekly delivered peritoneal dialysis (PD) dose, S2:86-87, S2:129-131
of CAPD, S2:86-87
of NIPD and CCPD, S2:87
- Weekly hemodialysis (HD)
thrice-, RRF contribution to urea clearance with, S2:59
twice-, dose of, S2:34
- Weight gain
by moderate renal failure subjects, 384
see also Intradialytic weight gain on HD
- White Americans, *see* Race and ethnicity
- White blood cell count (WBC) in IE patients, 522
- White blood cells, *see* Leukocytes
- White-coat hypertension, ABPM and, 596
- Who's who in USRDS, S1:5-7
- Whole blood glutathione (GSH), levels of RBC and, in HD and PD patients, 489-494
- Withdrawal of dialysis
as cause of mortality, S1:114-116
from patients in PVS, 291-296
- Women, renal transplantation in, *see* Race and ethnicity of ESRD patients, sex and; Sex
- Work groups, NKF-DOQI, *see* Anemia Work Group, NKF-DOQI; Hemodialysis Adequacy Work Group, NKF-DOQI; Peritoneal Dialysis Adequacy Work Group, NKF-DOQI; Vascular Access Work Group, NKF-DOQI
- Workshops on CRRT in ICU, S4:112
- Work-up, *see* Assessment
- World Wide Web, Internet, USRDS on, S1:25, S1:26
- Xanthogranulomatous pyelonephritis (XGP) in renal transplantation recipients, 846-848
- X-ray, chest, following placement of internal jugular vein catheter for HD, 690-692

